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The inner cell mass undergoes orchestrated cellular divisions resulting in the formation of 
the epiblast (EPI) and primitive endoderm (PrE). Understanding the process of cell fate 
specification is crucial to appreciate the intricacies of proper embryonic development. 
While the mouse embryo is an excellent model, limitations do exist with number, technical 
challenges, and accessibility, therefore, in my thesis I employed two cell-based models to 
recapitulate the EPI-PrE fate in vitro. Many signaling pathways have been implicated in 
this lineage decision, metabolism and its downstream products have been recently regarded 
as a driver of lineage commitment. Using various biochemical, molecular, and 
computational modalities, I sought to understand how metabolism and ROS play a role in 
XEN differentiation. In Chapter 2, I demonstrated that ROS generated by NOX1 and 
NOX4, which are regulated by the GATA6 transcription factor, is required to induce XEN-
like differentiation. While exogenous ROS supplementation promoted XEN-like 
differentiation, overexpressing Nox1 and/or Nox4 produced high levels of ROS yet failed 
to promote XEN-like differentiation. Next in Chapter 3, I examined if mitochondrial ROS 
played a role in XEN-like differentiation. Strikingly, the metabolic profile of XEN-like 
cells was glycolytic in nature. Furthermore, these observations were further supported 
using embryo-derived XEN cells (Chapter 4), which also relied on glycolysis as an energy 
source. Metabolomic and biochemical analyses showcased how embryo-derived XEN cells 
maintain high lactate levels by increased LDHA activity and re-routing pyruvate away 
from the mitochondria. More importantly, modulating pyruvate-lactate fate using chemical 
agents affected XEN differentiation in vitro. Collectively, my results emphasize how 
metabolism, and its products contribute to XEN differentiation, and more broadly serves 
to expand our knowledge of mammalian development. 
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 II 
Summary for Lay Audience 
One of the earliest cell type decisions that embryos make is the commitment of cells to 
either the epiblast (EPI), which gives rise to the embryo proper, or the primitive endoderm 
(PrE) lineage. Often neglected, the PrE supports the EPI by ensuring adequate nutrient and 
gas exchange, and later its involved in gut organ formation. Many factors play a role in the 
establishment of these lineages, but of interest to me is metabolism. 
Metabolism is a set of chemical reactions that ensure the survival of an organism, 
specifically, the building or breaking down of energy from food sources. Molecularly, 
understanding how metabolites and by-products of metabolism, such as reactive oxygen 
species (ROS), influence this lineage decision is crucial to understand normal embryonic 
development. Due to the lack of accessibility of EPI and PrE cells from the embryo, I 
turned to using embryonic stem (ES) cells and embryo-derived extraembryonic endoderm 
(XEN) cells, which can be maintained in vitro indefinitely under specific culture 
conditions. In addition, I employed the F9 model, which mimics the transition towards PrE-
like lineage when treated with differentiation factors. I hypothesized that both ES and F9 
cells have distinct metabolic and Nox (enzymes that generate ROS) expression profiles 
compared to their XEN counterparts, and that changes in these profiles direct cell fate 
determination. 
I found that GATA6, a PrE lineage inducer, increases Nox1 and Nox4 levels, which are 
required but not sufficient to form XEN, suggesting that additional mitochondrial ROS 
sources may be required for XEN differentiation. Surprisingly, XEN-like cells were more 
reliant on glycolysis than oxidative phosphorylation (OXPHOS), a similar observation was 
seen in embryo-derived XEN cells. Using cutting edge technologies, I implicated a key 
metabolite, lactate, as a driver of XEN differentiation in vitro. This thesis is the first to 
highlight a role for NOX-derived ROS in XEN-like differentiation and implicates lactate 
in the differentiation towards the XEN lineage. This knowledge helps us understand how 
factors influence fate decisions, which serves to enhance regenerative medicine therapies. 
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1 « Introduction » 
1.1 « Overview » 
1.1.1 Mouse development and stem cell fate 
Embryonic development begins with fertilization where an egg and a sperm unite to form 
a diploid cell, known as the zygote. The ability of the zygote to subsequently divide into 
multiple cells results in the formation of the embryo proper and extraembryonic structures 
required to support the embryo in utero (Figure 1-1). Preimplantation development, which 
begins from fertilization to the blastocyst stage, is highly conserved amongst mammalian 
species. Postimplantation development begins when the blastocyst interacts with the 
maternal uterine lining, which results in vascularization and significant structural changes 
to the embryo. Understanding how cells self-renew and differentiate into specific cell types 
is the foundation of embryonic development. Self-renewal describes the process by which 
stem cells divide symmetrically into identical daughter cells with a similar developmental 
potential or asymmetrically where only one cell shares the developmental potential of the 
mother cell [1]. The process of self-renewal is crucial to maintain and expand the number 
of stem cell progenitors in a niche and repopulate tissue after damage. Differentiation on 
the other hand is defined as the commitment of a stem cell towards a progenitor cell or a 
specific cell type [2]. The equilibrium between self-renewal and differentiation is crucial 
for development and to maintain organ function and integrity after injury.  
Advancements in the field of stem cell biology on how genes regulate cell fate have 
allowed us to further our understanding of normal development and disease. With 
approximately 200 different cell types present in the adult body, most of these cells contain 
the same DNA sequence. Thus, a layer of transcriptional and translational regulation exists 
to ensure specific cell type expression and commitment to a fate [3]. Typically, stem cells 
undergo specification followed by determination towards a cell lineage. Cell specification 
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is defined when cells differentiate autonomously in a neutral environment towards a 
specific lineage. However, these specified cells can revert to a stem cell fate. Alternatively, 
when cells are determined, these cells can irreversibly differentiate into a specific lineage 
even when placed in an environment that does not support the transition towards that 
specific lineage. One of the earliest cell fate decisions observed in the mammalian embryo 








Figure 1-1: Lineage specification during mouse preimplantation development. 
A schematic of the morphological changes and fate decisions during mouse 
preimplantation development from a zygote to the late blastocyst. The first lineage 
segregates at the morula stage giving rise to the ICM and TE. The second lineage 
commitment occurs at the early blastocysts where cells either commit to PrE or EPI. 
Blastomeres (grey), TE (trophectoderm, blue), ICM (inner cell mass, red), EPI (EPI, 




1.2 « Early mouse mammalian development and cell fate 
specification » 
1.2.1 Mouse preimplantation development: zygote to blastocyst 
In mouse, following fertilization, the zygote undergoes several mitotic divisions resulting 
in progressively smaller cells without significant change in overall embryo size. The 
embryo at this early stage is transcriptionally inactive, protein translation is exclusively 
based on maternal mRNA deposits from the oocyte prior to fertilization. At the 2-cell stage, 
the zygotic genome is activated, which results in the accumulation of zygotic RNA through 
detailed mechanisms reviewed here [4], but proteins synthesized from maternal mRNA can 
persist into later stages of development. The zygote and blastomeres from the 2- to the 8-
cell stage are considered totipotent, able to contribute to both embryonic and 
extraembryonic tissues. Despite being morphologically similar and having the ability to 
generate both tissue types, blastomeres from the 2-cell and 4-cell stage do have some 
heterogeneity [5,6]. At the 8-cell stage, synchronous compaction takes place where 
blastomeres polarize and tightly adhere to each other. Polarization of the blastomeres 
establishes apical-basal polarity where the basolateral domain is characterized by 
accumulation of adherens junction proteins, and the apical domain by tight junctions and 
cell polarity proteins. At embryonic day 3 (E3.0), the subsequent cleavage divisions give 
rise to the morula where the outermost cells maintain polarity while cells that move inside 
adopt an apolar morphology. Cells of the morula are no longer identical, and their divisions 
are asynchronous [7]. Developmental plasticity of these cells declines significantly when 
compared to the 2- to 8-cell blastomeres. At the morula stage, the outermost cells commit 
to the trophectoderm (TE) lineage while the innermost cells give rise to the inner cell mass 
(ICM) [8], which establishes the first lineage specification. After ICM-TE specification, 
through a process known as cavitation, the blastocyst forms a fluid-filled cavity, the 
blastocoel, largely driven by Na+-water movement. Briefly, a membranous structure forms 
to prevent fluid movement from the external environment into the blastocyst. Next, 
Na+/K+-ATPases preferentially localize to the basolateral surface of TE cells [9], thereby 
resulting in intracellular Na+ accumulation. The movement of water through aquaporins 
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into the cavity results in its expansion, giving rise to the blastocoel cavity [10]. The embryo 
adopts a characteristic blastocyst morphology, with cells being less developmentally 
plastic as they prepare for the second lineage commitment and implantation. 
1.2.2 Inner cell mass versus trophectoderm specification 
One of the first lineage commitments in the mammalian embryo is the specification of cells 
towards either embryonic or extraembryonic tissue. At the morula stage, the outermost 
cells are destined to give rise to the TE, and placenta later, while cells remaining inside 
form the ICM, comprising the embryo proper and supporting yolk sacs. Genetic analysis 
sheds light on the role of key regulators and transcription factors in this process, most 
notably SOX2 and CDX2, which are exclusive to their respective lineages [11,12]. SOX2 
is restricted to the nuclei of cells destined towards the ICM at the 16-cell stage, which is 
more evident in later stages [13]. This contrasts with NANOG, a marker typically 
associated with ICM cells at later stages yet is present in outermost cells at the 16-cell 
stage. Despite its abundance in future ICM cells, conditional deletion of maternal and 
zygotic Sox2 have no effect on the segregation of ICM and TE lineage, suggesting that 
other factors are also at play.  
Blastomeres enriched in Cdx2 mRNA are more likely to commit to a TE lineage [14], while 
those depleted of Cdx2 express Pou5f1 and Nanog in the outermost cells, resulting in 
embryo death [12]. These results suggest that CDX2 functions as a cell fate determinant; 
however, the inward migration of CDX2-positive outer cells at the 16-32 cell stage [14] 
indicates that cell polarity and position may act upstream of certain cell fate determinants 
like Sox2 and Cdx2. 
It is now widely recognised that the HIPPO signaling pathway links cell positional 
information to lineage-specific markers and cell fate determinants in the early mammalian 
embryo. This pathway is widely conserved in the animal kingdom [15,16] and plays a role 
in developmental processes such as tissue growth and homeostasis as well as disease [17]. 
Nishioka and colleagues were first to implicate HIPPO signaling in ICM-TE lineage 
decision [18]. Mechanistically, in future ICM cells the serine-threonine kinases LATS1/2 
are phosphorylated and activated by MST1/2, which phosphorylate YAP. This post-
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translational modification prohibits YAP from entering the nucleus and activating TEAD4, 
which typically activates Cdx2 expression [15,19-22]. However, HIPPO signaling in the 
outermost cells is inactive and this results in the expression of Cdx2 in the TE [18,23] and 
Gata3 [24], while maintaining the Sox2 gene in the off configuration [13]. Thus, when 
TEAD4 is deleted, embryos lack TE markers Cdx2, Eomes, Gata2/3 and Fgfr2, but express 
ICM-specific markers Oct3/4 and Nanog, and this is phenocopied when Lats2 is 
overexpressed [23]. Similarly, embryos containing a catalytically inactive LATS2 show 
reduced nuclear phosphorylated YAP and increased Cdx2 expression in the innermost cells 
[18]. Nevertheless, embryos lacking TE-specific transcription factors generate blastocysts 
but fail to implant with defects in placental development [25,26]. 
In addition to the direct regulation on YAP, other factors exist to regulate the HIPPO 
signaling pathway, namely, neurofibromatosis 2 (NF2) [27-31] and angiomotin (AMOT) 
[32-37]. NF2 recruits LATS1/2 to the plasma membrane, ultimately causing the 
phosphorylation of YAP [29], but when injected with a dominant-negative Nf2, embryos 
have mislocalized YAP, which causes the ectopic expression of Cdx2 [27]. In addition, 
embryos that lack maternal and zygotic Nf2 express Cdx2 in the ICM, suggesting that NF2 
is required for proper ICM-TE specification. AMOT also regulates the HIPPO pathway 
[35,37] and can interact with YAP and NF2 [32,35-37]. In the outermost cells, the PAR-
aPKC complex (see below) sequesters AMOT to the apical domain thereby preventing its 
interaction with LATS and keeping the pathway inactive [33,34]. While in the innermost 
cells, AMOT is localized to adherens junctions when bound to the F-actin and E-cadherin-
α/β-catenin-NF2 complex. This conformation of AMOT is unstable and results in its 
ubiquitination and degradation. In the innermost cells, LATS phosphorylate AMOT, which 
results in its release from F-actin and its stabilization, thus activating the HIPPO pathway 









Figure 1-2: Schematic of the HIPPO signaling pathway in outer and inner cells of 
the embryo.  
In the outer cells, AMOT is bound by F-actin, preventing it from binding to LATS1/2-
NF2 complex thus inhibit LATS1/2. Consequently, allowing YAP to translocate into 
the nucleus and binds to TEAD4 and induce the expression of TE marker Cdx2. In the 
inner cells, AMOT is localized to AJs by a F-actin-E-cadherin-α/β-catenin-NF2 
complex. LATS1/2 phosphorylate AMOT, which results in its release from the complex 
and stabilization, thus binding to LATS1/2 and enhancing LATS-dependent 
phosphorylation of YAP. The phosphorylation of YAP prevents it from entering the 
nucleus thereby inhibiting the expression of Cdx2 and the upregulates of Sox2. 
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While various players of the HIPPO signaling pathway play a crucial role in ICM-TE 
specification, researchers have shifted their focus on targets upstream of the pathway that 
link cell position and polarity to lineage decisions in the mammalian embryo. Historically, 
two models attempt to explain the first cell fate specification: the inside-outside model; and 
the cell polarity model. In the former, the position of a cell within the embryo dictates cell 
fate [38]. Tarkowski and Wroblewska observed that with the decrease in embryo volume, 
more cells were on the surface (outside) while fewer cells were on the inside. They 
concluded that the condition in which the outside and inside cells are in, are vastly different 
and that fate is a consequence of blastomere position. Alternatively, the cell polarity model 
relies on the acquisition of apical-basal polarity [39], which is based on the fact that the 8-
cell stage blastomeres polarize and form stable apical domains. This stability during cell 
division results in either two polar (outer) cells or one polar and one apolar (inner) cell 
[40]. The outcome of these divisions leads to the formation of an apolar ICM and a polar 
TE. Regarding this model, studies have implicated the PAR-aPKC complex in polarization 
and subsequently ICM-TE specification. Embryos with reduced levels of Pard6b cleave 
and compact properly but have a decrease in Cdx2 expression and fail to form cavities at 
the blastocyst stage [41], raising the question of whether a link exists between cell polarity, 
epithelium formation and specification. However, the deletion of maternal and zygotic E-
cadherin blocks the formation of a polar epithelium, but this does not block ICM-TE fate 
[42] and a higher ratio favouring Cdx2-expressing cells over ICM cells was observed in 
these embryos. Thus, epithelium formation is required for the normal allotment of ICM 
and TE cells rather than ICM-TE specification. 
With regard to ICM specification, Pou5f1 [43], Nanog [44] and Sox2 [45] are required for 
cell fate. Pou5f1 and Nanog are expressed in all cells early in development, but later they 
become more restricted in ICM cells. In the TE, however, CDX2 binds to OCT4 and 
prevents it from acting as a transcriptional activator [46]. Similarly, although Pou5f1null 
embryos generate blastocysts, they are unable to produce derivates of the ICM, and instead 
express TE lineage markers [47]. Finally, HIPPO signaling also ensures the activation of 
cell fate markers in ICM cells [48]. Thus, the differential activation of HIPPO signaling 
coupled with transcription factor-mediated cell fate decision provides a roadmap for the 
regulation of ICM-TE lineage specification. 
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1.2.3 Epiblast versus primitive endoderm specification 
Once the first lineage establishes the TE from the ICM, the second lineage decision 
determines the identity of the ICM: epiblast or primitive extraembryonic endoderm (PrE). 
All blastomeres at the 8-cell stage contain the transcription factors NANOG and GATA6, 
but more distinct localization takes place at the 32-cell stage where cells fated towards the 
epiblast contain NANOG while those that will form PrE contain GATA6 [11,49]. This 
mutual repression is seen in Gata6 mutant embryos that display uniform NANOG 
expression in the ICM [50,51], while the ICM of Nanog mutants contain GATA6 thereby 
repressing the epiblast fate [52]. Historically, the origin of these lineages was largely 
positional, with cells closer to the blastocoel cavity destined to form PrE whereas those 
bordering the TE form the epiblast. However, this model has been replaced through genetic 
analysis and lineage tracing experiments with results showing the epiblast or PrE lineages 
are genetically predetermined prior to separating into two layers [49,53-55]. Research has 
since shifted to elucidate the mechanisms involved in resolving the heterogeneity observed 
in the early ICM where two developmental models were proposed: cleavage history-
dependent; and stochastic gene activation [3].  
The cleavage history-dependent model reveals that ICM cells are poised towards the 
epiblast or PrE fate depending on when these cells arise. ICM cells are created at the 8- to 
16-cell (wave 1), the 16- to 32-cell (wave 2), and the 32- to 64-cell (wave 3) stages. Lineage 
tracing analysis has revealed that cells generated from wave 1 are primarily destined to the 
epiblast fate while cells generated from wave 2/3 are biased towards PrE [56]. However, 
another study using a Cre/Lox lineage tracing approach reached a different conclusion, 
where all cells of the ICM have an equal chance of adopting either cell fate regardless of 
their timing [57]. Nonetheless, these experiments highlight the developmental plasticity of 
the mammalian embryo, and more research is required to elucidate the signaling 
mechanisms and gene regulatory networks involved in epiblast-PrE specification. 
The stochastic gene activation model considers that the profile of gene expression in cells 
fated as ICM arise randomly, and independent of cellular divisions. Several studies using 
single-cell PCR analysis have implicated the FGF signaling pathway in PrE specification 
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where a subset of cells within the ICM stochastically express varying levels of either the 
ligand FGF4 or its receptor FGFR2 [11,58]. Epiblast cells express Fgf4 during blastocyst 
formation [11] while Fgfr2 is widely expressed in all ICM cells at E3.25, but becomes 
restricted to PrE cells at E3.5 [11,52,59,60]. Disrupting FGF signaling results in only 
epiblast cell [57,59,61] while supplementing with exogenous FGF4 is sufficient for all ICM 
cells to adopt a PrE fate [57]. Thus, while the FGF/MAPK signaling pathway is responsible 
for the specification of epiblast versus PrE fate (Figure 1-3), downstream effectors also 







Figure 1-3: FGF-MAPK signaling in the late blastocyst.  
EPI cells express and secrete FGF4, which signals in paracrine to PrE cells where it 
binds FGFR1 and FGFR2 activating ERK resulting in the increase in GATA6 and 
downregulation of NANOG. EPI cells express NANOG and FGF4 with low levels of 
FGFR1, while PrE cells express GATA6 and FGFR1 and FGFR2. EPI (EPI cells) and 
PrE (primitive endoderm cells), FGF4 (fibroblast growth factor 4), FGFR1 (fibroblast 
growth factor receptor 1), and FGFR2 (fibroblast growth factor receptor 2). This 
diagram was adopted and modified from (59). 
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The role of these effectors is evident when Grb2, encoding a SH2 domain-containing 
adaptor protein downstream of FGF/MAPK signaling pathway, is knocked out [53,62] or 
when the pathway is disrupted chemically [53,57,61], causing cells to express NANOG. 
FGF/MAPK signaling pathway also ensures the repression of Sox2 and Nanog in the PrE 
[13]; however, key pluripotency markers are also required for specification of these cells. 
For example, embryos that lack Sox2 have reduced expression of PrE markers Gata6 and 
Sox17 [13]. Pou5f1, another pluripotency marker is also required for PrE formation as the 
translated protein promotes the expression of Gata4 and Sox17 downstream of MAPK; it 
also promotes Gata6 expression and reduces Nanog expression in an POU5F1-independent 
manner [63]. In this model, POU5F1 in the epiblast cells is required to secrete FGF4, which 
interacts with FGFR2 on PrE cells to transduce the signal and upregulate key PrE markers. 
When Pou5f1 is deleted, embryos have normal NANOG and GATA6 levels; however, 
Gata6 expression declines drastically, which is partially attributed to the reduction in FGF4 
[63]. Therefore, pluripotency markers in the epiblast cells are required for PrE 
specification.  
Once the epiblast and PrE are specified, the next step is to ensure the maturation of these 
respective lineages. Particularly for PrE cells, mature markers such as SOX17, PDGFRα, 
GATA4 and SOX7 levels increase, and as described below, their temporal regulation relies 
on GATA6. At these later stages, genetic or chemical manipulation to alter cell number of 
either epiblast or PrE cells does not result in compensation by an increase in the other cell 
type since cells are committed. GATA6, whose message is expressed in cells from the 8-
cell stage becomes restricted to PrE cells at E3.75. While it is considered a master regulator 
of the endodermal lineage; it does so together with other factors and signaling pathways 
[53,64]. Prior to E3.75, Gata6 expression is independent of FGF signaling, but at later 
stages it requires FGF [53,57,59-61]. GATA6 is expressed in all ICM cells of Nanog-/- 
embryos, however, the levels of mature PrE markers GATA4 and SOX17 is significantly 
downregulated [65,66], implying other players are required for their expression. More 
importantly, the decline in FGF4 secreted by epiblast cells results in the reduction of Gata6 
expression in PrE cells [13,63]. Incidentally, Gata6 nulls die at E6.5-E7.5 [67] and the ICM 
cells of these embryos have detectable NANOG levels [50,51].  
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GATA6, as noted above, is the initial transcription factor in PrE specification, followed by 
the expression Sox17, Pdgfrα, Gata4 and lastly Sox7 [64]. Sox17 expression overlaps with 
other markers including Nanog, Pou5f1 and Gata6 at E3.5 [56,68], but by E4.5, Sox17 is 
expressed only in PDGFRA-expressing cells [49,64,68]. Nevertheless, Sox17-/- embryos 
generate PrE but die at midgestation due to improper development of the gut endoderm 
[68,69]. Similarly, the loss of the PDGFRα in PrE cells results in cell death [70]. Sox7, 
which is normally expressed at preimplantation, maintains its expression in Sox17 null 
embryos [64,69], and its compensation may explain the mild phenotype observed in Sox17 
mutants [64,69]. Regardless, overwhelming evidence indicates that a hierarchy in gene 
regulation is required for PrE formation.   
Other growth factors and signaling pathways are also involved in specifying PrE, including 
BMP where embryos treated with pathway inhibitors, including NOGGIN and 
dorsomorphin, have a reduced number of PrE cells [71]. Interestingly, the number of 
NANOG-positive cells is not altered and the epiblast versus PrE fate decision is not 
affected. Together these studies highlight the importance of transcription factors and 
signaling molecules implicated in lineage specification, and despite embryos being an 
excellent platform to decipher the mechanisms involved, technical difficulties limit the 
elucidation of these pathways. To overcome some of these shortfalls stem cells can be 





1.3 « In vitro models of cells within the inner cell mass » 
1.3.1 Mouse naïve and primed embryonic stem cells 
Since pluripotency is a transient state in vivo, researchers can capture various stages of 
development and maintain them indefinitely under defined culture conditions. These 
culture conditions either maintain cells in an undifferentiated state or induce differentiation 
towards a specific lineage. Pluripotent stem cells have been isolated from various 
vertebrates, with each cell type requiring defined conditions to ensure their maintenance. 
For instance, naïve embryonic stem (ES) cells of the preimplantation ICM can be isolated 
and maintained indefinitely [72,73]. Morphologically, these cells grow in domed-like 
colonies, have a high proliferation rate and clonogenicity, and can incorporate into the 
blastocyst and give rise to ectoderm, endoderm and mesoderm [74]. These cells were first 
isolated from ICM of 129 mouse strain and maintained on mitotically inactive mouse 
embryonic fibroblast cells (MEFs) and fetal bovine serum (FBS). While MEFs are still 
used today, potential contaminants resulting in confounding data limit the potential use and 
application of these ES cells, specifically in regenerative medicine. It is also challenging 
to pinpoint the factors secreted by MEFs and more importantly, even more difficult to 
ensure consistency from batch to batch; the latter also applies to FBS. To maintain ES cells 
feeder-free, leukaemia inhibitory factor (LIF) in combination with FBS was found to 
maintain proliferation and pluripotency of ES cells [75,76]. LIF causes its receptor and 
gp130 to dimerize, activating JAK and causing the phosphorylation of the LIF receptor and 
gp130. In turn, STAT3 is recruited to the complex where it is phosphorylated by JAK, 
causing homodimerization and translocation to the nucleus where it activates gene 
expression [77,78]. STAT3 is key as its ectopic expression can maintain pluripotency in 
the absence of LIF [79], while inactivating it compromises pluripotency and induces 
spontaneous differentiation [80]. The first serum-free and feeder-free system to culture ES 
cells and maintain them in the undifferentiated state relied on LIF and low doses of BMP4 
to inactivate the MAPK pathway [81]. The LIF-2i system has since been employed, and 
uses LIF alongside small molecule inhibitors of glycogen synthase kinase 3 (GSK3) and 
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the mitogen-activated protein kinase (MEK) pathway [82]. Overall, culturing naïve ES 
cells under LIF-2i system reduces heterogeneity in culture whilst maintaining pluripotency. 
Further down the developmental timeline, primed epiblast stem cells (EpiSCs) can be 
isolated from the post-implantation epiblast, and they differ morphologically from naïve 
ES cells by growing as flat colonies. EpiSCs possess low clonogenicity and are unable to 
form chimeras, but can give rise to all three lineages in a teratoma assay [74]. EpiSCs also 
differ from naïve ES cells in having one inactivated X chromosome [83], and while they 
express the core markers of pluripotency like naïve ES cells (OCT4, SOX2 and NANOG), 
they downregulate naïve-specific markers including KLF2/4, ESRRβ, REX1 and DPPA3 
and upregulate primed markers OTX2, T and ZIC2 [84]. The epigenetic landscape is also 
distinct between the two cell types, with higher global DNA methylation [85]. Primed 
EpiSCs are cultured under FGF2/Activin A to maintain their undifferentiated state [86,87], 
and while FGF2-MAPK signaling does not directly promote the epiblast lineage, it does 
suppress KLF2 and the neuroectodermal lineage [88]. In contrast, Activin A supports 
pluripotency by activating NANOG while suppressing mesodermal lineages by inhibiting 
SMAD2/3 levels [89]. 
While naïve-primed cells differ on many levels, including the expression profile of 
pluripotency core genes, DNA methylation, histone modification status, clonogenicity and 
chimera contribution [74], it is the culture conditions that contribute to this heterogeneity. 
For example, naïve ES cells cultured under LIF-2i system maintain high degree of 
hypomethylation on promoter regions. However, when cells are transitioned into naïve 
serum-LIF system, an increase in DNA methylation is observed, which is more prominent 
in the FGF2/Activin A system [90]. Conversely, transitioning naïve serum-LIF ES cells 
into the 2i-LIF system induces changes in the promoter occupancy of key naïve markers 
and downregulation of DNA methyltransferases and a reduction in global methylation [91].  
To fully exploit this in vitro system, ES cells can be converted interchangeably between 
the naïve and primed state using chemical agents or genetic means. Chemically, culturing 
primed EpiSCs under naïve conditions with LIF-2i results, albeit inefficiently, in 
reprogramming towards the naïve state. Genetically, however, overexpressing naïve 
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markers such as KLF4 promotes the conversion of EpiSCs to a naïve state, and these 
reprogrammed cells can contribute to chimeras and germline transmission [82,92]. Other 
naïve factors, including NANOG, ESRRβ and PRDM14 can also enhance the 
reprogramming efficiency of EpiSCs into naïve ES cells [93]. Alternatively, naïve ES cells 
can be converted into EpiSCs by culturing them in FGF2/Activin A [82,92,94]. Overall, 
obvious differences exist between the two populations of stem cells, and despite both being 
excellent tools to study early mammalian development, it is imperative to address culturing 
conditions when elucidating the mechanisms instructing cell fate.  
1.3.2 Mouse extraembryonic endoderm cells 
In addition to naïve ES cells, cells can be isolated and cultured indefinitely from the PrE, 
termed extraembryonic endoderm (XEN) cells. Morphologically, XEN cells are 
heterogenous being round and refractile or epithelial-like in culture [95]. While pluripotent 
stem cells have the ability to repopulate the ICM and give rise to chimeras, at least with 
naïve ES cells [74], XEN cells can only repopulate the parietal endoderm and not the 
visceral endoderm, suggesting that these cells are more reminiscent of the former. 
However, XEN cells isolated from the post-implantation blastocyst do contribute to the 
visceral endoderm [96]. More recently, XEN cells have been shown to contribute to the 
endoderm proper, mainly in the gut [97]. Although there are several methods to establish 
XEN cells, they were first isolated from the mouse blastocyst [95]. Other methods, 
however, are available including differentiating ES cells using exogenous factors [98-100], 
reprogramming fibroblast cells [101,102], or by overexpressing Gata4/6 [103,104] or 
Sox17 [105]. Regardless of their origin or derivation, XEN cells, typically cultured in the 
presence of serum without exogenous factors retain the ability to self-renew and 
differentiate when prompted. Identifying the extrinsic and intrinsic factors is key to 
understanding self-renewal and differentiation of XEN cells. For instance, naïve ES cells 
require the inactivation of MAPK signaling, but XEN cells rely on this signaling in vitro 
and in vivo [61]. Treating these cells in vitro with a MEK inhibitor leads to reduced 
proliferation and differentiation towards visceral endoderm [70,106]. Other players 
including LIF, Activin A and retinoic acid [100,107], are also involved in XEN cell 
differentiation in vitro.  
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Exogenous agents influence intrinsic mechanisms that are linked to transcription factors 
and epigenetic regulators that play a role in self-renewal and differentiation of XEN cells. 
Potent transcription factors such as GATA4, 6 and SOX17 differentiate ES cells towards 
the PrE fate [103-105,108] and are required as Gata6 nulls fail to differentiate when these 
cells are treated with retinoic acid and Activin A [98]. GATA6 promotes XEN induction 
by directly binding to the promoter region of endodermal markers thereby enhancing their 
expression, while also binding to regulatory regions of pluripotency genes to repress their 
expression [108]. In addition to these transcription factors, epigenetic modifications 
including DNA methylation, histone modifications and microRNAs play an intrinsic role 
in XEN induction. Genes associated with the PrE lineage are hypomethylated while those 
involved in pluripotency are hypermethylated [109]. Histones are also affected by 
methylation, and while XEN cells have low levels of the repressive H3K27me3, ES cells 
have high levels due to the expression of members of the Polycomb Repressive Complex 
2 [110]. Thus, both intrinsic and extrinsic mechanisms play a role in the maintenance and 
differentiation of XEN cells in vitro and a better insight into those mechanisms may help 
us understand how mouse and human development occurs in vivo. 
1.3.3 Mouse embryonal carcinoma cells 
While most of the studies today are focussed on induced, embryonic and cancer stem cells, 
much of the pioneering work arose from studies with embryonal carcinoma (EC) cells 
derived from teratocarcinomas [111]. EC cells share three distinct features: (1) they are 
malignant; (2) they can differentiate into any of the three germ layers or extraembryonic 
tissue; and (3) they can contribute to the development of chimeras, however, not reliably 
[112,113]. Although EC cells can be propagated indefinitely without supplementation of 
exogenous factors, the ability to culture them in vitro and their loss of “multipotentiality” 
was of paramount importance, leading to many studies that followed [114]. In fact, the 
suggestion that the study of EC cells would uncover genes involved in stem cell self-
renewal and pluripotency only serves to underscore the importance of EC cells [115]. 
Nevertheless, these lines have been and continue to be studied extensively [116-119].  
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F9 teratocarcinoma cells, one widely used mouse EC cell line that can give rise to tumours 
consisting almost exclusively of undifferentiated cells, exhibit a pseudodiploid karyotype 
[112,120,121]. Once considered nullipotent, studies would later reveal that F9 cells 
differentiate into XEN-like cells [122,123], and evidence indicates that they share many 
characteristics of ES cells [124]. In fact, F9 cells can be induced to form XEN-like cells by 
all-trans retinoic acid (RA) [125], a natural derivative of vitamin A (retinol), or by 
activating numerous signaling pathways involving canonical WNTs [126]. Thus, like ES 
cells, extrinsic [127] and intrinsic factors can influence the maintenance and differentiation 




Table 1: Key features of various cell lines used in this thesis 
 F9 ES* XEN 
Species Mouse Mouse Mouse 
Strain N/A 129P2/OlaHsd ICR 
Colony morphology Compact Compact Single cells 
Homogeneity Yes Yes No 
DNA methylation Low Low High 
X inactivation Partial No Yes 
Germ cell 
competence 
None Low None 
Teratoma formation High High Low 
Chimera 
contribution 
High High Low 
Marker expression OSKM, Rex1, Klf4 OSKM, Rex1, Klf4, 
Esrrb 
Gata4/6 and Dab2 
LIF requirement No Yes No 
RA responsiveness Yes Yes No 
FGF/MAPK 
dependence 
No No Yes 






1.3.3.1 Retinoic acid: lessons from the inducer 
RA is a potent teratogen and an important endogenous regulator of proper and 
extraembryonic endoderm [128]. RA signaling has many diverse roles in the differentiation 
of EC cells [99,129], most often leading to XEN-like lineages. RA-induced differentiation 
is accompanied by changes in gene expression in F9 cells [130-135] include c-Myc 
[136,137] and Wnt1, which have caught the attention of subsequent cancer-related studies. 
In the case of c-Myc in F9 cells, its levels decline with RA-induced differentiation [130] 
comparable to ES cells [138]. c-Myc is downstream of the WNT targetome [139], and its 
expression including other Wnt target genes has been reported during RA-induced 
differentiation in F9 cells [126,130,140]. These discoveries not only led to the assembly of 
complex cell signaling pathways and gene networks linked to EC cell differentiation but 
were the platform that many have since used to identify the crosstalk and autoregulatory 
loops that exist within and between EC and ES cells [141-147]. It is interesting to note that 
while many of these studies revealed that RA must repress certain genes during 
differentiation, little discussion has linked these genes to self-renewal and stemness in EC 
cells. In fact, despite the irony that stemness genes including c-Myc [136,148-151], Oct3/4 
[152-154] and Sox2 [155-157] had already been identified in EC cells, their specific roles 
in self-renewal and pluripotency would not be elucidated until later [115,158]. Meanwhile, 
studies showing expression of genes such as K-fgf and Hst-1 [159-161] provided the 
framework that gene activity was sufficient and necessary to keep EC cells in the 
pluripotent state. In addition to these studies and others involving c-Myc [148,162-166], 
Pou5f1 [154,167-169], and Sox2 [155,156], further evidence that pluripotency genes must 
be developmentally regulated in the early embryo came from reports that Nanog [170,171], 
and Foxm1 [172] are down-regulated in F9 cells in response to RA treatment. Foxm1, a 
member of the Forkhead box of transcription factors, is an interesting example as we know 
it plays pivotal roles in cell proliferation, differentiation, and self-renewal, and acts 
downstream of canonical Wnt/b-catenin signaling [173,174]. Thus, while much of the 
focus was initially on ways to differentiate EC cells, subsequent efforts are underway to 




1.4 « Metabolism, pluripotency and differentiation » 
1.4.1 Overview of glycolysis and oxidative phosphorylation  
Stem cells possess long-term capacity to self-renew, thereby replenishing aged or damaged 
cells in an organ. Thus, the immense demand for energy production and metabolites to act 
as building blocks for substrates and co-factors has driven the field to investigate the role 
of metabolism in pluripotency and differentiation. Metabolism is a process of anabolic and 
catabolic reactions that take place in an organism to ensure survival. All mammalian cells 
generate ATP as an energy molecule through catabolic reactions of macromolecules 
(carbohydrates, proteins, and lipids). In the case of glycolysis, ATP is generated in an 
oxygen-independent pathway in the cytoplasm, while oxidative phosphorylation 
(OXPHOS) yields ATP from an oxygen-dependent mitochondrial pathway. Glycolysis is 
a series of enzymatic reactions that convert glucose into pyruvate to generate a net of 2 
ATP molecules per molecule of glucose. Cells that are exclusively glycolytic further 
convert pyruvate into lactate, which is either used intracellularly or excreted 
extracellularly. Alternatively, when oxygen is abundant, pyruvate is taken up into the 
mitochondria and is oxidized into acetyl-CoA, which yields 34 ATPs per molecule of 
glucose, thereby making it a more efficient process. Despite being less efficient, ATP 
generated from glycolysis occurs at a faster rate than from OXPHOS [175], and when 
glucose supply is sufficient, glycolysis is the preferred bioenergetic pathway for highly 
proliferative cells. 
Glycolysis is divided into three phases: 1) energy investment; 2) splitting; and 3) energy 
production [176]. During the energy investment phase, glucose is phosphorylated by 
hexokinase (HK) into glucose-6-phosphate (G6P). This first step of glycolysis requires 
ATP and is irreversible. G6P isomerizes and is phosphorylated by the phosphofructokinase 
(PFK) enzyme into fructose-1, 6-bisphosphate. In the splitting phase, fructose-1, 6-
bisphosphate is separated by an aldolase into glyceraldehyde-3-phosphate (G3P) and its 
isomer, dihydroxyacetone phosphate. Finally, triose phosphate isomerase converts 
dihydroxyacetone phosphate into G3P, which is used in energy production. In this last 
phase, G3P is converted into 1,3-bisphosphoglycerate by glyceraldehyde-3-phosphate 
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dehydrogenase (GAPDH), also yielding NADH2. ATP is produced by phosphoglycerate 
kinase acting on 1, 3-bisphosphoglycerate to generate 3-phosphoglycerate, which 
isomerizes into 2-phosphoglycerate by phosphosphoglycerate mutase. Enolase then 
converts 2-phosphoglycerate into the high energy molecule phosphoenolpyruvate, which 
is catalyzed by pyruvate kinase to form pyruvate and a second molecule of ATP. Pyruvate 
is reduced by lactate dehydrogenase A (LDHA) into lactate, and this requires NADH2, 
which gets oxidized to NAD+ and as a result, NAD+ is recycled and reused in glycolysis. 
Incidentally, lactate can be converted back into pyruvate by the LDHB enzyme, to 
participate in OXPHOS metabolism. 
OXPHOS is an oxygen-dependent means to generate ATP. In the presence of oxygen, 
pyruvate enters the mitochondria to be processed in the Tricarboxylic Acid Cycle (TCA), 
also called the Citric Acid or Krebs cycle [177]. The mitochondrial pyruvate 
dehydrogenase complex (PDC) catalyzes the oxidative decarboxylation of pyruvate into 
acetyl-CoA, and oxaloacetate is added by the enzyme citrate synthase to generate citrate. 
Citrate isomerizes and oxidatively decarboxylated into α-ketoglutarate through isocitrate 
dehydrogenase, which is also oxidatively decarboxylated into succinate. In the process of 
generating succinate, ATP, CO2 and NADH are produced. Succinate is oxidized by 
succinate dehydrogenase into fumarate and FADH2, with fumarate being hydrated into 
malate, which is oxidized by malate dehydrogenase to regenerate oxaloacetate and NADH. 
The TCA cycle does not generate sufficient ATP, instead, electrons are removed and used 
to generate NADH and FADH2. These molecules, however, flow through the electron 
transport chain (ETC) creating a proton gradient that powers an ATP synthase to generate 












Figure 1-4: An overview of the conversion of glucose through glycolysis and 
OXPHOS. 
Glucose enters the cells through glucose transporters where it is phosphorylated into 
G6P by the activity of the HK enzyme in non-reversible manner. Following various 
steps, phosphoenol pyruvate is generated, which is converted into pyruvate and ATP is 
generated. Pyruvate has two fates, it can be reduced into lactate via LDHA, and reversed 
back into pyruvate through the activity of LDHB. Alternatively, pyruvate is pumped 
into the mitochondria through MPCs where PDC catalyzes the oxidative 
decarboxylation of pyruvate into acetyl-CoA, which in turn is broken down to generate 
reducing power though the Krebs cycle. The generated NADH and FADH2 are used the 
ETC to eventually result in the production of ATP.  
 
 25 
1.4.2 Metabolic profile of the blastocyst and pluripotent stem cells 
Recently, interest has focussed on understanding how metabolism can influence cell fate 
commitment in the developing embryo; specifically, the interplay between metabolism and 
the epigenome to drive changes in pluripotency and differentiation. Pioneering work 
identified conditions that allowed the culturing and maintenance of blastocysts ex vivo 
[178,179], and results show at the 1-2 cell stage the embryo requires pyruvate, while shortly 
afterwards either pyruvate or lactate can be used [180]. Interestingly, neither glucose nor 
glutamine alone can support development at these early stages. The inability to utilize 
glucose is largely due to the high ratio of ATP-to-ADP, which allosterically inhibits the 
activity of PFK, thereby inhibiting glycolysis [181]. As development progresses, an 
increase in the demand for ATP occurs, and there is an increase in oxygen consumption 
[182], and the ATP is primarily used for blastocoel expansion [183]. In addition, HK and 
PFK inhibition also plays a role in the reduced reliance on glycolysis in the early embryo 
[181]. The blastocyst converts half of its glucose into lactate, despite sufficient oxygen 
levels for OXPHOS, known as the “Warburg Effect” named after Otto Warburg [184]. The 
lactate generated is secreted through monocarboxylic acid transporters (MCTs) out of the 
cell suggesting that lactate, acting as one of the extrinsic factors, may play a role in 
mammalian development. 
LDHB, which preferentially converts lactate into pyruvate, is highly expressed at the 
preimplantation stage [185], and when glucose is depleted in culture the metabolically 
flexible blastocyst can compensate by an increase in pyruvate uptake. Pyruvate is used as 
an energy source, but it also serves as an antioxidant to sequester reactive oxygen species 
(ROS) that can be detrimental to the embryo. Furthermore, both pyruvate and lactate 
regulate metabolic function by controlling the redox state of the cell [186]. 
Mechanistically, pyruvate is required for zygotic genome activation at the 2-cell stage, 
where pyruvate-mediated translocation of the PDC to the nucleus is required to generate 
the acetyl-CoA essential for epigenetic modifications required for genome activation [187]. 
However, LDHA, which converts pyruvate into lactate is enriched in the late blastocyst 
and as the embryo prepares for implantation, this lactate creates a low pH environment as 
it is secreted by MCTs, which aid in breaking down the uterine lining [188]. In addition, 
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this acidosis acts to induce VEGF recruitment, which promotes angiogenesis, further 
facilitating development [189]. These studies highlight the few roles of glucose-derived 
lactate in embryonic development. 
Glucose is typically used as an energy source, but alternatively it is also used for the 
synthesis of precursors for macromolecule biogenesis. Glucose can be redirected into the 
hexokinase biosynthesis pathway (HBP) to synthesize the UDP-O-GlcNAc moiety that 
plays a role in ICM-TE specification [190] or XEN differentiation (Appendix-Section 2). 
In the apical cells, which later become TE, YAP1 must be O-GlcNAcylated to translocate 
into the nucleus and activate the transcription of Cdx2. Blocking either O-GlcNAcylation 
or treating embryos with 2-deoxyglucose, which inhibits glycolysis and HBP, blocks 
YAP1 activation and Cdx2 expression. Tead4-/- embryos fail to form a blastocoel or implant 
under oxidative stress conditions [191]. Specifically, Tead4-/- embryos develop properly 
when cultured under 5% oxygen tension, and this was abrogated when glucose, amino acids 
and glutamine were supplemented, thereby driving OXPHOS metabolism and ROS 
production. The pentose phosphate pathway (PPP) uses glucose to generate the ribose 
moiety for nucleic acid synthesis and the NADPH for lipid and other macromolecule 
synthesis [192]. Nucleotide synthesis and sphingolipid signaling activate mTOR allowing 
for the translation of Tfap2c [190]. Collectively, YAP1-TEAD4-TFAP2C complex binds 
and upregulates TE-specific genes in apical cells. Finally, results show glucose and 
glycolysis are preferentially utilized in the developing embryo to ensure low levels of ROS 
are generated to maintain genomic integrity and reduce the chance of lipid and protein 
oxidation [193]. Although previous studies have used the embryo as a model in order to 
understand the role of metabolism in development, it remains technically challenging and 
data can be confounded by culture conditions and the scarcity of tissue [194]. Again, to 
circumvent these problems there has been a transition to using stem cells as an in vitro 
model to study the interplay between metabolism, epigenetics, and fate decision. 
Differences between naïve and primed stem cells were discussed earlier with reference to 
morphology, culture conditions, gene regulatory networks, and epigenetic signatures 
(Section 1.3.1). Indeed, metabolic differences also exists between naïve and primed stem 
cells with naïve ES cells exhibiting a metabolic profile reliant on both glycolysis and 
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OXPHOS [195]; while, EpiSCs are exclusively dependent on glycolysis, largely due to 
increased glucose uptake through various transporters [196]. The high proliferation rate of 
pluripotent stem cells and an extended S-phase imposes the demand for macromolecule 
generation. The high glycolytic flux in pluripotent cells also provide substrates for the PPP. 
These metabolic preferences reflect substrate utilization and are regulated by key 
pluripotency factors. During early stages of development, low levels of HK2 and 
dependence on pyruvate reduces the reliance on glycolysis [185]. However, in ES cells, 
OCT4 directly binds to the Hk2 and Pkm2 promoter regions upregulating their expression 
thereby increasing their glycolytic rate [197]. More importantly, overexpressing Hk2 or 
Pkm2 maintains high glycolytic rates and hampers ES cell differentiation, suggesting that 
metabolism influences cell fate. Similarly, OCT4, SOX2 and NANOG bind the enhancer 
region of the Glut1 gene, thereby increasing glucose uptake in ES cells [198]. Furthermore, 
the regulation of many metabolic enzymes does not have to rely solely on key transcription 
factors. One example is the miR-290 cluster that represses MBD2, a “reader” of methylated 
CpGs, resulting in an increase in c-Myc expression and its downstream targets Pkm2 and 
Ldha, which encode essential glycolytic enzymes [199]. RNA-binding proteins including 
LIN28a/b also play roles in regeneration and development [200] as they are known to 
repress OXPHOS related transcripts, thereby enhancing the naïve-to-primed transition 
[201]. Incidentally, the Lin28a/b locus is regulated by c-MYC, which is known to be an 
important factor that enhances glycolytic metabolism [199].  
Many reports have detailed how cell fate changes are influenced by glucose metabolism 
[202,203], but other than substrate availability and enzymes level, hypoxia, and the 
transcription factors hypoxia-inducible factor 1α and 2α (HIF1α and HIF2α, respectively) 
are major regulators. At atmospheric levels referred to as normoxic conditions (21% O2), 
HIF1α and HIF2α are hydroxylated by an oxygen-dependent prolyl hydroxylase, and 
subsequently ubiquitinated by the von Hippel-Lindau tumour suppressor protein resulting 
in their degradation [204-206]. However, under hypoxic conditions, HIF1α and HIF2α are 
stabilized and form heterodimers with HIF1β [207]. This HIF complex accumulates in the 
nucleus where it activates response genes, some of which are involved in glycolytic 
metabolism such as members of the pyruvate dehydrogenase kinase (PDK) family and 
LDHA [195,208]. Thus, the fate of pyruvate is indirectly regulated by HIF1α, as evident 
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in EpiSCs where under normoxic conditions HIF1α is stabilized, PDKs are upregulated, 
and the pyruvate dehydrogenase complex is phosphorylated and inactivated [195,209]. 
Concomitantly, pyruvate is converted into lactate by increased levels of LDHA in these 
cells [195]. In addition, stabilized HIF1α or overexpressing an oxygen-insensitive form of 
the protein that mimics hypoxic conditions reduces OXPHOS metabolism and promotes a 
glycolytic phenotype that enhances the transition of naïve ES cells to the primed-like state 
[195]. While the low level of mitochondrial respiration in EpiSCs is partially explained by 
the HIF1α stabilization, deregulation in ETC components is also seen [195]. Most genes 
encoding the ETC components, most notably from complex IV (cytochrome c oxidase), 
are significantly downregulated in EpiSCs relative to naïve ES cells and this may be the 
result of low levels of peroxisome proliferator-activated receptor-γ coactivator-1β and 
ESRRβ [195]. Collectively, the action of ESRRβ and HIF1α play integral role in regulating 
the metabolism in the naïve and primed states, respectively. 
Although studies have focused on the role of metabolism in the specification of naïve to 
the primed state, few reports detail how metabolism is involved in XEN differentiation. 
Choi and colleagues characterized the metabolic profile of all three lineages of the 
blastocyst using Seahorse XF technology to measures metabolic rate of energy producing 
pathways, such as glycolysis and mitochondrial respiration [210]. This group found that 
basal mitochondrial respiration was significantly lower in XEN cells when compared to ES 
cells, and when challenged with a mitochondrial uncoupler, respiration of XEN cells was 
higher and suggested they may have the ability to use OXPHOS metabolism. Despite this 
finding, the derivation method and cell culture conditions may have confounded their 
results leading to the reported metabolic discrepancies. For example, XEN cells 
reprogrammed from fibroblasts have elevated Hk2 and Glut1 levels [101], but Gata4-
induced ES cells display a gradual reduction in the above targets [211]. Nonetheless these 
studies highlight the metabolic complexity and plasticity of XEN cells. 
While the role of glycolysis is crucial, the mitochondria is involved in fatty acid oxidation, 
glutamine and amino acid metabolism, calcium homeostasis, and waste management, to 
name a few [212], but specifically its ETC is the primary source of cellular ROS. One of 
the most important determinants of mitochondrial activity is its structure with naïve ES 
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cells exhibiting round to circular shaped mitochondria with irregular cristae [195]. Primed 
EpiSCs and XEN cells, however, have oval mitochondria with prominent cristae [195,210]. 
The dynamic process of mitochondrial fission and fusion are tightly regulated and is 
usually balanced to maintain a healthy mitochondrial population. During fission, 
mitochondrial fission factor (MFF) recruits dynamin-related protein 1 (DRP1) from the 
cytosol to constrict the mitochondrial tubules. Chemical inhibition or genetic ablation of 
Drp1 is sufficient to induce mitochondrial remodelling and enhance fusion, which is also 
as seen in iPSCs where it results in blocking reprogramming [213]. Conversely, 
mitochondrial transmembrane GTPases mitofusion-1 and 2 (MFN1 and MFN2, 
respectively) enhance fusion of the outer mitochondrial membrane while optic atrophy 1 
(OPA1) augments the process on the inner mitochondrial membrane and cristae folds. It is 
important to note that MFN1, 2 and OPA1 are all required for viable embryonic 
development [214,215], while differentiation requires Ca2+ signaling facilitated by MFN2, 
which tethers the mitochondria to the endoplasmic reticulum [216]. Overall, mitochondrial 
structure is proxy for its activity, but despite its immature structure in pluripotent stem 
cells, it still possesses the ability to modulate metabolism and thus play a pivotal role 
instructing lineage-specific decisions.  
1.4.3 ROS, NADPH oxidases and development 
ROS can have positive and negative consequences on development. The mitochondria and 
OXPHOS are major sources of ROS, which are typically classified as by-products of the 
incomplete reduction of oxygen from metabolic processes. There are various forms of ROS 
such as superoxide anion (O2−), hydrogen peroxide (H2O2) and hydroxyl radical (HO•). 
When concentrations are above physiological levels, ROS puts the cell in a state of 
oxidative stress [217]. However, at physiological levels, ROS act as a signaling molecule 
[218]. In mouse embryos, H2O2 levels increase during the first cleavage, and this continues 
to hatching [219], but culturing embryos under exogenous H2O2, exceeding normal levels, 
impacts their development and results in embryo arrest [220]. In fact, ES cells cultured for 
short periods in 150μM H2O2 undergo a transient G2/M cell cycle arrest but recover due to 
the upregulation of scavenging machinery to combat oxidative stress [221]. However, long-
term exposure caused growth arrest and apoptosis due to an exhaustion of the antioxidant 
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defense system. Pluripotency markers, including Pou5f1, Nanog, and Sox2, are 
downregulated in ROS-treated ES cells, triggering the upregulation of mesoderm and 
endoderm markers [222] that can be attenuated when antioxidants are supplemented to the 
culture media. Results showing the exposure to ROS impacts pluripotency and chronic 
exposure to hypoxic conditions can induce apoptosis [223] underscore the importance of 
tightly regulating ROS levels to ensure proper embryonic development. 
In addition to mitochondrial ROS and its role in physiological processes, cells modulate 
and fine-tune oxidative bursts involving ROS released by the NAPDH oxidase (NOX) 
family of membrane-associated proteins. Activity and amount of ROS released by NOX is 
constitutively active or regulated by cytosolic factors including calcium ions [224]. 
Regulation dictates what form of ROS is produced, but in general the NADPH-dependent 
reduction of oxygen forms O2−, which can be converted by other enzymes into H2O2 [225]. 
In humans seven NOX proteins are present, NOX1-5, DUOX1 and 2; mice lack a NOX5 
homologue [226]. Different NOX isoforms are expressed in specific subcellular 
compartments thereby leading to compartmentalized redox signaling: NOX1-5 are tethered 
to the plasma membrane, NOX4 is the only isoform present in the mitochondria, NOX2, 
4, and 5 are ER-specific, and NOX4 and 5 are tethered to the nuclear membrane. To be 
functional, various combinations of these subunits including p22phox, p47phox, NCF2 
(p67phox), p40phox, NOXO1, NOXA1 and RAC 1/2, must assemble for the NOX complex 
to generate ROS. Although the exception is NOX4, which only requires p22phox to make it 
the only constitutively active isoform, the question remains as to what NOX is responsible 
and how does ROS influence differentiation?  
Nox gene expression in ES cells is generally low relative to various tissues, yet significant 
ROS levels generated by these NOXs were detected [227]. Interestingly, pan-NOX 
inhibitors diphenyleneiodonium (DPI) and apocynin impaired stem cell proliferation with 
apocynin reducing NANOG levels through PI3K/AKT inhibition and the activation of the 
canonical WNT/b-catenin signaling. However, DPI enhanced both PI3K/AKT and MAPK 
signaling with no effect on WNT/b-catenin signaling. In favour of differentiation, 
embryoid bodies derived from ES cells were found to express high levels of p67phox, a 
cytosolic activator of NOX2, and a significant amount of intracellular ROS was detected 
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[228]. Furthermore, directed differentiation of ES cells towards cardiomyocytes requires 
NOX2 [229]. Similarly, F9 cells treated with H2O2 induced differentiation in the absence 
of RA, and when F9 cells were treated with RA and DPI this differentiation was blocked 
[230]. Together, these findings highlight the role ROS generated from these enzymes play 





1.5 « Hypothesis and Study Aims » 
Broadly, changes in metabolism precede fate commitment and are active in dictating fate. 
In this thesis, I used mouse non-stem cell (F9 cells) and stem cell (ES and XEN cells) 
models to showcase their ability to recapitulate and shed light on many aspects of in vivo 
development. Initially, I hypothesized that undifferentiated F9 cells have a distinct NOX1/4 
expression profile and metabolic phenotype when compared to their differentiated XEN-
like cells. Furthermore, I employed the ES-XEN stem cell model to decipher the metabolic 
changes between the two populations. This research investigates the role metabolism, and 
its by-products play in differentiation towards the XEN lineage through the following 
objectives:  
Chapter 2: Identify a transcription factor that regulates Nox1 and Nox4 expression and 
determine if the activity of these two enzymes is necessary and/or sufficient for F9 cell 
differentiation. 
 Key finding: ROS generated by NOX1 and NOX4, which are regulated by the 
GATA6 transcription factor, is necessary but not sufficient for F9 cell differentiation 
towards XEN-like lineage. 
Chapter 3: Characterize the metabolic profile of differentiated F9 cells and assess if 
metabolism can influence cell fate. In addition, comment on whether cell passage 
influences metabolism and cell fate. 
 Key finding: Differentiated F9 cells exhibit a reliance on glycolytic metabolism, 
and despite having structurally mature mitochondria this is largely due to disruption in ETC 
complex II components. Extensive passaging altered metabolic profile of F9 cells without 
influencing differentiation potential. 
Chapter 4: Determine the bioenergetic profile of embryo-derived XEN cells and elucidate 
the role of lactate in XEN differentiation in vitro. 
 Key findings Feeder-free XEN cells maintain high lactate levels by increased 
LDHA activity and re-routing pyruvate away from the mitochondria. Exogenous lactate 
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supplementation or promoting intracellular lactate accumulation enhances XEN 
differentiation in vitro. 
Overall, my results highlight how ROS and metabolism contribute to XEN differentiation 
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2 « NOX1 and NOX4 are required for the differentiation of 





2.1 « Introduction » 
Mouse primitive endoderm formation can be recapitulated in vitro using F9 
teratocarcinoma cells, which are chemically differentiated to form extraembryonic 
endoderm (XEN)-like cells when treated with retinoic acid (RA) [1] or to parietal 
endoderm (PE)-like cells when treated with RA and cAMP analog [2]. F9 cell 
differentiation is accompanied by the appearance of molecular markers, and morphological 
changes, many resulting from the activation of the canonical WNT/β-catenin pathway [1]. 
When WNT is absent, a destruction complex serves to phosphorylate β-catenin marking it 
for ubiquitination and proteasomal degradation. When present, WNT binds to a Frizzled 
receptor causing Dishevelled (DVL) to move towards the plasma membrane, where it 
recruits AXIN out of the destruction complex making it non-functional and allowing β-
catenin to accumulate and translocate to the nucleus where it binds to and activates the T-
cell-factors-Lymphoid enhancer factors (TCF-LEF) family of transcription factors. We 
previously reported that differentiation is also accompanied by a burst of reactive oxygen 
species (ROS), which is necessary as F9 cells treated with antioxidants or when treated 
with a non-specific NADPH oxidase inhibitor failed to differentiate [3]. H2O2 treatment 
alone induces XEN-like differentiation indicates that ROS are sufficient to initiate this 
process [3]. To explore this further, we recently reported that DVL in undifferentiated F9 
cells associates with nucleoredoxin (NRX) a redox sensitive protein that scavenges ROS, 
and is known to play a role in differentiation [4]. This association and regulation of the 
WNT/β-catenin pathway occurs in other systems [5-8], and we propose that this inhibition 
prevents aberrant canonical Wnt signaling when WNT is absent as DVL in this state cannot 
recruit AXIN away from a destruction complex. Thus, in the presence of ROS, NRX 
dissociates from DVL and the Wnt pathway is primed awaiting the ligand. 
The source of the ROS when F9 cells are treated with RA was investigated and the 
candidates identified are members of the NADPH oxidase (NOX) family, which are 
sources of superoxide anions and H2O2 [9]. In F9 cells Nox1-4 and Duox2 are upregulated 
following RA treatment [3]. Duox1 is not RA-responsive and may not be involved in XEN-
like differentiation. Nox1 and Nox4 are upregulated to the greatest extent following RA 
treatment and given the previous reports suggesting a link differentiation, we specifically 
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selected NOX1 and NOX4 to interrogate as the candidates involved in the ROS production 
during RA-induced differentiation in F9 cells.  
To address that the activity of NOX1 and/or NOX4 is/are responsible for producing the 
ROS that is necessary and sufficient to induce F9 cells to differentiate, we first tested and 
found Nox1/4 genes are under the control of GATA6, the master regulator of endoderm 
differentiation [10]. Inhibiting all NOX activity, or specifically inhibiting NOX1 blocked 
differentiation, and knocking down Nox1 or Nox4 expression using an siRNA approach 
complemented the chemical inhibitor data. Confident from these studies that both NOX 
proteins were necessary for differentiation, we expected that their overexpression would 
induce XEN-like differentiation. However, despite the overexpression of each having 
increased ROS levels, no significant difference in β-catenin-dependent TCF activity 
relative to controls was seen and neither would induce XEN-like differentiation. Together, 
these results indicate that RA-induced differentiation of F9 cells requires a coordinate 





2.2 « Materials and Methods » 
2.2.1 Cell culture conditions and transfections 
Mouse teratocarcinoma F9 cells (ATCC) were cultured in Dulbecco’s modified Eagles 
medium (Lonza) supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin-
streptomycin (Lonza) and incubated at 37°C and 5% CO2. Cells were treated with 10−7 M 
retinoic acid (RA all-trans; Sigma Aldrich) or dimethyl sulfoxide (DMSO; Caledon) as a 
negative control. Cells were co-treated with 1μM VAS2870 (Sigma) and RA 24 hours after 
seeding and grown for 3 days or co-treated with 250nM ML171 (Tocris) and RA and grown 
for 4 days as described above. F9 cells were reverse transfected using Lipofectamine 2000 
(Thermo Fisher Scientific). Freshly passaged cells were added to a 35mm dish already 
containing a total of 4μg of DNA plasmid. Culture media was replenished 6–8h post-
transfection and transfected cells were selected using antibiotics. 
2.2.2 Plasmids 
The following plasmids were used: pCMV-Gata6 (Provided by Dr. E. E. Morrisey, 
University of Pennsylvania); pcDNA-mNox4 (Gift from Dr. M. Jaconi, University of 
Geneva), pcDNA3.1-mNox1 (Addgene #58340), pRL-TK (Gift from Dr. R. DeKoter, 
University of Western Ontario), piLenti-siRNA-GFP against Nox1 and Nox4 (abm; Table 
2). Plasmids were transiently expressed and are under a constitutively active promoter. 
Table 2: siRNA sequences against mouse Nox1 and Nox4 
Target Sequence (5’ to 3’) 
piLenti-siRNA-GFP-Nox1 #1 CTATTTAACTTCGAACGCTACAGAAGAAG 
piLenti-siRNA-GFP-Nox1 #2 TGCTTCCATCTTGAAATCTATCTGGTACA 
piLenti-siRNA-GFP-Nox4 #1 ACATTTGGTGTCCACTTTAAAGTAGTAGG 
piLenti-siRNA-GFP-Nox4 #2 TCCAGTGGTTTGCAGATTTACTCTGTGTG 
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2.2.3 Immunoblot analysis 
Protein lysates were collected in RIPA buffer containing 150mM sodium chloride, 1.0% 
Triton X-100, 0.5% deoxycholate, 0.1% SDS and 50mM Tris pH 8.0. Protein 
concentrations were determined using the DC™ Protein Assay (Bio-Rad), and 20–50μg of 
protein lysate was mixed 2:1 with 3X SDS loading buffer containing 10% β-
mercaptoethanol and separated on 10% polyacrylamide gels by electrophoresis for 2h with 
100V at 4°C. Following electrophoresis, the proteins were wet-transferred 
electrophoretically to Immunoblot PVDF membrane (Bio-Rad) for 16 h with 20V at 4°C 
using a Tris-glycine transfer buffer containing 20% methanol. Membranes were incubated 
in Tris buffered saline with 0.1% Tween-20 (TBS-T) containing 10% w/v skim milk 
powder for 1h shaking at room temperature, then incubated with primary antibody 
overnight at 4°C. Following 3 washes 5 min each in TBS-T, membranes were incubated 
with secondary antibody for 2 h at room temperature, followed by 3 washes for 10 min 
each in TBS-T. SuperSignal West Pico Chemiluminescent Detection Kit (Thermo Fisher 
Scientific) was used to detect the presence of secondary antibodies conjugated to 
horseradish peroxidase (HRP). Signals were captured using a Molecular Imager Gel Doc 
XR system (Bio-Rad) with Quantity One Software. The primary antibodies used were 
directed against KERATIN-8 (1:10; 55 kDa, Developmental Studies Hybridoma Bank), 
OCT4 (1:1000; 45 kDa, Cell Signaling Technology), DAB2 (1:10000; 96 kDa, BD 
Transduction Laboratories), NOX1 (1:10000; 65 kDa, Thermo Fisher Scientific), NOX4 
(1:10000; 67 kDa, Novus Biologicals) and β-ACTIN (1:10000; 43 kDa, Santa Cruz; β-
ACTIN levels do not change significantly between cell types or treatments.) dissolved in 
3% Bovine Serum Albumin w/v in TBS-T. Secondary anti-rat (1:1000), anti-mouse 
(1:1000) and anti-rabbit (1:1000) antibodies were HRP-conjugated and dissolved in 3% 
skim milk w/v in TBS-T. 
2.2.4 Quantitative reverse transcription polymerase chain reaction 
Total RNA from treated and/or transfected cells was isolated and collected using the 
RNeasy Mini Kit (Qiagen). RNA was reverse transcribed into first strand cDNA using the 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and the 
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manufacturer's recommendations. The CFX Connect Real-Time PCR Detection System 
(Bio-Rad) was used for qRT-PCR analysis. Each reaction contained 500nM of each primer, 
SensiFAST SYBR Mix (FroggaBio), and 1μL of cDNA. Primers were designed to Gata6, 
Dab2, Nox1, Nox4 and L14 (Table 3). Analysis of gene expression was determined using 
the comparative cycle threshold method. Gene expression was normalized to the 
constitutively expressed L14 gene and relative values were normalized by comparing 
treatments to DMSO-treated and/or control plasmid transfected control cells to determine 
fold change. L14 expression does not change significantly between cell types or treatments. 
2.2.5 TCF reporter assay 
Cells were transfected with pGL3-BARL and pRL-TK (transfection control) and then 
treated with DMSO (vehicle control), RA, or co-transfected with Nox1 or Nox4 plasmids 
in equal amounts of DNA. Protein lysates were collected 3 days post-treatment or post-
transfection using the Dual-Glo Luciferase Assay System and the manufacturer's 
recommendations (Promega). Luciferase expression was quantified using the GloMax 
Multi Detection System (Promega). Values were presented as relative luminescence 
derived from the quotient of firefly luminescence (pGL3-BARL) and Renilla luminescence 
(pRL-TK). 
2.2.6 ROS detection 
Intracellular ROS was detected using both an Amplex Red Assay and CM-H2DCFDA 
(Thermo Fisher Scientific). Briefly, Amplex Red was prepared in DMSO, and cells were 
treated following manufacturer’s instructions with slight modifications. Following 
treatment or transfection, cells were detached and resuspended in 100μM Amplex Red in 
measurement media buffer (120mM KCl, 5mM KH2PO4, 5mM EDTA, 10mM HEPES, 
5mM MgCl2 at pH 7.40) supplemented with 40μg/mL Saponin (Sigma) and 0.2units/mL 
HRP (Thermo Fisher Scientific). Immediately after incubation, cells were seeded onto an 
opaque 96-well plate and florescence was measured at Ex/Em of 530/590nm using the 
GloMax Multi Detection System (Promega). Values were normalized to protein 
concentration. For CM-H2DCFDA staining cells following treatment with DMSO or RA 
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were incubated in Hank’s Balanced Salt Solution for 15 min at 37°C and 5% CO2 with 
2μM CM-H2DCFDA dissolved in DMSO and 10μg/ml Hoechst 33342 (Thermo Fisher 
Scientific). Immediately after incubation, cells were rinsed twice with PBS and images 
were captured using a Zeiss Axio Observer A1 inverted microscope with a QImaging 
Retiga CCD. 
Table 3: Primer sequences for mouse qRT-PCR target genes 
Target Forward sequence (5’ to 3’) Reverse sequence (5’ to 3’) 
Gata6 ATGGCGTAGAAATGCTGAGG TGAGGTGGTCGCTTGTGTAG 
Dab2 GGAGCATGTAGACCATGATG AAAGGATTTCCGAAAGGGCT 
Nox1 AATGCCCAGGATCGAGGT GATGGAAGCAAAGGGAGTGA 
Nox4 GATCACAGAAGGTCCCTAGCA GTTGAGGGCATTCACCAAGT 
L14 GGGAGAGGTGGCCTCGGACGC GGCTGGCTTTCACTCAAAGGCC 
2.2.7 MTT assay 
F9 cells were cultured and treated with DMSO, RA, VAS2870 or ML171 for 4 days 
followed by incubation in MTT reagent (Sigma) for 2–4 hours at 37°C and 5% CO2. Media 
was removed and DMSO was added to solubilize crystals, and then plates were incubated 
overnight in the dark. Absorbance values were measured at 570nm with a reference 
wavelength at 650nm using the GloMax®-Multi Detection System (Promega). 
2.2.8 Statistical analysis  
Data from qRT-PCR, densitometric analysis of immunoblots and Luciferase assays were 
gathered format least three independent biological replicates. qRT-PCRs were run in 
technical duplicates. Comparisons of data between control and experimental groups were 
performed using a one-way ANOVA with Tukey’s honest significant difference (HSD) 
post-hoc test or a Student’s t-Test (SPSS Statistics for Windows Version 19.0, IBM Corp. 
Released 2010, Armonk, NY). Student’s t-Test was used for statistical analysis of data 
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when comparing control to only one experimental data set and (*) was used to denote 
significant difference. All other data were analyzed using a one-way ANOVA followed by 
Tukey’s HSD test and letters were used to indicate significant differences. P-values were 
considered statistically significant at the 0.05 level. Statistical data are presented as the 





2.3 « Results » 
2.3.1 RA increases NOX1 and NOX4 levels and ROS production 
F9 cells treated with RA for 4 days showed a significant increase (P < 0.05) in the 
expression of Nox1 (Figure 2-1A) and Nox4 (Figure 2-1B), as we have shown previously 
[3]. Furthermore, NOX1 and NOX4 protein levels also increased after RA treatment 
(Figure 2-1C), however, the levels of accessory subunits required for NOX protein 
function, including NOXA1, NOXO1 and p22PHOX (Figure 2-1D), or the transcripts 
encoding Rac1 (Figure 2-1E), did not appear to change during differentiation. Thus, the 
subunits to generate functional NOX1 and NOX4 were present in undifferentiated F9 cells. 
More importantly, elevated ROS production accompanying differentiation was detected 
visually by CM-H2DCFDA (Figure 2-1F), and the significant increase in levels were 
validated quantitatively using Amplex Red (Figure 2-1G). When F9 cells were 
differentiated towards a PE-like lineage, Nox1 (Figure 2-2A) and Nox4 (Figure 2-2B) 
transcript levels decreased significantly (P < 0.05) when compared to DMSO- and RA-
treated F9 cells. It should be noted, however, that a significant oxidative state (P < 0.05; 
Figure 2-2C) was maintained, thus suggesting another potential source of ROS, 



















































































































Figure 2-1: RA increases NOX1 and NOX4 levels and ROS production.  
Total RNA and protein were harvested from F9 cells treated with either DMSO or 
RA for 4 days. (A) Nox1 and (B) Nox4 expression following DMSO or RA treatment. 
(C) NOX1 and NOX4 protein levels following DMSO and RA treatment. (D) Protein 
levels of NADPH oxidase complex accessory subunits NOXA1, NOXO1, and 
p22Phox following DMSO and RA treatment. (E) Rac1 expression following DMSO 
or RA treatment. (F) ROS detection using CM-H2DCFDA or (G) Amplex Red in F9 
cells treated with either DMSO or RA. β-ACTIN was used as a loading control. A 
total of 3-5 independent experiments were analyzed and results presented as mean ± 




























































































Figure 2-2: F9 cells show reduction in Nox1 and Nox4 expression yet maintain 
high oxidative state at PE. 
Total RNA was collected from F9 cells induced to differentiate into XEN-like and 
PE-like cells. Expression of Nox1 (A) and Nox4 (B) following DMSO, RA, and RA 
with db-cAMP treatment. (C) Oxidative state of F9 cells following treatment with 
DMSO, RA, RA with db-cAMP. A total of 4 independent experiments were 
analyzed and results are presented as mean ± SEM. Letters denote groups of 
significance (P < 0.05) tested by a One-Way ANOVA followed by a Tukey’s test. 
 
 60 
2.3.2 Gata6 induction results in increased NOX1 and NOX4 levels  
Gata6, a master regulator of PrE formation, is significantly upregulated (P < 0.05) in F9 
cells treated with RA (Figure 2-3A). This evidence, together with the presence of GATA-
binding sites in the Nox1 promoter [11], and that GATA6 is responsible for increased Nox1 
transcription in Caco-2 cells [12] led us to propose that GATA6 might be responsible for 
the upregulation of Nox1 and Nox4 in F9 cells. To address this, we overexpressed Gata6 
and then analyzed Nox1 and Nox4 expression and protein levels using qRT-PCR and 
immunoblot analysis, respectively. When Gata6 was overexpressed alone (Figure 2-3B), 
it induced XEN-like differentiation [10], as evident by the increase in the differentiation 
markers DAB2 and KERATIN-8, and the decrease in the pluripotency marker OCT4 
(Figure 2-3C). Gata6 overexpression also induced a significant increase (P < 0.05) in Nox1 
(Figure 2-3D) and Nox4 (Figure 2-3E) expression. These changes were also associated with 
an apparent increase in the levels of NOX1 and NOX4 protein (Figure 2-3F), which were 
comparable to those seen in RA-treated F9 cells. Together, results indicate that changes in 
NOX1 and NOX4 levels accompany F9 cell differentiation and would suggest that the 
increase in ROS is due in part to these changes. Thus, studies were conducted to determine 






































































































































Figure 2-3: Gata6 induction results in increased NOX1 and NOX4 levels.  
Total RNA and protein were collected from F9 cells treated with DMSO or RA or 
transfected with pcDNA3.1-EV (EV) and treated with either DMSO or RA or transfected 
with pcDNA3.1-Gata6 (Gata6) and cultured 4 days. (A) Gata6 expression of F9 cells 
treated with DMSO or RA. (B) Gata6 expression of F9 cells transfected with EV or 
Gata6. (C) Immunoblot analysis for DAB2, KERATIN-8 and OCT4 in F9 cells 
transfected with EV and treated with DMSO or RA or F9 cells ectopically expressing 
Gata6. (D) Nox1 and (E) Nox4 expression in F9 cells transfected with EV and treated 
with DMSO or RA, or F9 cells ectopically expressing Gata6. (F) Immunoblot analysis 
for NOX1 and NOX4 in F9 cells transfected with EV and treated with DMSO or RA, or 
F9 cells ectopically expressing Gata6. β-ACTIN was used as a loading control. A total 
of 3 independent experiments were analyzed and results are presented as mean ± SEM. 
* denotes significance (P < 0.05) tested by a Student’s t-Test, whereas letters denote 




2.3.3 Pan-NOX inhibition blocks RA-mediated differentiation 
Our previous study revealed that Diphenyleneiodonium chloride (DPI), an inhibitor of 
flavoenzymes that produce ROS attenuates RA-induced XEN-like differentiation [3]. DPI 
is used frequently to inhibit ROS production, but since it acts on numerous 
oxidoreductases, including the NOX proteins [13] the source of the ROS may not be 
completely NOX-dependent. To test the hypothesis that the activity of the NOX proteins 
is necessary for XEN-like differentiation, F9 cells were treated with NOX inhibitors.  
First, the pan-NOX inhibitor, VAS2870 [14,15] was used to determine specifically if 
members of the NOX family were necessary for F9 cells to differentiate to XEN-like cells. 
VAS2870 inhibits NOX1, NOX2 [15] and NOX4 [14], and although it can inhibit all NOX 
isoforms it does not serve as an antioxidant because it has no O2- scavenging effect [14]. 
VAS2870 treatment showed no significant effect on cell viability relative to the DMSO 
control (Figure 2-4A), but it did cause a significant reduction (P < 0.05) in the amount of 
ROS produced in cells co-treated with RA (Figure 2-4B). Cells treated with DMSO-, RA-, 
VAS2870-, or co-treated with VAS2870 and RA were examined using qRT-PCR for Dab2 
(Figure 2-4C), and immunoblot analysis for DAB2, KERATIN-8 and OCT4 (Figure 2-
4D). Results show that Dab2 expression was not significantly different between DMSO 
and VAS2870. The expression of Dab2 in F9 cells treated with RA alone was, as expected, 
significantly higher (P < 0.001) from the DMSO treatment, but surprisingly dramatically 
reduced in cells treated with RA and VAS2870 (Figure 2-4C). Immunoblot analysis 
showed comparable results with elevated DAB2 levels following RA treatment alone 
(Figure 2-4D). A similar increase was seen with the KERATIN-8 marker, while OCT4 
levels decreased with RA treatment. The OCT4 signal, however, remained elevated in 
VAS2870 and RA-treated cells, and was comparable to that seen in DMSO-treated cells 
(Figure 2-4D). Thus, inhibiting NOX activity attenuates RA-mediated differentiation, 





2.3.4 NOX1-specefic inhibition attenuates RA-induced 
differentiation 
F9 cells were treated with 250nM of ML171, the IC50 of this NOX1-specific inhibitor [16]. 
ML171 has no ROS scavenging effects [16], and at this concentration it did not influence 
F9 cell viability (Figure 2-4A). Co-treatment with RA, however, showed significantly 
lower ROS levels than those seen in RA-treated F9 cells alone (Figure 2-4B). qRT-PCR 
analysis revealed that Dab2 expression in DMSO- and ML171-treated F9 cells were not 
significantly different from each other, but both were significantly different (P < 0.001) 
from that in RA-treated F9 cells, and F9 cells co-treated with RA and ML171 (P < 0.05) 
(Figure 2-4E). Since Dab2 expression in cells co-treated with RA and ML171 was 
significantly lower (P < 0.05) than that in RA-treated F9 cells (Figure 2-4E), but not as low 
as that in cells co-treated with RA and VAS2870 (Figure 2-4C) this suggest that inhibiting 
NOX1 alone was not sufficient in completely attenuating XEN-like differentiation. 
Immunoblot analysis for DAB2 and KERATIN-8 showed no signals in DMSO- or ML171-
treated F9 cells (Figure 2-4F). F9 cells co-treated with ML171 and RA, however, showed 
DAB2 and KERATIN-8 signals (Figure 2-4F), but they appeared to be of less intensity 
than that seen in the RA alone lane. OCT4 signals were seen in DMSO-, ML171 and RA- 
and ML171-treated F9 cells, but again the intensity appeared reduced in RA-treated F9 
cells with or without ML171 (Figure 2-4F). Since NOX4 was not targeted chemically, as 
there are no known specific inhibitor(s) that do not have ROS scavenging effects or 
additionally target other NOX proteins [16], we can only conclude that NOX proteins are 































































































































Figure 2-4: Chemical inhibition of NOX proteins attenuates RA-mediated 
differentiation of F9 cells.  
(A) MTT cell viability assay of F9 cells treated with DMSO, RA, VAS2870 or ML171. 
(B) F9 cells were treated with DMSO, RA, VAS2870 and RA, or ML171 and RA and 
assayed for ROS production using Amplex Red. (C) Dab2 expression of F9 cells treated 
with DMSO, RA, VAS2870, or VAS2870 and RA. (D) Immunoblot analysis for DAB2, 
KERATIN-8, and OCT4 in F9 cells treated with DMSO, RA, VAS2870, or VAS2870 
and RA. (E) Dab2 expression of F9 cells treated with DMSO, RA, ML171, or ML171 
and RA. (F) Immunoblot analysis for DAB2, KERATIN-8 and OCT4 in F9 cells treated 
with DMSO, RA, ML171, or ML171 and RA. β-ACTIN was used as a loading control. 
A total of 4 independent experiments were analyzed and results are presented as mean 
± SEM. Letters denote groups of significance (P < 0.05) tested by a One-Way ANOVA 
followed by a Tukey’s test. 
 
 67 
2.3.5 Nox1 and Nox4 knockdown decreases ROS production 
To corroborate the chemical inhibitor data, F9 cells were transfected with a siRNA vector 
to knockdown Nox1, Nox4 expression or a scrambled siRNA and treated with DMSO or 
RA as negative and positive controls, respectively. Since there is a significant increase (P 
< 0.05) in Nox1/4 expression after RA treatment (Figure 2-1A, B), F9 cells were treated 
with RA and the siRNA knockdown efficiency was compared to that seen with the RA-
treated scrambled siRNA control. F9 cells containing Nox1 (Figure 2-5A) and Nox4 (Figure 
2-5C) siRNAs showed significantly less expression of the respective Nox genes (P < 0.05) 
when compared to the RA-treated scrambled control. The levels of NOX1 (Figure 2-5B) 
and NOX4 (Figure 2-5D) were examined to test if the knockdown effects were seen at the 
protein level. Results show that levels were significantly lower (P < 0.05) in cells 
containing the targeting siRNAs and treated with RA, compared to RA-treated F9 cells 
transfected with the scrambled siRNA. Furthermore, knocking down NOX1 and NOX4 in 
F9 cells treated with RA showed a significant reduction (P < 0.05) in ROS levels compared 
















































































































































































Figure 2-5: Nox1 and Nox4 knockdown reduces ROS production.  
Total RNA was collected from F9 cells transfected with scrambled (scr) si-RNA, si-
Nox1 and/or si-Nox4 siRNA and cultured 4 days with RA treatment. (A) Expression 
of Nox1 and (B) NOX1 protein levels following transfection with scr or si-Nox1 and 
RA treatment. (C) Expression of Nox4 and (D) NOX4 protein levels following 
transfection with scr or si-Nox1 and RA treatment. (E) ROS production detected using 
Amplex Red of F9 cells transfected with scr, si-Nox1, or si-Nox4 and treated with RA. 
β-ACTIN was used as a loading control. A total of 3 independent experiments were 
analyzed and results are presented as mean ± SEM. * denotes significance (P < 0.05) 
tested by a Student’s t-Test, whereas letters denote groups of significance (P < 0.05) 
tested by a One-Way ANOVA followed by a Tukey’s test. 
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2.3.6 Nox1 and Nox4 knockdown attenuates RA-induced 
differentiation 
qRT-PCR and immunoblot analysis were used to determine if the knockdowns would 
affect Dab2 (Figure 2-6A) or levels of DAB2, KERATIN-8, and/or OCT4 protein (Figure 
2-6B-D). Analysis showed that compared to RA treatment, a significant reduction (P < 
0.05) in Dab2 expression (Figure 2-6A) was seen when either Nox1 or Nox4 expression 
was knocked down. Also, there was no significant difference between the individual 
knockdowns compared to that due to the knockdown of both genes together. As expected, 
DAB2 and KERATIN-8 levels were low or not detected in cells transfected with the 
scrambled siRNA and treated with DMSO, however they did increase significantly in cells 
treated with RA (Figure 2-6B, D). Also, it is interesting to note that DAB2 levels in cells 
transfected with the targeted siRNAs and treated with RA were not significantly different 
between those transfected with the scr siRNA and treated with either DMSO or RA. 
However, KERATIN-8 levels were significantly lower in cells transfected with targeted 
siRNAs and treated with RA than RA treated cells transfected with scr siRNA (P < 0.05) 
(Figure 2-6D). OCT4 levels were high in the DMSO-treated scr siRNA control cells, but 
these were significantly reduced (P < 0.05) in F9 cells transfected with either the scr siRNA 
and treated with RA or those transfected with the siRNA targeting vectors and treated with 
RA (Figure 2-6B, C). Together with the inhibitor data, these results would indicate that 


























































































































































































































Figure 2-6: Nox1 and Nox4 knockdown attenuates RA-induced differentiation.  
RNA was collected from F9 cells transfected with scrambled (scr) si-RNA, si-Nox1 
and/or si-Nox4 siRNA and cultured 4 days with RA treatment. (A) Dab2 expression of 
F9 cells transfected with scr, si-Nox1, or si-Nox4 and treated with RA. (B) Immunoblot 
analysis for DAB2, KERATIN-8, and OCT4 in F9 cells transfected with scr, si-Nox1, 
or si-Nox4 and treated with RA. (C) Densitometric analysis for OCT4, and (D) DAB2, 
KERATIN-8 in F9 cells transfected with scr, si-Nox1, or si-Nox4 and treated with RA. 
β-ACTIN was used as a loading control. A total of 3 independent experiments were 
analyzed and results are presented as mean ± SEM. Letters and symbols denote groups 
of significance (P < 0.05) tested by a One-Way ANOVA followed by a Tukey’s test. 
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2.3.7 Overexpressing Nox1 and Nox4 increases ROS production 
Since the inhibitor and genetic knockdown studies attenuated differentiation, and our 
earlier study showing F9 cells treated with H2O2 differentiate into XEN-like cells [3], it 
seemed logical to propose that Nox overexpression should induce F9 cell differentiation. 
Towards that end, F9 cells were transfected with pcDNA3.1-EV and treated with either 
DMSO or RA or transfected with pcDNA3.1-Nox1 or -Nox4. The relative degree of 
overexpression was determined by qRT-PCR, and results showed an approximate 700 and 
1800-fold increase for Nox1 (Figure 2-7A) and Nox4 (Figure 2-7B), respectively. 
Similarly, NOX1 and NOX4 protein levels were higher in F9 cells transfected with the 
respective Nox construct (Figure 2-7C, D). Having established that transfection resulted in 
elevated NOX1 and NOX4 levels, we examined if this would affect ROS levels. For the 
positive control, F9 cells transfected with pcDNA3.1-EV and treated with RA showed a 
significant increase (P < 0.05) in ROS levels over those seen in transfected cells treated 
with DMSO (Figure 2-7E). Note that the levels seen following RA treatment were 
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Figure 2-7: Overexpressing Nox1 and Nox4 increases ROS production.  
Total RNA was collected from F9 cells transfected with an empty vector (EV) control, 
pcDNA3.1-Nox1 or pcDNA3.1-Nox4 and cultured 4 days. (A) Nox1 and (B) Nox4 
expression following transfection of pcDNA3.1-Nox1 or pcDNA3.1-Nox4, 
respectively, and relative to EV transfected cells. (C) NOX1 and (D) NOX4 protein 
levels following transfection of pcDNA3.1-Nox1 or pcDNA3.1-Nox4, respectively, 
relative to EV transfected cells. (E) ROS production using Amplex Red in F9 cells 
transfected with EV and treated with DMSO or RA or transfected with pcDNA3.1-Nox1 
or pcDNA3.1-Nox4. β-ACTIN was used as a loading control. A total of 3 independent 
experiments were analyzed and results are presented as mean ± SEM. * denotes 
significance (P < 0.05) tested by a Student’s t-Test, whereas letters denote groups of 
significance (P < 0.05) tested by a One-Way ANOVA followed by a Tukey’s test. 
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2.3.8 Nox overexpression activates canonical Wnt signaling, but 
does not promote differentiation 
The overexpression results and those from earlier studies [3,4] suggested that the increased 
levels in ROS due to ectopic Nox1 or Nox4 expression would activate canonical WNT/β-
catenin signaling. To test this F9 cells were co-transfected with Nox1 or Nox4, and the 
firefly luciferase pGL3-BARL reporter that is used as readout for active WNT/β-catenin 
signaling [17]. All cells were transfected with the Renilla luciferase construct, TK-RL to 
normalize for luciferase expression. RA-treated F9 cells transfected with pcDNA3.1-EV 
showed a significant increase (P < 0.05) in TCF activity compared to the DMSO control 
(Figure 2-8A). F9 cells overexpressing Nox1 or Nox4 also showed increased TCF activity, 
however, this increase was less than that seen in RA-treated F9 cells and was not significant 
from either RA or DMSO treatments (Figure 2-8A). Nevertheless, F9 cells overexpressing 
Nox1 or Nox4 were analyzed for XEN-like differentiation, and as expected Dab2 
expression relative to the L14 loading control was significantly higher (P < 0.001) in RA-
treated F9 cells than that in DMSO treated cells (Figure 2-8B, C). Dab2 expression 
resulting from either the overexpression of Nox1 (Figure 2-8B) or Nox4 (Figure 2-8C) was 
not significantly different from that in DMSO-treated F9 cells, suggesting that 
differentiation had not occurred. Similarly, DAB2 protein was only present in RA-treated 
cells, and this evidence of differentiation was seen in the corresponding increase in 
KERATIN-8 and concomitant decrease in OCT4 levels (Figure 2-8D). KERATIN-8 
signals were not seen in DMSO-treated, Nox1-, Nox4-, or Nox1 and Nox4-overexpressing 
cells, and the appearance of OCT4 in the same samples was indicative that cells had not 
differentiated because of Nox1 and/or Nox4 overexpression (Figure 2-8D). Thus, even 
though overexpressing Nox1 or Nox4 in F9 cells increased ROS levels, there was no 
significant activation of Wnt/β-catenin signaling or XEN-like differentiation. Therefore, 
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Figure 2-8: Nox overexpression activates canonical Wnt signaling but does not 
promote differentiation.  
(A) Dual-luciferase assay of TCF activity in F9 cells transfected with EV and treated 
with DMSO or RA or transfected with pcDNA3.1-Nox1 or pcDNA3.1-Nox4. Dab2 
expression in F9 cells transfected with EV and treated with DMSO or RA or transfected 
with (B) pcDNA3.1-Nox1 or (C) pcDNA3.1-Nox4. (D) Immunoblot analysis for DAB2, 
KERATIN-8, and OCT4 in F9 cells transfected with EV and treated with DMSO or RA, 
or transfected with pcDNA3.1-Nox1, pcDNA3.1-Nox4 or both vectors. β-ACTIN was 
used as a loading control. A total of 3 independent experiments were analyzed and 
results are presented as mean ± SEM. Letters denote groups of significance (P < 0.05) 
tested by a One-Way ANOVA followed by a Tukey’s test. 
 
 77 
2.4 « Discussion » 
ROS, which are by-products of metabolic processes produced through the incomplete 
reduction of oxygen, create oxidative stress on cells, and damage nucleic acids, proteins, 
and lipids. Although this damage is linked to age-related and other human disease 
pathogenesis, recent studies now show cells benefitting from ROS as a second messenger 
to modulate biological processes such as differentiation, apoptosis, and proliferation 
[18,19]. F9 cells are induced to form XEN-like cells when treated with RA, an in vitro 
process that mimics a very early event in mouse embryogenesis. Differentiation is 
accompanied by numerous changes in gene expression and morphology and requiring 
several signaling pathways. One of these pathways involves canonical WNT/β-catenin 
signaling [1], where Wnt6 is induced by GATA6 [10] a master regulator of PrE formation. 
Regulation of this WNT pathway occurs in a redox-regulated manner [3] involving NRX 
and DVL, the latter serving as a lynchpin in the three major WNT signaling pathways [4]. 
We have shown previously that cytosolic ROS plays a role in F9 cell differentiation [3]. 
ROS impact positively on the canonical WNT/β-catenin signaling pathway, and the Nox 
genes that are upregulated in response to RA were identified as candidates responsible for 
this cytosolic ROS [3]. 
The expression profiles of the six mouse Nox genes led us to interrogate Nox1 and Nox4, 
which were the most upregulated in differentiated F9 cells [3]. In addition to RA (Figure 
2-1A-D), both genes are upregulated, and the level of the corresponding proteins increase 
in response to GATA6 (Figure 2-3D-F). Previous studies provide evidence for a link 
between GATA6 and Nox genes, specifically Nox1, which is activated directly by GATA6 
[11,12]. NOX1 impact on WNT signaling occurs in colonic and intestinal epithelial cells 
[8,20], and it is known to post-transcriptionally increase the levels of Keratin-8 [21], a 
cytokeratin encoded by transcripts that increase during RA-induced F9 cell differentiation 
[22]. Furthermore, NOX1 and NOX4 activate the p38 MAPK pathway in mouse and 
human cells [23,24], which is also required to inhibit GSK-3β thereby maintaining WNT 
in the on-state during XEN-like differentiation [25]. Evidence for NOX4 interacting with 
WNT signaling or regulated by GATA transcription factors is not as compelling as NOX1. 
However, it is interesting to note a study showing the opposite scenario exists in 
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cardiomyocytes, where NOX4 increases Gata4 expression [26]. Other reports have linked 
NOX4 to cell proliferation, cytoskeletal reorganization, migration and differentiation [27-
30], which incidentally are processes that F9 cells participate in during differentiation [31]. 
Having identified that NOX1 and NOX4 were under the regulation of GATA6, we next 
used chemical inhibitors to test whether the activity of both NOX proteins was required for 
differentiation. A previous study from our lab using the non-specific flavoenzyme inhibitor 
DPI, demonstrated the necessity for ROS in the differentiation of F9 cells [3]. Since DPI 
acts on other non-NOX flavoenzymes [13], we refined the approach and used a pan-NOX 
and NOX1-specific inhibitor to test their effects on differentiation (Figure 2-4). Both 
inhibitors affected differentiation at the gene and protein levels, but VAS2870, the pan-
NOX inhibitor was more potent than ML171, the selective inhibitor of NOX1 activity 
(Figure 2-4). Although there could be many reasons to explain this, the fact that all the 
NOX proteins were being inhibited by VAS2870 would suggest that multiple NOX 
proteins contribute to the ROS required for differentiation. This argument would be tested 
later as these chemical inhibitor studies proved informative but required a genetic approach 
to corroborate the data. Mouse knockout models exist for all 6 Nox genes [14,32,33], but 
disrupting any one of them individually or in combination does not appear to have obvious 
effects in embryos. Therefore, an alternative strategy was to use siRNAs, which have had 
some success in knocking down the expression of specific Nox genes [14]. This approach 
was used to knockdown Nox1 and/or Nox4 gene expression, and it resulted in reduced 
expression and protein levels of NOX1 and NOX4 (Figure 2-5A-D). Knockdown led to the 
attenuation of differentiation, as evident by the decrease in the markers of differentiation, 
and the maintenance of pluripotency as noted by the persistence of the OCT4 signal (Figure 
2-6A-D). Together with the inhibitor results, this data adds support that NOX activity, 
specifically from NOX1 and NOX4, is necessary for XEN-like differentiation. While 
encouraged by these results, the contribution to the differentiation process by the two other 
Nox genes and Duox2 that are upregulated by RA in F9 cells needs to be considered and is 
currently under investigation. 
Although NOX1 and NOX4 are members of the NOX subfamily that require p22phox, the 
former generates primarily superoxide, while the major product of the latter is H2O2 [34]. 
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Nox4 is widely expressed in human, while Nox1 is much more restricted [32]. Nevertheless, 
there is overlap in places where functional redundancy might explain why the in vivo 
knockout models do not show obvious phenotypes. This does not appear to be the case for 
the F9 in vitro cell model as there was a common effect seen when knocking down either 
Nox1 or Nox4. Thus, it is possible that attenuating the activity of one NOX isoform in vitro 
reduces the total amount of ROS required for differentiation, and this cannot be 
compensated by the other members. The overexpression of either Nox1 and/or Nox4 
(Figure 2-7A-D) in F9 cells nevertheless resulted in increased ROS levels (Figure 2-7E), 
and what appeared to be a modest increase in canonical WNT signaling (Figure 2-8A). 
However, these increases were not sufficient to induce differentiation as seen following the 
application of exogenous H2O2 [3]. Although there is much debate centered on the recently 
reported Nox1, Nox2 and Nox4 triple knockout mouse model [33], our data would indicate 
that ROS produced individually by at least two of the NOX isoforms is necessary in the F9 
cell model, suggesting that other sources of ROS such as mitochondrial may be required 
for F9 cell differentiation and must be elucidated (Chapter 3). 
Building from previous studies our model now adds to the signaling hierarchy and crosstalk 
within these networks where RA induces Gata6 expression, which in turn regulates several 
genes including Wnt6 [10], Nox1 and Nox4 (this study). The subsequent increase in ROS 
permits NRX to dissociate from DVL, thereby priming the WNT pathway [4] prior to the 
appearance of the WNT6 ligand that is sufficient to promote XEN-like differentiation [1]. 
WNT6 signaling is attenuated in a negative feedback loop involving Dickkopf-1 [35], and 
this is required for XEN-like cells to complete their differentiation to PE-like cells [36]. 
Given the report showing canonical WNT signaling activates RAC1 and this in turn 
increases RAC1-dependent NOX1 activity that produces the ROS needed to oxidize NRX 
and dissociate it from DVL in order to keep the pathway in the on-state [8], it is tempting 
to speculate that a similar mechanism occurs in F9 cells in response to RA. However, since 
NOX4 is not RAC1-dependent [9], and is required for XEN-like differentiation (this 
study), canonical WNT signaling must be stimulating NOX4 activity in another manner. 
Given that the production of ROS is increased as a direct result of increased NOX4 
expression [37], the possibility exists that increased NOX4 activity is the result of an 
upregulation in the Nox4 gene by active WNT signaling. Towards that end, experiments 
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are underway to test if the Nox genes are WNT target genes or simply downstream in the 
pathway. Whatever the case, that aberrant WNT signaling is prevalent in cancer biology 
[38,39] underpins the importance of better understanding the crosstalk imparted by NOX 
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3 « Metabolic profile and differentiation potential of 





3.1 « Introduction » 
Metabolism provides substrates for energy expenditure [1-3], and can modulate the 
epigenome thereby influencing cell fate [4-6]. Typically, somatic cells rely on oxidative 
phosphorylation (OXPHOS) to generate ATP, while proliferative cancer and stem cells use 
glycolysis [7-11]. ATP requirements in proliferative cells are high and although OXPHOS 
is more efficient in generating ATP, sufficient glucose flux in glycolysis compensates for 
the rate of ATP production [12-14]. This categorization of metabolic profiles is distinct in 
early mammalian embryos [15]. Naïve embryonic stem (ES) cells use glycolysis and 
OXPHOS, whereas primed epiblast stem cells (EpiSCs), having structurally mature 
mitochondria capable of OXPHOS, transition from bivalent metabolism to glycolysis 
[16,17]. Studies show that trophoblast stem cells preferentially use OXPHOS to produce 
ATP [18]. However, the metabolic profile of extraembryonic endoderm (XEN) stem cells, 
which can be recapitulated using F9 cells, remains unknown [19-21]. We reported that F9 
cells require increased levels of cytosolic reactive oxygen species (ROS) to differentiate 
into XEN-like cells [22-24], but the role of the mitochondria, a major source of ROS, has 
not been investigated.  
Mitochondria and metabolism play a key role in the reprogramming of somatic cells to 
induced pluripotent stem cells (iPSCs). These events require a metabolic transition from 
OXPHOS to glycolysis for cells to sustain proliferation and to reset the epigenetic 
landscape [25-27]. The acquisition of pluripotency is not immediate as iPSCs that have 
undergone few passages share a molecular and epigenetic signature reminiscent of their 
somatic counterparts, whereas prolonged passaging resets their profile closer to ES cells 
[28-30]. However, and although not universal [31,32], ES cells passaged extensively 
develop abnormal karyotypes, yet maintain pluripotency and differentiation potential [33]. 
While studies have focused on the metabolic status of stem cells or the effects of passaging 
on their ability to differentiate, an understanding of how the two are linked is limited.  
In this report, we aim to characterize the metabolic profile of differentiated F9 cells and 
assess if metabolism can influence cell fate. In addition, investigate whether cell passage 
influences metabolism and cell fate. To address this, two populations of F9 cells were 
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investigated and results show that early and late passage cells had similar differentiation 
potential, but each have dramatically different metabolic profiles. These differences 
observed were due to changes in the expression and protein levels of pyruvate 
dehydrogenase kinases (PDKs), which regulate the activity of pyruvate dehydrogenase 
(PDH) complex thereby influencing the metabolic profile of cells. Additionally, genes 
encoding mitochondrial fusion proteins were upregulated in early passage F9 cells, while 
relative levels of mitochondrial electron transport chain (ETC) proteins were disrupted in 
late passage cells. Surprisingly, culturing either cell population under their preferred 
metabolic conditions enhanced the exit from pluripotency and promoted XEN-like 
differentiation. More importantly, late passage cells possessed an abnormal karyotype, 
resulting in increased proliferation rates, which were correlated to significant increases in 
the expression of cell cycle regulators.  
First, we demonstrate that early versus late passage F9 cells retain their ability to 
differentiate into XEN-like cells, however, this ability to occur in cells that have different 
metabolic profiles and chromosomal composition. Second, differentiated F9 cells exhibit 
a metabolic profile reliant on glycolytic metabolism. Together our work underpins the 
importance of monitoring the physiology of stem cell populations to ensure their quality as 





3.2 « Material and Methods » 
3.2.1 Cell culturing conditions  
F9 cells (Sigma) were cultured at 37°C and 5% CO2 on 0.1% gelatin coated plates in 
DMEM (Lonza) supplemented with 10% heat inactivated FBS (Thermo Fisher Scientific) 
and 1% penicillin-streptomycin (Thermo Fisher Scientific). All cultures were tested and 
were negative for mycoplasma [34] and cells under 20 passages were classified as being 
early. To induce XEN-like differentiation, cells were treated daily for 72h with 100nM All-
trans retinoic acid (RA; Sigma) or treated daily with 100nM RA and 10mM db-cAMP 
(RDB; Sigma) to induce parietal endoderm-like cells. Cells treated with DMSO served as 
a negative control. 
3.2.2 Generation of PDK1-stable cell lines 
F9 cells were plated as described above and reverse transfected using Lipofectamine 2000 
(Thermo Fisher Scientific). Briefly, 200,000 cells were seeded in 35mm gelatin-coated 
plates already containing 4μg of DNA plasmid. Culture media was replaced 6h post 
transfection and cells were allowed to grow for 24h. Following incubation, media was 
changed, and cells were selected with 2mg/ml G418 (Gemini Bio-Products) for 2 weeks. 
Cells were trypsinized and seeded at low density allowing single colony formation. Single 
clones were selected and propagated for downstream analysis. pcDNA 3.1 plasmid was 
generously provided by Dr. Robert C. Cumming (UWO) and DDK-MYC-
mPDK1 overexpression construct was purchased from Origene. Plasmids were integrated 
randomly in the genome as validated by sequencing and are under a constitutively active 
promoter.  
3.2.3 RNA isolation and quantitative reverse-transcription PCR 
analysis 
Total RNA, isolated at 72h from cells using a RNeasy Mini kit (Qiagen), was reverse 
transcribed into first strand cDNA using the High-Capacity cDNA Reverse Transcription 
kit (Applied Biosystems). Quantitative reverse transcription-PCR (qRT-PCR) reactions, 
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containing 500nM of each primer (Table 4), SensiFAST SYBR Mix (FroggaBio), and 
cDNA, were carried out using a CFX Connect Real-Time PCR Detection System (Bio-
Rad). Results were analyzed using the comparative cycle threshold (2−ΔΔCt) method 
with L14 serving as the internal control. 
 
3.2.4 Immunoblot analysis 
Protein lysates were harvested using RIPA buffer (10mM Tris-HCl pH 8.0, 1 mM EDTA, 
0.5mM EGTA, 1% Triton X−100, 0.1% sodium deoxycholate, 0.1% SDS, and 140mM 
Primer Name Forward sequence Reverse sequence
Ldha TGG CGA CTC CAG TGT GCC TG AGG CAC TGT CCA CCA CCT GCT
Ldhb GGG AAA GTC TCT GGC TGA TGA A CTG TCA CAG AGT AAT CTT TAT CGG C
Thbd GGA GCA CGA ATG AAC CCA GA CTT GCA CAC GAA CGT CCA TC
Oct4 CCC AAT GCC GTG AAG TTG GA GCT TTC ATG TCC TGG GAC TCC T
Gata6 ATG GCG TAG AAA TGC TGA GG TGA GGT GGT CGC TTG TGT AG
Dab2 GGA GCA TGT AGA CCA TGA TG AAA GGA TTT CCG AAA GGG CT
Glut1 CTT CAT TGT GGG CAT GTG CTT C AGG TTC GGC CTT TGG TCT CAG
Glut2 TTCCAGTTCGGCTATGACATCG CTGGTGTGACTGTAAGTGGGG
Glut3 TCATCAATGCACCTGAGACAATC GTCCCTCACTTGGTAGGTCTT
Glut4 CTG TAA CTT CAT TGT CGG CAT GG AGG CAG CTG AGA TCT GGT CAA AC
Glut8 CCC TTC GTG ACT GGC TTT G TGG GTA GGC GAT TTC CGA GAT
Glut9 TTG CTT TAG CTT CCC TGA TGT G GAG AGG TTG TAC CCG TAG AGG
Mt-co1 CAG TCT AAT GCT TAC TCA GC GGG CAG TTA CGA TAA CAT TG
Ndufb8 TGT TGC CGG GGT CAT ATC CTA AGC ATC GGG TAG TCG CCA TA
Sdhb CGA AAG CGA CAT GGC GGT TC GGT CCT GGA GAA ATG CTG ACA C
Pdk1 GAC TGT GAA GAT GAG TGA CCG GGG CGT TTC AAC ACG AGG CCG GG
Pdk2 AGG GGC ACC CAA GTA CAT C TGC CGG AGG AAA GTG AAT GAC
Pdk3 TCC TGG ACT TCG GAA GGG ATA GAA GGG CGG TTC AAC AAG TTA
Pdk4 GGA TTA CTG ACC GCC TCT TTA GTT GCA TTC CGG GAA TTG TCC ATC
Pdp1 ATGCCAGCACCAACTCAACT GGGTGTGTACCTCAGACGATT
Pdp2 CAGCCCTCAAGTGTGGTTCTC CTCTTCCTCGGTTGATGTGTG
Mfn1 CCT ACT GCT CCT TCT AAC CCA AAG GAC GCC AAT CCT GTG A
Mfn2 AGA ACT GGA CCC GGT TAC CA CAC TTC GCT GAT ACC CCT GA
Opa1 TGG AAA ATG GTT CGA GAG TCA G CAT TCC GTC TCT AGG TTA AAG CG
Drp1 CAG GAA TTG TTA CGG TTC CCT AA CCT GAA TTA ACT TGT CCC GTG A
Fis1 AGA GCA CGC AAT TTG AAT ATG CC ATA GTC CCG CTG TTC CTC TTT
Cdkn1a AAG TGT GCC GTT GTC TCT TCG AGT CAA AGT TCC ACC GTT CTC G
Cdkn1b TCA AAC GTG AGA GTG TCT AAC G CCG GGC CGA AGA GAT TTC TG
Ccnd1 GCG TAC CCT GAC ACC AAT CTC CTC CTC TTC GCA CTT CTG CTC
Cdk4 ATG GCT GCC ACT CGA TAT GAA TGC TCC TCC ATT AGG AAC TCT C
Cdk6 GCT TCG TGG CTC TGA AGC GCG TGG TTT CTG TGG GTA CGC CGG
Rb1 TTG GAG TCC GAT TGT ATT ACC GT AGC ACA GGC CAG TAA AGA CAT
Cdkn2a CGC AGG TTC TTG GTC ACT GT TGT TCA CGA AAG CCA GAG CG
Cdkn2c GGG GAC CTA GAG CAA CTT ACT AAA TTG GGA TTA GCA CCT CTG AG
Cdkn2d CTG GAA GAA GTC TGC GTC GG GTC TTG CCA AAG CGG TTC AG
P53 CAC GTA CTC TCC TCC CCT CAA T AAC TGC ACA GGG CAC GTC TT
L14 GGG TGG CCT ACA TTT CCT TCG GAG TAC AGG GTC CAT CCA CTA AA
qRT-PCR primer list for mouse target genes
Table 4: qRT-PCR primer sequences for mouse targets 
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NaCl) supplemented with HALT™ protease cocktail inhibitor (Thermo Fisher Scientific). 
Protein concentrations were determined using a DC™ Protein Assay (Bio-Rad) and 5–
40μg of lysates were prepared in 5X SDS loading buffer (300mM Tris-HCl pH 8.0, 10% 
SDS, 20mM EDTA, 0.1% bromophenol blue, and 50% glycerol) and 10% β-
mercaptoethanol. Proteins were separated on 5–15% polyacrylamide gels for 2h at 100V 
and then transferred onto polyvinylidene difluoride membranes (Bio-Rad) for 2h at 250mA 
and 4°C. Membranes were placed in Tris-buffered saline with 0.1% Tween-20 (TBS-T) 
containing 5% w/v skim milk powder and shaken at room temperature for 30 min. 
Membranes were then incubated overnight at 4°C with a primary antibody (Table 5). After 
extensive washing with TBS-T, membranes were incubated with secondary antibodies 
(Table 5) for 2h at room temperature and signals were detected using a Immobilon Classico 
Western HRP substrate (Milllipore Sigma). Images were collected using a ChemiDoc™ 
Touch Imaging System (Bio-Rad); for densitometric analysis, images were analyzed using 
Image Lab™ (Bio-Rad). 
3.2.5 Karyotype analysis 
Early- and late-passage F9 cells were cultured on 0.1% gelatin-coated coverslips and 
allowed to reach 80% confluency. Cells were treated with 0.2μg/ml colcemid (Cayman 
Chemical) for 2h at 37°C, followed by trypsinization and suspension in pre-warmed 
0.075M KCl solution for 20 mins at 37°C. Cells were fixed in acetic acid-methanol solution 
and then transferred onto pre-chilled glass slides. Chromosomes were stained with 4′,6-
diamidino-2-phenylindole mounting media containing ProLong™ Gold Antifade 
Mountant and examined using an Axio Imager A1 microscope (Carl Zeiss). Thirty 
representative images were taken of each cell and chromosomes were counted manually 
for statistical analysis. 
3.2.6 Detection of mitochondrial ROS and membrane potential  
Mitochondrial ROS and membrane potential were detected using MitoSOX™ Red 
Mitochondrial Superoxide indicator (MitoSOX; Thermo Fisher Scientific) and 
Tetramethylrhodamine, methyl ester perchlorate (TMRM; Thermo Fisher Scientific), 
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respectively. Briefly, cells were seeded onto 0.1% gelatin-coated plates and allowed to 
differentiate as described above. At 96h, cells were washed with phosphate-buffered saline 
and incubated with 100nM MitoSOX or TMRM for 30 min at 37°C and 5% CO2. Images 
were captured on an Axio Observer A1 Inverted microscope (Carl Zeiss) equipped with a 
Retiga 1300 camera (QImaging). Relative fluorescence intensity was quantified using 
ImageJ 1.48V software (NIH). 
 
 






















































































Goat Anti-Rabbit IgG-HRP Sigma AQ132P 1:10000
Goat Anti-Mouse IgG-HRP






Table 5: List of reagents and antibodies used in this study 
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3.2.7 Measuring ATP levels, glucose uptake, and lactate 
production 
ATP levels were measured using a CellTiter-Glo® Luminescent Cell Viability Assay 
(Promega). Briefly, cells were cultured and differentiated as described above. At 72h, cells 
were trypsinized, suspended in 100µl of media, and added to a 96-well plate. After adding 
100µl of CellTiter-Glo® reagent, cells were lysed for 2 min and incubated for 10 min in the 
dark at room temperature. Luminance was recorded using a Modulus™ II microplate 
multimode system (Promega) and an integration time of 1.0s. For glucose uptake and 
lactate production, cells were cultured and differentiated as above, and at 72h media was 
removed and centrifuged at 4°C for 10 min at 10,000 r.p.m. Media was analyzed for 
glucose and lactate using a BioProfile®400 Chemical Analyzer (Nova Biomedical) at 
GCRC Metabolomics Core Facility (McGill University). Protein concentration was used 
to normalize values. 
3.2.8 Cytotoxicity assay 
F9 cells were cultured in 0, 2, 4, and 6 mM dichloroacetate (DCA) and assayed for viability 
using a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay 
(Sigma). Briefly, media was removed 24h post treatment and MTT reagent was added to 
cells cultured for 6h at 37°C and 5% CO2. To dissolve formazan crystals, DMSO was added 
to cells, which were shaken in the dark overnight at room temperature. Absorbance values 
at 570nM with a reference wavelength at 650nM were collected using the Modulus™ II 
microplate system described above. 
3.2.9 Scanning electron microscopy 
F9 cells were cultured and differentiated as mentioned above. Briefly, cells were washed 
in 0.1M phosphate buffer and fixed with 2% glutaraldehyde for 30 mins, followed by 
osmium tetroxide for 2h at 4°C. After fixation, cells were dehydrated in a graded series of 
ethanol (50, 50, 75, 85, 95, and 100%) for 5 min each. Samples were air-dried and sputter-
coated with gold particles for 10 mins. Samples were viewed and images collected on a 
Hitachi S-3400N microscope. 
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3.2.10 Statistical analysis 
All values are presented as mean ± SEM from at least three biological replicates. 
Comparisons between two groups were done using a Student’s t-test. Comparisons 
between three or more groups were done using a one-way analysis of variance (ANOVA) 
followed by a Tukey’s honest significant difference test. Chromosomal distribution 
frequency was tested by χ2-test for the Goodness of Fit.  
All data analyses were conducted using SPSS (Version 21.0, IBM Corp.) and graphs were 
generated using Prism software (Version 7.0d, 2017). P-values were considered significant 





3.3 « Results » 
3.3.1 Late-passage F9 cells differentiate into XEN-like lineage 
Undifferentiated late passage F9 cells grew in compact colonies while those induced to 
form XEN-like or PE-like adopted a stellate-like phenotype (Figure 3-1A). Oct4 expression 
in RA-induced cells was like controls (Figure 3-1B), but protein levels were reduced 
significantly (Figure 3-1F, G). This was more dramatic in cells induced to PE by RA and 
db-cAMP (RDB; Figure 3-1B, F, G). Increased expression of Gata6 and Dab2 (Figure 3-
1C, D, respectively) and levels of DAB2 (Figure 3-1F, H) and KERATIN-8 (Figure 3-1F, 
I) were evidence that F9 cells had differentiated into the XEN-like cells. Finally, significant 
increases in Thrombomodulin (Thbd) expression (Figure 3-1E) and in THBD levels (Figure 
3-1F, J) indicated that cells had differentiated to PE-like. Collectively, these results support 
the findings that late passage F9 cells differentiate efficiently towards XEN-like and PE-






























































































































































































































































Figure 3-1: Late passage F9 cells differentiate into XEN-like cells.  
(A) Scanning electron micrographs of undifferentiated F9 cells (DMSO), XEN-like 
(RA) and PE-like (RDB). White arrows indicate differentiated cells. Expression of 
(B) Oct4, (C) Gata6, (D) Dab2 and (E) Thbd in F9 cells treated with DMSO, RA or 
RDB for 72h. L14 was used a constitutive gene for qRT-PCR. (F) Representative 
immunoblot and densitometric analyses of (G) OCT4, (H) DAB2, (I) KERATIN-8 
and (J) THBD normalized to β-ACTIN during F9 cell differentiation. Values are 
presented as mean ± SEM of at least 3 biological replicates. Significance was tested 
using a One-Way ANOVA followed by a Tukey’s test. *P < 0.05. 
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3.3.2 Mitochondrial activity during late-passage differentiation 
Although ROS generated from cytoplasmic sources accompanies F9 cell differentiation 
[22,35,36], mitochondrial sources were never examined thoroughly. To address this, late 
passage F9 cells were treated with DMSO-, RA- or RDB and then stained with MitoSOX 
to detect mitochondrial superoxide (Figure 3-2A-C) or with TMRM for mitochondrial 
activity (Figure 3-2E-G). XEN-like cells showed a significant increase in mitochondrial 
superoxide levels relative to controls (Figure 3-2D), but not mitochondrial activity (Figure 
3-2H). Significant differences in superoxide levels and mitochondrial activity were also 
noted in PE-like cells (Figure 3-2D, H, respectively). These changes suggested that 
differentiation was accompanied by an increase in OXPHOS, which was supported by the 
increase in ATP levels in these cells (Figure 3-2I). Cells were also assayed for changes in 
metabolites in the media, and results showed that overall, a significant decrease in glucose 
uptake (Figure 3-2J), but not lactate production (Figure 3-2K) occurred in XEN-like cells. 
To examine if these changes were due to altered expression of glucose transporters [37], 
cells were differentiated, and then assayed for Glut 1-4, 8 and 9 (Figure 3-2L). Glut1, 3 
and 9 expressions increased significantly in XEN-like cells, while Glut3 and 9 were 
significantly upregulated in PE-like cells. Conversely, Glut4 transcript abundance 
decreased in XEN-like cells, while Glut2 and 8 expressions remained unchanged. These 
results suggested that Glut4 is likely the key glucose transporter during RA-induced 





































































































































Figure 3-2: Differentiated late passage F9 cells display increased 
mitochondrial ROS production, membrane potential and ATP levels.  
(A-C) Fluorescence images and quantification of F9 cells (D) stained with 
MitoSOX to detect mitochondrial superoxide in undifferentiated F9 cells, PrE-like 
(RA treatment) and PE-like (RDB treatment). (E-G) Fluorescence images and 
quantification (H) of F9 cells stained with TMRM to detect mitochondrial 
membrane potential during F9 cell differentiation. (I) ATP levels, (J) relative 
glucose uptake, (K) and lactate production were also measured during 
differentiation. (L) Differential expression of Glut1-4, 8 and 9 seen during the 
differentiation of late passage F9 cells. L14 was used a constitutive gene for qRT-
PCR. Values are presented as mean ± SEM of at least 3 biological replicates. 
Significance was tested using a One-Way ANOVA followed by a Tukey’s test. *P 
< 0.05, ***P < 0.001. (Scale bar, 20μm). 
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3.3.3 Metabolic changes accompanying late-passage 
differentiation 
To examine the metabolic profile, late passage F9 cells were differentiated and then 
analyzed to detect transcripts encoding lactate dehydrogenase A (LDHA), which promotes 
the conversion of pyruvate to lactate, and LDHB, which catalyzes the reverse reaction. 
Ldha expression was significantly downregulated in differentiated F9 cells, but only in PE-
like cells at the protein level (Figure 3-3C, D). However, Ldhb transcripts were only 
significantly downregulated in XEN-like cells (Figure 3-3A), and a similar trend was seen 
at the protein level (Figure 3-3C, E). The expressions of Pdk1-4 (Figure 3-3B), which 
encode PDK isoforms that phosphorylate and inactivate the PDH complex, were examined 
(Figure 3-3B). Results show that Pdk1 was significantly downregulated during 
differentiation, while Pdk2 was significantly upregulated relative to controls (Figure 3-3B). 
Similar results were seen at the protein level (Figure 3-3F, G, H). Despite these increases, 
PDH-E1αpSer232 (Figure 3-3F, I) and PDH-E1αpSer293 (Figure 3-3F, K) levels were reduced 































































































































































































































































































Figure 3-3: Differentiated late passage F9 cells downregulate transcripts and 
enzymes involved in inhibiting OXPHOS metabolism.  
Relative transcript abundance of (A) Ldha and Ldhb and (B) Pdks during F9 cell 
differentiation. L14 was used a constitutive gene for qRT-PCR. (C) Representative 
immunoblot and densitometric analyses (D, E) of LDHA and LDHB, respectively, during 
F9 cell differentiation. (F) Representative immunoblot showing PDK1, PDK2, PDH-
E1αpSer232, PDH-E1αpSer293, and PDH-E1α levels, and densitometric analysis of (G) 
PDK1, (H) PDK2, (I) PDH-E1αpSer232 and (K) PDH-E1αpSer293 levels. β-ACTIN served 
as a loading control. Values are presented as mean ± SEM of at least 3 biological 
replicates. Significance was tested using a One-Way ANOVA followed by a Tukey’s test. 
*P < 0.05, **P < 0.01. 
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To further examine the role of PDK1 in XEN-like differentiation, Pdk1-expressing stable 
lines were generated (Figure 3-4). As expected, clones overexpressing PDK1 showed 
significantly higher levels of Pdk1 expression (Figure 3-4A) and protein levels (Figure 3-
4E, F) over controls. To test the functionality of the exogenous PDK1, PDH-E1αpSer232 was 
assayed, and results show its levels were significantly higher than those in controls (Figure 
3-4E, G). Next, Oct4 expression and protein levels were examined and found to be reduced 
significantly in control cells treated with RA (Figure 3-4B, H, respectively), but neither 
were affected by RA in PDK1-overexpressing cells (Figure 3-4B, H). Despite seeing 
changes in OCT4 levels between the two clones, Gata6 expression did not differ (Figure 
3-4C). However, while Dab2 expression was significantly upregulated in control XEN-like 
cells, there was no significant difference when compared to Pdk1-overexpressing cells 
(Figure 3-4D). In converse, DAB2 protein levels were significantly lower when Pdk1 was 
overexpressed (Figure 3-4I). Lastly, overexpressing Pdk1 attenuated RA-induced 
differentiation as evident by the levels of KERATIN-8, which were not significantly 
different from controls (Figure 3-4J). Together, these results indicate that the 
overexpression of Pdk1, and inactivation of the PDH complex in F9 cells, maintains 






















































































































































































































































































































Figure 3-4: Overexpression of PDK1 attenuates RA-induced differentiation of late 
passage F9 cells.  
qRT-PCR of relative abundance of (A) Pdk1, (B) Oct4, (C) Gata6 and (D) Dab2 in 
pcDNA 3.1 clone 1 (pcDNA C1) or DDK-MYC-mPDK1 clone 5 (DDK-MYC-mPDK1 
C5)-overexpressing F9 cells treated with DMSO or RA for 96h. L14 was used a 
constitutive gene for qRT-PCR. Representative immunoblot (E) and densitometric 
analysis of (F) PDK1, (G) PDH-E1αpSer232, (H) OCT4, (I) DAB2, and (J) KERATIN-8 in 
pcDNA C1 or DDK-MYC-mPDK1 C5-overexpressing F9 cells treated with DMSO or 
RA for 96h. β-ACTIN served as a loading control. Values are presented as mean ± SEM 
of at least 3 biological replicates. Significance was tested using a One-Way ANOVA 
followed by a Tukey’s test. *P < 0.05.  
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3.3.4 Passaging alters metabolism but not differentiation potential 
Since passage number influences stem cell quality and fate [38-42], we asked whether F9 
cells at early passages (<20) exhibited a differentiation and metabolic profile like that in 
late passage cells. Examining markers of differentiation (Gata6, Dab2 and Thbd) showed 
similar expression profiles between the two populations (Figure 3-5A-C). Similarly, OCT4 
levels were higher in the undifferentiated state, and KERATIN-8 levels higher in the 
differentiated state (Figure 3-5D-F). Thus, early, and late passage F9 cells exhibited similar 
differentiation profiles, and it was expected that the metabolic profiles would be similar.  
To test this, the expression of Ldh transcripts and the levels of protein were examined 
(Figure 3-6A-C). No significant differences in the abundance of Ldha and Ldhb were 
detected in early passage cells, and at the protein level, both levels were significantly 
reduced in PE-like cells (Figure 3-6B, C). Differences were seen, however, in the 
expression of Pdks, and while the decreasing Pdk1 trend with differentiation was 
maintained between the two populations (Figure 3-7A and Figure 3-3B, respectively), Pdk3 
and Pdk4 expression was upregulated significantly only in early passage cells (Figure 3-
7A). No significant difference in the abundance of Pdk2 was evident in early passage cells 
(Figure 3-7A), which contrasts that seen in late passage cells (Figure 3-3B). At the protein 
level, PDK1 levels dropped significantly with differentiation (Figure 3-7B, C), while 
PDK4 levels increased significantly in PE-like cells (Figure 3-7B, E). Despite the increase 
in Pdk3 expression (Figure 3-7A), PDK3 levels remained unchanged in differentiated early 
passage cells (Figure 3-7B, D). These differences in PDK profiles prompted further 
investigation into the phosphorylation status of PDH-E1αpSer293, which in late passage F9 
cells decreased with differentiation (Figure 3-3F, K). In early passage cells, PDH-E1αpSer293 
levels increased significantly, but only in PE-like cells (Figure 3-7B, F). To explain the 
increase, pyruvate dehydrogenase phosphatases (PDPs), which dephosphorylate serine 
residues and subsequently activate the PDH complex, were examined (Figure 3-7G). 
Results show Pdp1 and Pdp2 expression was significantly downregulated in response to 
RA treatment, but only in early passage cells, suggesting that the increase in PDH-
E1αpSer293 levels is due to PDK4. To test whether the PDH complex was inactive, lactate 
levels in the media and glucose uptake were measured in early passage undifferentiating 
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and differentiated cells (Figure 3-7H and I, respectively). Media from PE-like cells showed 
significantly more lactate (Figure 3-7H) when compared to controls, and this was 
accompanied by a significant increase in glucose uptake (Figure 3-7I). The relative 
abundance of Glut1-4, 8 and 9 in early passage F9 cells was also examined, and while 
Glut1 and 3 expression was significantly upregulated in XEN-like, Glut2 and 4 expressions 
were only upregulated significantly in PE-like cells (Figure 3-7J). Glut8 expression was 
downregulated significantly in XEN-like cells (Figure 3-7J), unlike that seen in late 
passage cells (Figure 3-2). Collectively, the results indicate that unlike late passage F9 
cells, those that have not been passaged extensively transition from OXPHOS metabolism 






















































































































































Figure 3-5: Early passage F9 cells differentiate to extraembryonic endoderm-
like cells when treated with RA or RDB.  
Relative (A) Gata6, (B) Dab2 and (C) Thbd expression in untreated (DMSO), PrE-
like (RA) and PE-like (RDB). L14 was used a constitutive gene for qRT-PCR. (D) 
Representative immunoblot and densitometric analyses of (E) KERATIN-8 and (F) 
OCT4 abundance normalized to β-ACTIN during F9 cell differentiation. Values are 
presented as mean ± SEM of at least 3 biological replicates. Significance was tested 


























































































Figure 3-6: LDHA and LDHB levels are downregulated during early passage F9 
cell differentiation.  
(A) Relative Ldha and Ldhb in untreated (DMSO), PrE-like (RA) and PE-like (RDB). 
L14 was used a constitutive gene for qRT-PCR. (B) Representative immunoblot and 
densitometric analyses (C) of LDHA and LDHB levels normalized to β-ACTIN during 
F9 cell differentiation. Values are presented as mean ± SEM of at least 3 biological 
replicates. Significance was tested using a One-Way ANOVA followed by a Tukey’s 






























































































































































































































































































Figure 3-7: Differentiated early passage F9 cells upregulate transcripts and 
enzymes involved in glycolysis.  
(A) qRT-PCR of Pdk1-4 expression, representative immunoblot (B) of PDK1, PDK3, 
PDK4, PDH-E1αpSer293 and PDH-E1α, and densitometric analysis of (C) PDK1, (D) 
PDK3, (E) PDK4 and (F) PDH-E1αpSer293 during F9 cell differentiation. β-ACTIN served 
as a loading control. (G) qRT-PCR analysis of Pdp1 and Pdp2 transcripts, (H) lactate 
production and (I) glucose uptake during F9 cell differentiation. (J) Differential 
expression of Glut1-4, 8 and 9 seen during the differentiation of early passage F9 cells. 
L14 was used a constitutive gene for qRT-PCR. Values are presented as mean ± SEM of 
at least 3 biological replicates. Significance was tested using a One-Way ANOVA 
followed by a Tukey’s test. *P < 0.05, **P < 0.01, ***P < 0.001. 
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3.3.5 Mitochondrial dynamics in early- vs. late-passage cells  
Since passage number influenced metabolism but not the differentiation potential of F9 
cells, the focus turned to delineate if other metabolic-related changes exist between the two 
populations, particularly in the electron transport chain (ETC) proteins. Analysis revealed 
that undifferentiated and differentiated early passage cells express comparable levels of all 
ETC subunits, except for succinate dehydrogenase complex iron sulfur subunit B (SDHB) 
in complex II (Figure 3-8A, B). While differentiation of late passage cells to PE-like cells 
caused a significant decrease in the levels of MTCO1 (complex IV), SDHB (complex II) 
and NDUFB8 (complex I; Figure 3-8C, D). To explain the disruption in ETC protein levels, 
the expression profiles of genes involved in mitochondrial fission and fusion were 
examined. Early passage cells showed no significant change in Drp1, Opa1 and Fis1 
expression, which encode proteins that promote mitochondrial fission; however, Mfn1 and 
2 expression was significantly upregulated in PE-like cells (Figure 3-8E). No obvious 
changes were detected in late passage cells (Figure 3-8F), and despite seeing elevated 
mitochondrial ROS levels and increased activity in differentiated late passage cells (Figure 
3-2A-H), the data suggests that the mitochondria in both early and late passage cells are 
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Figure 3-8: ETC components and mitochondrial dynamics are deregulated in 
differentiated late passage F9 cells.  
Representative immunoblots and densitometric analyses of subunits in the ETC seen 
during the differentiation of (A, B) early and (C, D) late passage F9 cells. Relative 
transcript abundance of mitochondrial fusion proteins (Mfn1 and Mfn2), and 
mitochondrial fission proteins (Drp1, Opa1 and Fis1) during the differentiation of (E) 
early and (F) late passage F9 cells. L14 was used a constitutive gene for qRT-PCR. 
Values are presented as mean ± SEM of at least 3 biological replicates. Significance was 
tested using a One-Way ANOVA followed by a Tukey’s test. *P < 0.05, ***P < 0.001.  
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3.3.6 Glycolysis promotes differentiation of early-passage F9 cells 
If early passage F9 cells transition towards glycolysis during differentiation, then 
promoting glycolysis in these cells should induce differentiation. To test this, early passage 
cells were treated with UK5099, a non-competitive inhibitor of the mitochondrial pyruvate 
uptake transporter. A 50µM concentration was selected, and results show that treatment in 
combination with RA caused a significant reduction in the abundance of Oct4 relative to 
RA alone (Figure 3-9A). Although these results suggested cells were exiting the pluripotent 
state, treatment alone or in combination with RA showed no additive effects on Dab2 
expression (Figure 3-9B). OCT4, DAB2, and KERATIN-8 levels were also analyzed, and 
as expected OCT4 levels were significantly lower in RA-treated cells, and even lower in 
the treatment with UK5099 (Figure 3-9C, D). DAB2 levels, like the corresponding 
expression data were not significantly different between RA or RA and UK5099 treatments 
(Figure 3-9C, E); however, under the same conditions, KERATIN-8 levels were 
significantly higher (Figure 3-9C, F). Thus, culturing early passage cells under conditions 
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Figure 3-9: Glycolysis promotes differentiation of early passage F9 cells.  
qRT-PCR analysis of (A) Oct4 and (B) Dab2 in F9 cells differentiated without or with 
UK5099 to inhibit mitochondrial pyruvate transport. L14 was used a constitutive gene 
for qRT-PCR. (C) Representative immunoblot of DAB2, KERATIN-8 and OCT4, 
and densitometric analyses of (D) OCT4, (E) DAB2 and (F) KERATIN-8 levels in 
F9 cells treated with RA or RA and 50μM UK5099. β-ACTIN served as a loading 
control. Values are presented as mean ± SEM of at least 3 biological replicates. 




3.3.7 OXPHOS enhances the exit from pluripotency in late-
passage cells 
Since promoting glycolysis in early passage F9 cells enhanced their ability to differentiate, 
then promoting OXPHOS in late passage cells should augment differentiation. To test this 
hypothesis, late passage cells were cultured in increasing concentrations of dichloroacetate 
(DCA), a competitive PDK inhibitor, and then assayed for changes in metabolism and 
differentiation (Figure 3-10). Cells cultured in the highest concentration of DCA (6mM) 
showed a significant reduction in cell viability (88 ± 1%; Figure 3-10A); however, 6mM 
DCA was selected as it caused the most significant reduction in PDH-E1αpSer232 and PDH-
E1αpSer293 levels (Figure 3-10B-D), resulting in significantly higher ATP levels (Figure 3-
10E). As for differentiation, DAB2 and KERATIN-8 levels were significantly higher than 
the controls, but only in cells co-treated with RA and DCA (Figure 3-10F-H). Since the 
results would indicate that cell differentiation was augmented by DCA, OCT4 levels in the 
cells should be dramatically decreased. This was tested, and results show OCT4 levels were 
significantly reduced in RA-treated cells relative to controls (Figure 3-10F, I). As expected, 
these levels were even more reduced in cells treated with RA and DCA (Figure 3-10F, I) 
suggesting that promoting OXPHOS in late passage cells not only enhanced their exit from 
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Figure 3-10: OXPHOS promotes differentiation of late passage F9 cells.  
(A) MTT viability assay, representative immunoblot (B) of PDH-E1αpSer232, PDH-
E1αpSer293 and PDH-E1α, and densitometric analyses of (C) PDH-E1αpSer232 and (D) PDH-
E1αpSer293 of F9 cells treated with 0, 2, 4 and 6mM DCA. (E) Relative ATP levels in 
untreated and 6mM DCA-treated F9 cells. (F) Representative immunoblot of DAB2, 
KERATIN-8 and OCT4, and densitometric analyses of (G) DAB2, (H) KERATIN-8 and 
(I) OCT4 in F9 cells treated with RA or RA and 6mM DCA. β-ACTIN served as a loading 
control. Values are presented as mean ± SEM of at least 3 biological replicates. 
Significance was tested using a One-Way ANOVA followed by a Tukey’s test. *P < 0.05, 
**P < 0.01, ***P < 0.001. 
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3.3.8 Genomic integrity and cell cycle regulation in early- vs. late-
passage 
Although metabolic changes can influence genomic integrity [43], reports have shown that 
extensive passaging of adherent cells and ES cells can induce genetic abnormalities thereby 
affecting cellular metabolism [44,45]. To address this, karyotyping was used to determine 
whether chromosomal composition could explain the variations observed between early 
and late passage cells. Analysis revealed approximately 60% of the early passage F9 cells 
have the proper karyotype, while less than 5% of the late passage F9 cells had the optimal 
chromosome number (Figure 3-11A). Furthermore, the chromosome frequency 
distribution of early passage cells was significantly different from the late passage cells 
(χ2=42.868, df=2, P < 0.001, Figure 3-11B). Cell proliferation was examined as this is 
known to be affected by chromosomal abnormalities [46]. Results showed early passage 
cells proliferated at a significantly lower rate than late passage cells (Figure 3-11C). An 
examination of various cell cycle regulators including Cdkn1a, Cdkn1b, Cdkn2a, Cdkn2c, 
Cdkn2d, Ccnd1, Cdk4, Cdk6, P53 and Rb1 revealed that except for Cdkn2a, the other cell 
cycle markers were upregulated in late passage cells (Figure 3-11D). Together, this loss of 
genomic integrity could account for the differences in the proliferation rates and metabolic 


















































































Figure 3-11: Early passage F9 cells display a genetically stable karyotype and 
proliferate slower than late passage F9 cells.  
(A) Number of Chromosome, (B) chromosomal frequency, and (C) growth curve of 
early and late passage F9 cells. (D) Differential expression of genes encoding proteins 
involved in cell cycle regulation and progression between early versus late passage F9 
cells. Values are presented as mean ± SEM of at least three biological replicates. 
Significance was tested using a one-way ANOVA followed by a Tukey’s test. 







Figure 3-12: Differentiation potential, metabolic profile, and genomic integrity of 
early versus late passage F9 cells.  
F9 embryonal carcinoma stem-like cells differentiate towards a XEN-like lineage and 
switch their metabolic profile depending on their passage. Early passage cells (less than 
20) transition from OXPHOS towards glycolysis while late passage cells do the opposite. 
Additionally, late passage cells accumulate more ROS and genetic abnormalities. 
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3.4 « Discussion » 
Stem cells hold great potential for regenerative medicine applications; however, 
understanding their physiology in vitro is crucial to ensure the delivery of quality cells to 
patients. We used F9 cells to determine the metabolic profile during XEN-like 
differentiation, and how passaging may affect their metabolic profile and differentiation 
potential. Two cell populations were examined and although each differentiated and 
upregulated markers of XEN-like and PE-like lineages respectively (Figure 3-1, 3-5), their 
metabolic profiles differed drastically. During differentiation, late passage F9 cells 
transitioned from glycolysis to OXPHOS resulting in an increase in mitochondrial ROS 
levels and mitochondrial activity, both correlated with increased ATP production (Figure 
3-2). The increase in OXPHOS during differentiation is explained by the reduction in 
PDK1 levels (Figure 3-3F, G), resulting in reduced PDH-E1αpSer232 (Figure 3-3F, I), and 
PDH-E1αpSer293 (Figure 3-3F, K) levels. Conversely, overexpressing Pdk1 attenuated RA-
induced differentiation in these cells (Figure 3-4). A similar trend occurs with iPSCs, 
hESCs and MSCs, which are glycolytic in nature due to an inactive PDH complex shuttling 
pyruvate to lactate [25,26], but employ OXPHOS when differentiated [27,47,48]. The 
opposite scenario occurs in the mouse embryo as naïve ES cells exhibit bivalent 
metabolism, while differentiated primed EpiSCs use glycolysis [16], similar to 
differentiated early passage cells as they increased lactate production (Figure 3-7G), with 
elevated levels of PDK4 (Figure 3-7B, E), and concomitant increased levels of PDH-
E1αpSer293 (Figure 3-7B, F). During the differentiation of adult stem cells, elevated lactate 
levels and subsequent increased acetyl-CoA levels enhance histone H3K9 acetylation, a 
prelude required for differentiation [49]. However, this is not universal, and the fact that 
other stem cells transition towards OXPHOS when they differentiate [50], highlight cell-
specific differences regulated by the intricacies of the metabolome.  
The metabolome is directly affected by the mitochondria [51], whose activity is linked to 
substrate availability and structure [52]. ETC protein stoichiometry dictates the flow of 
electrons, which influences mitochondrial activity [53]. As described earlier, iPSCs 
upregulate glycolytic enzymes during the early stages of reprogramming [26,27], and this 
coincides with the downregulation of proteins in complex I and IV, and the upregulation 
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of proteins in complex II, III and V [54]. Although the metabolic profile of iPSCs is similar 
to differentiated early passage cells, there were no detectable changes to complex I and IV 
in these cells (Figure 3-8A-B). In contrast, the reduction in protein levels in these 
complexes were seen in differentiated late passage cells, which favor OXPHOS during 
differentiation (Figure 3-8C-D). Nevertheless, the disruption of ETC stoichiometry in late 
passage cells explains the elevation in mitochondrial ROS (Figure 3-2A-D). Surprisingly, 
these elevated mitochondrial ROS levels were not accompanied by changes in the levels 
of mitochondrial dynamic proteins (Figure 3-8F) that are typically associated with 
mitochondria actively generating ATP [55]. Instead, an increase in the expression of Mfn1 
and Mfn2, which encode mitochondrial fusion-promoting proteins, was seen in 
differentiated early passage cells (Figure 3-8E). Similarities exist with primed EpiSCs and 
hESCs, which possess oval-shaped mitochondria with dense matrix, prominent cristae, and 
high mtDNA copy number, but have reduced mitochondrial respiration rates due to 
deficiencies in in complex I and IV [16]. These inconsistencies in the literature confounded 
the interpretation of our data, and details to explain the differences in metabolic profile 
seen between early versus late passaged F9 cells led us to examine other possibilities. 
Genomic integrity was one possible explanation, as long-term passaging of stem cells can 
promote chromosomal abnormalities resulting in loss of pluripotency and low contribution 
to chimeras [32]. In our report, early and late passage F9 cells shared similar pluripotency 
and differentiation profiles (Figure 3-1, 3-5); however, based on a comparison with other 
stem cell lines, we were unable to assign candidates that would implicate their involvement 
in the metabolic differences seen in the two F9 cell populations. It is known that mouse ES 
cell lines cultured for prolonged periods develop abnormal karyotypes yet maintain 
pluripotency and differentiate when grown as embryoid bodies [33]. Our results revealed 
dramatic differences in the karyotypes of early and late passage F9 cells (Figure 3-11A, 
B), and these would have profound effects on the physiology of each population. 
Differences included altered levels of ROS (Figure 3-2A-D) and elevated Cdkna1 and p53 
levels (Figure 3-11D), the latter affecting the proliferation rate in late passage F9 cells 
(Figure 3-11C). Interestingly, these characteristics are seen in late passage MSCs [47] and 
hESCs [56], and although they are attributed to abnormal karyotypes, other cell lines retain 
proper chromosomal composition and show no apparent change in cell proliferation rate or 
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pluripotency potential [56]. Thus, like early and late passage F9 cells, stem cells have 
properties that may or may not change with passaging, suggesting that culturing methods 
and passage number are not the only factors promoting chromosomal degradation [57].  
Overall, our results demonstrate that early versus late passage F9 cells can differentiate 
into XEN-like lineages, while utilizing different metabolic profiles (Figure 3-12). 
Moreover, culturing either population under conditions that favor their profile enhances 
their exit from pluripotency and promoted differentiation. Although several reports have 
documented the differentiation of F9 cells into XEN-like cells [58-63], none have 
addressed the mechanisms in reference to metabolic profile or altered karyotypes that 
accompany extensive passaging. Thus, the desired differentiation phenotype of cells may 
come at a cost if genomic integrity is compromised. Future studies should investigate 
whether embryo-derived XEN cells behave similarly to either early or late passage 
populations. Furthermore, our findings underpin the importance of continually scrutinizing 
a stem cell population and assessing metabolic phenotypes in addition to differentiation 
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4 « Lactate accelerates mouse ES cell differentiation 





4.1 « Introduction » 
The early mammalian blastocyst is comprised of two distinct layers: the inner cell mass 
(ICM) and trophectoderm. The ICM houses pluripotent epiblast stem cells and primitive 
endoderm cells, and the latter differentiate into parietal and visceral endoderm cells. 
Various ES cells have been cultured at different developmental time-points [1], each 
requiring specific conditions. For instance in mouse, ES cells isolated from the ground state 
epiblast (preimplantation) represent a naïve pluripotent state and can be artificially 
maintained under LIF and serum/BMP [2,3] or defined conditions of LIF-2i in N2B27 
media where dual inhibition of glycogen synthase kinase 3 and mitogen-activated protein 
kinase pathways maintain pluripotency [4]. However, shortly after implantation, epiblast 
stem cells, which are the in vitro counterparts of the primed epiblast, require Activin A and 
FGF2 in culture [5,6]. In addition to differences in culture conditions, both ES and epiblast 
stem cells differ in their expression profile of pluripotency core genes, DNA methylation, 
histone modification status, clonogenicity and chimera contribution [7]. XEN cells, which 
contribute to both embryonic and extraembryonic endoderm tissue in mouse [8], have been 
first derived by isolation from the blastocyst [9], differentiated using exogenous factors 
[10-12], reprogrammed from fibroblast cells [13,14], or form after the overexpression of 
Gata4/6 [15,16] or Sox17 [17]. In addition, evidence indicates that the metabolic state 
between embryonic and extraembryonic lineages differs [18], suggesting that metabolism 
may be sufficient to influence lineage commitment. 
ES cells exhibit a bivalent metabolic profile, relying on glycolysis and oxidative 
phosphorylation (OXPHOS) to generate energy, while epiblast stem cells are exclusively 
glycolytic, despite displaying a mature mitochondrial ultrastructure [19]. Although the 
majority of studies have focused on ES and epiblast stem cells, recent reports on 
extraembryonic cells show they are reliant on OXPHOS metabolism [18], with a similar 
mitochondrial ultrastructure to epiblast stem cells [19,20]. In addition, we have previously 
shown that differentiated F9 cells, a model of XEN-like differentiation, rely on glycolytic 
metabolism, produce high levels of lactate, and express of Mfn1 and Mfn2 (Chapter 3) [21]. 
However, details on the comprehensive intracellular profile of metabolites and their role 
during differentiation remains unknown. 
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Small metabolites have garnered attention with their role in maintaining pluripotency, 
promoting differentiation, and enhancing reprogramming efficiency of induced pluripotent 
stem cells [22-24]. These small compounds play integral roles in energy production and 
epigenetic modifications. For instance, short-chain and saturated fatty acids can modulate 
histone deacetylases and the epigenetic landscape and thus are implicated in enhancing the 
efficiency of stem cell differentiation [25,26]. Also, the depletion of threonine or loss of 
threonine dehydrogenase (TDH) impacts stemness [27], while supplementation of L-
threonine maintains pluripotency [28]. Therefore, naturally occurring metabolites play an 
important role in regulating pluripotency and differentiation of stem cells by modulating 
the metabolic and epigenetic landscape. 
In this report we used a multi-omics approach to identify metabolic changes in mouse ES 
and XEN cells and have further characterized the metabolic pathways involved in 
regulating XEN differentiation in vitro. Overall, we observed a significant reduction in the 
survival of feeder-free XEN cells following glycolytic inhibition. Transcriptomic and 
proteomic profiling implicate lactate metabolism in regulating the differentiation towards 
the XEN lineage. Strikingly, lactate was enriched intra- and extracellularly in feeder-free 
XEN cells and promoting intracellular lactate accumulation or supplementing with 
exogenous L-lactate enhanced XEN induction. Together our results elucidate an 
unacknowledged role for lactate in XEN cell differentiation in vitro, which further our 
understanding of the role metabolites play in stem cell differentiation with potential 






4.2 « Experimental procedures » 
4.2.1 ES, XEN, and cXEN cell culture 
The ES-E14TG2a embryonic stem (ES) cell line was obtained from the University of 
California, Davis. ES cells were cultured feeder-free on 0.1% gelatin-coated tissue culture 
plates in ES media (LIF-2i): 50/50 neurobasal/DMEM-F12 media (Thermo Fisher 
Scientific), 1X N2 supplement (Thermo Fisher Scientific), 0.5X B27 (without retinoic acid; 
Thermo Fisher Scientific), 2mM GlutaMAXTM (Thermo Fisher Scientific), 0.1mM β-
mercaptoethanol (Thermo Fisher Scientific), 100U/ml units of LIF (Millipore-Sigma), 
3µM CHIR99021 (ApexBio) and 1µM PD 0325901 (ApexBio). ES cells were passaged 
every 3–4 days using Accutase (Thermo Fisher Scientific) and used to passage 30. ES 
media was changed daily to maintain optimal growth and reduce spontaneous 
differentiation. 
E4 extraembryonic endoderm (XEN) cells, generously donated by Cheryle Seguin, UWO 
[9], were cultured in RPMI 1640 medium (Thermo Fisher Scientific) supplemented with 
15% fetal bovine serum (Thermo Fisher Scientific), 2mM GlutaMAXTM and 0.1mM β-
mercaptoethanol. XEN cells were passaged every 2–4 days using TrypLE Express (Thermo 
Fisher Scientific) up to passage 20. 
Chemically induced XEN (cXEN) differentiation was performed following a previously 
established protocol [12]. Briefly, ES cells were seeded onto 0.1% gelatin-coated tissue 
culture plates in base XEN media (RPMI 1640 media, 0.5X B27 without insulin, 2mM 
GlutaMAXTM and 0.1mM β-mercaptoethanol) for 2 days. To induce XEN differentiation, 
base XEN medium was supplemented with 100U/ml units of LIF, 3µM CHIR99021 and 
20ng/ml Activin A (R&D Systems), which was replaced with fresh media every 2 days. 
All lines were grown at 37°C and 5% CO2 and contained a normal chromosomal karyotype 
and negative for mycoplasma [29] at the beginning of the project. 
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4.2.2 RNA isolation, cDNA synthesis and qRT-PCR analysis  
Cellular RNA was extracted from cells using QIAshredder/RNAeasy Mini kit (Qiagen) 
and reverse transcribed into cDNA using the High-Capacity cDNA Reverse Transcription 
kit (Thermo Fisher Scientific). For quantitative RT-PCR, reactions contained 500nM of 
forward and reverse primers [21], SensiFAST SYBR Mix (FroggaBio), and cDNA. 
Reactions were run on a CFX Connect Real-Time PCR detection system (Bio-Rad), and 
results presented using the comparative cycle threshold (2−ΔΔCt) method with Rpl14 serving 
as the internal control. 
4.2.3 RNA sequencing analysis 
Total RNA was extracted as in section 4.2.2 and quantified using a NanoDrop 2000 
spectrophotometer (Thermo Fisher Scientific) and Agilent 2100 bioanalyzer (Agilent 
Technologies). Library construction and sequencing were performed using the BGISEQ-
500 platform (Beijing Genome Institute). Clean reads were mapped to a reference genome 
(GRCm38-mm10) using Bowtie2 [30] and gene expression levels were calculated with 
RSEM [31]. Differentially expressed genes were detected with DEseq2 [32] with fold 
change ≥ 2.0 and P ≤ 0.0001, and GO-term enrichment and KEGG analyses were 
conducted using David v6.8 [33,34]. Three independent biological replicates were used for 
each line. 
4.2.4 Protein extraction, quantification and immunoblot analysis 
Total cell lysates were harvested using RIPA buffer supplemented with protease and 
phosphatase inhibitors (Thermo Fisher Scientific). Protein concentrations were quantified 
using a DCTM protein assay (Bio-Rad). Approximately 5–20µg of protein was separated on 
5–15% polyacrylamide gels at 100V, then transferred onto PVDF membranes (Bio-Rad) 
overnight at 4°C at 20V. Membranes were washed in TBS-T with 0.1% Tween-20 and 
blocked with 5% skim milk powder for 30 minutes at room temperature with gentle 
shaking. Membranes were probed with primary antibodies [21] overnight at 4°C followed 
by washes with TBS-T and secondary antibody incubation for 2 hours at room temperature. 
Images were captured using a ChemiDoc™ Touch Imaging System (Bio-Rad). 
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4.2.5 Proteomic analysis 
Sample preparation, handling and quantification were performed according to [35]. 
Briefly, cells were pelleted and 50μg of protein was quantified by ionic detergent 
compatible Pierce 660nm Protein Assay Reagent (Thermo Fisher Scientific) in 8M Urea, 
50mM ammonium bicarbonate, 10mM dithiothreitol, and 2% SDS lysis buffer. Lysates 
were sonicated, reduced, and alkylated followed by precipitation in chloroform/methanol 
[36], and digested samples were resuspended in 0.1% formic acid in preparation for LC-
MS/MS. One microgram of tryptic peptides was injected into a Waters nano-Acquity 
HPLC system (Waters, Milford, MA) coupled to an ESI Orbitrap mass spectrometer 
(Orbitrap Elite or QExactive, Thermo Fisher Scientific). MS raw files were examined using 
MaxQuant (1.6.5.0) and the Human Uniprot database. Bioinformatic analyses were 
performed in Perseus (1.5.8.5), and statistical analyses performed using multiple sample t-
test with a permutation FDR set at 0.05. GO-term enrichment and KEGG analyses were 
conducted using David v6.8 [33,34]. Three independent biological replicates were used for 
each line. 
4.2.6 Detection of total ATP levels 
Total ATP levels were measured using the CellTiter-Glo® Luminescent Cell Viability 
Assay (Promega). Cells were detached and re-suspended in media and aliquoted into 96-
well plate. Cells were lysed in CellTiter-Glo® reagent, incubated in the dark for 10 minutes, 
and luminance recorded using a Modulus™ II microplate multimode system (Promega). 
4.2.7 Detection of extracellular lactate levels 
Cells were cultured under normal conditions until reaching 70% confluency. Media from 
each cell population was collected, centrifuge at 14000g at 4°C for 10 minutes and analyzed 
using a BioProfile®400 Chemical Analyzer (Nova Biochemical), at the GCRC 




4.2.8 Metabolomic analysis 
Three million cells, cultured for 4 days under normal conditions, per sample were used for 
extraction and analysis. Samples were analyzed for metabolites involved in glycolysis, and 
TCA cycle, as well as amino acids, fatty acid, and lipids. Sample preparation, handling and 
quantification were carried out as in [37] by The Analytical Facility for Bioactive 
Molecules, The Hospital for Sick Children, Toronto, Canada. Briefly, cells were harvested 
in 80% methanol (vol/vol) solution, centrifuged at 14,000g for 5 minutes at 4°C. Samples 
were aliquoted and lyophilized prior to injection. Approximately 20μl of LC/MS grade 
water was used to resuspend samples and 5–10μl was injected into a LC-MS/MS system 
which was a SCIEX 5500 QTRAP mass spectrometer (SCIEX) coupled with an Agilent 
1290 HPLC stack (Agilent Technologies). MultiQuant (v3.0; SCIEX) was used for 
analysis. Three independent biological replicates were used for each line. 
4.2.9 Data and code availability 
Data files can be obtained from accession number GEO: GSE159855. Proteomic and 
metabolomic datasets are underpowered and were not deposited for public access. 
4.2.10 Statistical analysis 
All values are presented as mean ± SEM from at least three biological experiments. In some 
instances (TEM experiments), three technical replicates were also included. Comparisons 
between two groups were performed using Student’s t-test, while comparisons between 
three or more groups were done using one-way ANOVA test followed by Tukey’s honest 
significant difference test. All graphs and statistics were generated using Prism (v8.4.3). 





4.3 « Results » 
4.3.1 ES cells are less sensitive to glycolytic inhibition than XEN 
cells 
A recent report characterized the metabolic profile of XEN cells as reliant on OXPHOS 
metabolism [18]. Albeit informative, this study derived and maintained XEN cells on 
inactivated mouse embryonic fibroblasts, which are oxidative in nature [38] and are known 
to reduce the reliance of pluripotent stem cells on glycolysis [39]. To address if culturing 
methods influence the metabolic profiles, ES-E14TG2a embryonic stem cells (ES cells) 
and embryo-derived extraembryonic endoderm cells (XEN cells) [9] were cultured under 
feeder-free conditions in media containing 50mM 2-Deoxy-D-glucose (2-DG; glycolysis 
inhibitor) or 2.5µM oligomycin (OXPHOS inhibitor), and results were compared with cells 
grown under control conditions (LIF-2i for ES cells and RPMI 1640 with FBS for XEN 
cells; Figure 4-2). ES cells displayed domed-homogenous colonies while XEN cells had 
two distinct morphologies present in culture, spindle-like or round and refractile in nature 
(Figure 4-1A). Both populations expressed the respective pluripotency or endodermal 
genes as detected by qRT-PCR or immunoblot analysis (Figure 4-1B-H). 
ES colony shape appeared to be insensitive to 2-DG or to oligomycin treatment; however, 
XEN cells lost their distinct morphologies, particularly in the 2-DG treatment and adopted 
a spindle-like morphology, suggestive of cell stress (Figure 4-2A). In contrast to a previous 
report [18], XEN cells were more sensitive to glycolytic inhibition (5.87% ± 1.82) than 
OXPHOS inhibition with oligomycin (41.3% ± 7.30; P < 0.01; Figure 4-2B). Since ES 
cells are metabolically bivalent [19], the significant reduction in cell viability observed 
under both treatments was expected (P < 0.01) and not significantly different between the 
two treatments (2-DG: 45.3% ± 8.84 versus oligomycin: 62.7% ± 5.24; Figure 4-2B). 
Despite this reduction in cell viability, no change in relative total ATP levels was observed 
between the two populations and treatments (Figure 4-2C). Collectively, our findings 
support the notion that feeder-free XEN cells are more sensitive to glycolytic inhibition 
















































































































































Figure 4-1: Morphological and molecular analysis of ES and XEN cells in vitro.  
(A) A representative phase contrast micrograph of ES and XEN cells cultured under 
maintenance conditions under free-feeder conditions. (B) Immunoblot analysis of 
OCT4 (pluripotency marker) and DAB2, GATA6, and KERATIN-8 (extraembryonic 
endoderm markers). β-ACTIN served as a loading control. (C, D) Bar graph of 
expression level of Oct4 and Nanog in ES and XEN cells under maintenance 
conditions. Rpl14 was used a constitutive gene for qRT-PCR. (n = three biological 
replicates, ***P <0.001). (E-H) Bar graph of expression level of Gata6, Sox7, Dab2, 
and Foxa2 in ES and XEN cells under maintenance conditions. Rpl14 was used a 

























































































































Figure 4-2: XEN cells are more sensitive to glycolytic inhibition.  
(A) Representative phase contrast images of ES and XEN cells cultured under control, 
50mM 2-DG, and 2.5µM oligomycin. Solid arrows are indicative of round XEN 
morphology. Dashed arrows are indicative of stellate XEN morphology. Scale bars = 
100µm. (B) Relative cell viability of ES and XEN cells under control, 50mM 2-DG 
and 2.5µM oligomycin conditions. (C) Total ATP levels in ES and XEN cells under 
control, 50mM 2-DG and 2.5µM oligomycin conditions. (n = three biological 
replicates, ns = not significant, **P < 0.01, ***P <0.001). 
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4.3.2 Intracellular metabolomic profiling of ICM cells 
Since feeder-free ES and XEN cells responded differently to metabolic inhibitors, we 
exploited the feeder-free system to identify changes in intracellular metabolites between 
the two populations. For metabolite identification, untargeted metabolomics was used to 
measure the relative levels of intracellular metabolites (Figure 4-3). We identified 142 
intracellular metabolites of which 18 were significantly enriched in ES cells and 68 in XEN 
cells (Figure 4-3A). Next, targeted metabolomics was performed to quantify the levels of 
amino acids (Figure 4-3B) and metabolites involved in glycolysis and the tricarboxylic acid 
(TCA) cycle (Figure 4-3C). Several amino acids were significantly enriched in XEN cells, 
including proline, serine, and threonine, which are reported to play a role in pluripotency 
and differentiation [27,28,40,41]. While most metabolites involved in glycolysis and TCA 
cycle were not statistically significant, intracellular lactate and 2-hydroxyglutarate were 
significantly higher in XEN cells when compared with ES cells (P < 0.05; Figure 4-3C). 
Together, our data indicate that XEN cells exhibit a unique metabolite profile that is distinct 

























































Figure 4-3: Intracellular metabolomic analysis of ES and XEN cells.  
(A) Volcano plots of differentially expressed metabolites from untargeted LC/GC-
MS/MS metabolomics of ES and XEN cells cultured under normal conditions. (Fold 
change > 1 and P < 0.05). Metabolites enriched in ES cells are highlighted in purple 
(38 metabolites) and metabolites enriched in XEN cells are highlighted in orange (105 
metabolites). (B, C) Levels of key intracellular metabolites generated by glycolysis, 
TCA cycle, and amino acid detected by targeted LC/GC-MS/MS analysis of ES and 
XEN cells cultured under normal conditions. Metabolites are expressed in ng and were 
normalized to cell number. (n = three biological replicates, ns = not significant, *P < 
0.05, **P <0.01). 
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4.3.3 Transcriptomic and proteomic analysis showcases the 
importance of metabolic pathways during embryonic 
development 
Bulk transcriptomic and proteomic analyses were performed on three biological replicates 
of ES and XEN cells to compare global gene expression and protein abundance patterns 
and assign molecular pathway(s) to better our understanding of the landscape of each 
population. I found that 2742 genes (Figure 4-4A) and 165 proteins (Figure 4-4B) were 
significantly enriched in the ES population. In contrast, 1716 genes (Figure 4-4A) and 298 
proteins (Figure 4-4B) were significantly enriched in XEN cells. As expected, markers of 
pluripotency including Nanog, Sox2, OCT4 and ESRRB were enriched in the ES 
population, while XEN markers such as Gata4/6, Sox7/17, Dab2, and PDGFRA were 
significantly enriched in XEN cells (Figure 4-4A, B). Differentially expressed genes and 
proteins enriched in either ES or XEN cells were selected and analyzed by gene ontology 
to classify targets based on their associated biological process (Figure 4-5A-D), cellular 
compartment (Figure 4-5E-H) and molecular process (Figure 4-5I-L). Targets from ES 
cells were enriched for biological processes associated with multicellular organism 
development and regulation of transcription (Figure 4-5A, B). Conversely, XEN cells 
terms were associated with various signaling pathways, endodermal development, and 
extracellular matrix organization (Figure 4-5C, D) to list a few. 
Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis was also 
performed on genes and proteins to identify biological pathways specific to each 
population (Figure 4-4C-G). XEN cells expressed targets primarily involved in 
proteoglycan metabolism and endoplasmic reticulum processing (Figure 4-4F, G), as 
reported previously [18]. However, targets involved in metabolism of xenobiotics by 
cytochrome P450 and glucose/pyruvate metabolism were enriched in the ES population 
and represent two common KEGG pathways between the RNAseq and MS datasets (Figure 
4-4C, D). Notably, three targets that were highly enriched in both datasets and linked to 
glucose metabolism were aldehyde dehydrogenase 1 family member B1 (ALDH1B1), 
phosphoenolpyruvate carboxykinase 2 (PCK2) and lactate dehydrogenase B (LDHB, 
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Figure 4-4E). Together, these data suggest that these targets and their metabolites may play 































































































































































































































































































































































Figure 4-4: Bulk transcriptomic and proteomic analysis of ES and XEN cells.  
(A) Volcano plots of differentially expressed genes from bulk RNA sequencing of ES 
and XEN cells cultured under normal conditions. (Fold change > 2 and adjusted P < 
0.01). Genes enriched in ES cells are highlighted in purple (2742 genes) and genes 
enriched in XEN cells are highlighted in orange (1716 genes). (B) Volcano plots of 
differentially expressed proteins from bulk proteomics of ES and XEN cells cultured 
under normal conditions. (Fold change > 2 and adjusted P < 0.01). Proteins abundant in 
ES cells are highlighted in purple (165 proteins) and proteins abundant in XEN cells are 
highlighted in orange (298 proteins). (C) Dot plot representing enriched KEGG 
pathways in ES cells from transcriptomic dataset. (D) Dot plot representing enriched 
KEGG pathways in ES cells from proteomic dataset. (E) Venn diagram of common 
targets from both transcriptomic and proteomic datasets for specific KEGG pathways. 
(F) Dot plot representing enriched KEGG pathways in XEN cells from transcriptomic 
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Figure 4-5: GO term analysis of ES and XEN cells. 
(A, B) Bar graph representing top 10 enriched GO biological processes terms in ES 
cells from transcriptomic and proteomic datasets. (C, D) Bar graph representing top 
10 enriched GO biological processes terms in XEN cells from transcriptomic and 
proteomic datasets. (E, F) Bar graph representing top 10 enriched GO cellular 
compartments terms in ES cells from transcriptomic and proteomic datasets. (G, H) 
Bar graph representing top 10 enriched GO cellular compartments terms in XEN cells 
from transcriptomic and proteomic datasets. (I, J) Bar graph representing top 10 
enriched GO molecular functions terms in ES cells from transcriptomic and 
proteomic datasets. (K, L) Bar graph representing top 10 enriched GO molecular 
functions terms in XEN cells from transcriptomic and proteomic datasets. 
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4.3.4 Enzymes involved in lactate homeostasis are upregulated in 
XEN cells 
Pyruvate is converted into lactate by the activity of LDHA and converted back by LDHB; 
since the latter was enriched in the ES population (Figure 4-4A-E), and lactate was enriched 
in XEN cells intracellularly (Figure 4-3C), we sought to further investigate the levels of 
enzymes involved in lactate metabolism. qRT-PCR results showed significantly higher 
Ldha/Ldhb mRNA abundance in XEN cells compared with ES cells (P < 0.01, Figure 4-
6A), and this was confirmed at the protein level using immunoblot analysis (Figure 4-6B). 
Extracellular lactate levels were also measured, and results showed significantly higher 
levels in XEN cells (P < 0.05, Figure 4-6C). Furthermore, the expression of the lactate 
transporter Mct1 (Figure 4-6D), but not Mct4 (Figure 4-6E), was significantly upregulated 
in XEN cells (P < 0.0001) and is a prime candidate linked to these high extracellular lactate 
levels.  
Pyruvate can also be oxidized in the mitochondria by the pyruvate dehydrogenase complex 
(PDC) to generate acetyl-CoA. This conversion is dependent on the activity of the PDC, 
which is negatively regulated by phosphorylation of the E1α subunit by members of the 
pyruvate dehydrogenase kinase (PDK) family. Expression analysis shows that Pdk1, 2 and 
4, but not Pdk3, were significantly downregulated in XEN cells (Figure 4-6F-I). Similarly, 
immunoblot analysis revealed low levels of PDC-E1αSer232/Ser293 in XEN cells (Figure 4-
6J), indicating that the PDC is active and would suggest higher OXPHOS activity. 
However, expression analysis of the mitochondrial pyruvate carriers Mpc1 (Figure 4-6K), 
but not Mpc2 (Figure 4-6L), showed significantly reduced expression in XEN cells (P < 
0.0001). Thus, despite having an active PDC, pyruvate in XEN cells fails to enter the 
mitochondria, and instead is preferentially converted to lactate by the enhanced LDHA 
activity (Figure 4-6A, B). These results suggest that lactate may participate in specifying 
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Figure 4-6: Levels of enzymes involved in pyruvate metabolism in ES and XEN 
cells.  
(A) Bar graph of qRT-PCR analysis of Ldha/Ldhb ratio in ES and XEN cells. Rpl14 
was used a constitutive gene for qRT-PCR. (n = three biological replicates, **P <0.01). 
(B) Representative immunoblot analysis showing levels of LDHA and LDHB in ES 
and XEN cells. β-ACTIN served as a loading control. (n = three biological replicates). 
(C) Bar graph of extracellular quantification of lactate levels in ES and XEN cells by 
BioProfile®400 Chemical Analyzer. (n = three biological replicates, *P < 0.05). (D, E) 
Bar graph of expression level of Mct1 and Mct4 in ES and XEN cells. FPKM was used 
for RNAseq data. (n = three biological replicates, ****P <0.0001). (F-I) Bar graph of 
FPKM of Pdk1-4 in ES and XEN cells. (n = three biological replicates, ns = not 
significant, **P <0.01, ****P <0.0001). (J) Representative immunoblot analysis 
showing levels of PDK1, PDK4, PDC-E1αpSer232, PDC-E1αpSer293, and PDC-E1α in ES 
and XEN cells. (n = three biological replicates). (K, L) Bar graph of expression level 
of Mpc1 and Mpc2 in ES and XEN cells. FPKM was used for RNAseq data. (n = three 
biological replicates, ***P <0.001). 
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4.3.5 Promoting intracellular lactate enhances XEN differentiation 
Given the previous data highlighting a potential role for lactate in XEN cells, we sought to 
directly assess whether modulating lactate metabolism influenced XEN induction in vitro 
(Figure 4-8). We adopted a previously defined chemical cocktail [12] to induce naïve 
mouse ES cells towards the XEN lineage. Exogenous supplementation with LIF, Activin 
A and CHIR99021 (inhibitor of glycogen synthase kinase 3) in the absence of insulin 
(Figure 4-7A) promotes differentiation towards the XEN lineage as evident by elevated 
Gata6 and Dab2 transcript and low levels of Nanog and Oct4 (Figure 4-7B-E).  
To test whether lactate metabolism plays a role in XEN differentiation, we used two 
approaches. In the first, three inhibitors were selected, two of which would promote 
intracellular lactate accumulation (UK5099 and AZD3965), while the other would promote 
pyruvate uptake into the mitochondria (Dichloroacetate, DCA). In the second approach, 
media was supplemented with exogenous L-lactate and cells were assessed for markers of 
pluripotency and XEN differentiation. UK5099 is a potent pan MPC inhibitor that prevents 
pyruvate uptake into the mitochondria [42,43], while AZD3965, a highly-specific MCT1 
inhibitor, reduces lactate secretion in human stem cells [39] and cancer cells [44]. The latter 
was used since MCT1 is the predominant transporter responsible for exporting lactate 
extracellularly in XEN cells (Figure 4-6D). Neither UK5099, AZD3965 or L-lactate 
affected Oct or Nanog expression (Figure 4-8C, F, G, J, K); however, Oct4 expression was 
slightly but significantly downregulated (P < 0.05) in ES cells cultured under LIF-2i and 
UK5099 (Figure 4-8B). In contrast, DCA-treated ES cells cultured with LIF-2i had slightly 
elevated Oct4 and Nanog expression when compared to controls (Figure 4-8N, O). 
Next, ES cells were induced towards the XEN lineage under control conditions or treated 
with inhibitors or supplemented with L-lactate. ES cells treated with UK5099 in XEN 
induction media were not viable after 48h post treatment (Figure 4-8D, E), while 
surprisingly those cultured with either AZD3965 (Figure 4-8H, I) or supplemented with L-
lactate (Figure 4-8L, M) for 96h showed enhanced Gata6 and Dab2 expression when 
compared to controls. Conversely, when ES cells were treated with DCA in XEN induction 
media, thereby promoting pyruvate uptake into the mitochondria and reducing intracellular 
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lactate, Gata6 and Dab2 expression were significantly downregulated when compared to 
controls (P < 0.05, Figure 4-8P, Q). Therefore, promoting intracellular lactate 
accumulation was associated with enhanced XEN induction in vitro, highlighting a novel 
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Figure 4-7: In vitro induction of ES cells towards the XEN lineage. 
(A) Schematic diagram of the methodology of cXEN induction in vitro. (B, C) Bar 
graph of expression level of Nanog and Oct4 in ES cells induced towards the XEN 
lineage over 8 days. Rpl14 was used a constitutive gene for qRT-PCR. (n = three 
biological replicates). (D, E) Bar graph of expression level of Gata6 and Dab2 in ES 
cells induced towards the XEN lineage over 8 days. Rpl14 was used a constitutive gene 











































































































































































































































































































































































































Figure 4-8: Intracellular lactate enhances XEN differentiation in vitro.  
(A) Schematic diagram of glucose metabolism and the metabolic enzymes involved. 
Green is indicative of treatments that increase intracellular lactate and red is indicative 
of treatment that decrease intracellular lactate. (B, C) Bar graph of expression level of 
Oct4 and Nanog in ES cells in 2i-LIF with or without 50µM UK5099 for 48h. Rpl14 
was used a constitutive gene for qRT-PCR. (n = three biological replicates, *P <0.05). 
(D, E) Bar graph of expression level of Gata6 and Dab2 in ES cells induced towards 
a XEN lineage with or without 50µM UK5099 for 96h. Rpl14 was used a constitutive 
gene for qRT-PCR. (n = three biological replicates, *P <0.05). (F, G) Bar graph of 
expression level of Oct4 and Nanog in ES cells in 2i-LIF with or without 250nM 
AZD3965 for 48h. Rpl14 was used a constitutive gene for qRT-PCR. (n = three 
biological replicates). (H, I) Bar graph of expression level of Gata6 and Dab2 in ES 
cells induced towards a XEN lineage with or without 250nM AZD3965 for 96h. Rpl14 
was used a constitutive gene for qRT-PCR. (n = three biological replicates, *P <0.05). 
(J, K) Bar graph of expression level of Oct4 and Nanog in ES cells in 2i-LIF with or 
without 5mM L-lactate for 48h. Rpl14 was used a constitutive gene for qRT-PCR. (n 
= three biological replicates). (L, M) Bar graph of expression level of Gata6 and Dab2 
in ES cells induced towards a XEN lineage with or without 5mM L-lactate for 96h. 
Rpl14 was used a constitutive gene for qRT-PCR. (n = three biological replicates, *P 
<0.05). (N, O) Bar graph of expression level of Oct4 and Nanog in ES cells in 2i-LIF 
with or without 5mM DCA for 48h. Rpl14 was used a constitutive gene for qRT-PCR. 
(n = three biological replicates, *P <0.05, **P <0.01). (P, Q) Bar graph of expression 
level of Gata6 and Dab2 in ES cells induced towards a XEN lineage with or without 
5mM DCA for 96h. Rpl14 was used a constitutive gene for qRT-PCR. (n = three 






Figure 4-9: Schematic representation of the role lactate plays in XEN 
differentiation in vitro.  
Schematic of ES cells (in purple) and XEN cells (in orange) displaying different 
LDHA-to-LDHB and pyruvate-to-lactate ratios depending on the developmental stage. 
In addition, supplementation with L-lactate or treatment with MCT1 inhibitor, 
AZD3965, enhances intracellular lactate accumulation and therefore, XEN induction. 
However, treatment with DCA, a PDK inhibitor, blocked XEN differentiation in vitro.  
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4.4 « Discussion » 
We have shown previously that F9 cells mimic the transition to a XEN-like lineage when 
co-treated with retinoic acid and a cAMP analog, and more importantly, these cells 
exhibited a metabolic phenotype reliant exclusively on glycolysis [21]. While recent 
reports have expanded on the metabolic profiles observed in the early embryonic lineages 
[18,19], a comprehensive analysis of the metabolites and their roles during development 
remains lacking. Our data indicates that feeder-free XEN cells are sensitive to glycolytic 
inhibition when compared with OXPHOS inhibition (Figure 4-2A, B). This phenomenon 
is also observed in mouse primed stem cells, human stem cells [19] and canine epiblast 
stem cells [45], suggesting that these characteristics are adaptive mechanisms linked to a 
developmental stage. Furthermore, XEN cells possess altered glycolytic enzyme levels 
involved in pyruvate and lactate homeostasis (Figure 4-6). Recent reports suggested that 
XEN cells rely on OXPHOS metabolism for energetic needs [18]; however, the 
developmental stage and culture condition of XEN cells may influence their metabolic 
profile. For instance, primitive endoderm cells are present within the ICM at 3.5 days post 
fertilization, and they further commit into parietal and visceral endoderm cells shortly after 
implantation. A similar phenomenon is observed between preimplantation naïve versus 
post-implantation primed ES cells, which display distinct metabolic profiles [19], 
suggesting that XEN cells may exhibit a unique metabolic signature depending on their 
developmental stage. In addition, the localization of XEN cells varies depending on the 
stage of development, where primitive endoderm cells reside within the ICM, visceral 
endoderm cells surround the epiblast while parietal endoderm cells interact with 
trophoblast stem cells are along the inner surface of the trophectoderm [46]. Therefore, the 
precise identity of these XEN cells and their interaction with the microenvironment may 
influence their metabolic needs. Lastly, culture conditions vary between trophoblast, ES 
and XEN cells, and it is known that the latter can be derived using various culture 
conditions and supplements [9-13,15-17,47-49]. Together, the ability to derive XEN cells 
by various means would contribute to their heterogeneity [9,48] and potentially affect the 
metabolic profile of these cells. For example, XEN cells can be generated by the 
overexpression of Gata4 in ES cells [15,49] or reprogramming fibroblasts using a chemical 
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cocktail [13]. While both methods result in the establishment of XEN cells, Gata4-induced 
ES cells display gradual reduction in hexokinase 2 (HK2) and glucose transporter 1 
(GLUT1) levels [50], while XEN cells reprogrammed from fibroblasts display elevated 
levels of those same markers [13]. Together, these differences highlight the metabolic 
complexity and plasticity of all cells in the developing embryo, and of XEN cells 
specifically. 
As the embryo develops its metabolic needs shift to meet energetic demands for growth 
and development and this metabolic rewiring is dependent on extrinsic and intrinsic cues. 
The blastocyst resides in a hypoxic environment, with oxygen tension dropping 
significantly during implantation [51]. This hypoxic environment results in the 
stabilization of hypoxia-inducible factor one alpha (HIF1α), resulting in the increase in 
enzymes shifting the metabolic profile towards glycolysis. During implantation, however, 
angiogenesis promotes reoxygenation of the embryo triggering a switch to OXPHOS. 
Despite residing in a similar environment, trophoblast stem cells rely on OXPHOS 
metabolism, largely to fuel the sodium/potassium ion pumps required for blastocoel 
expansion [52]. While extrinsic factors such as the microenvironment are important, 
intrinsic factors play a key role in remodeling metabolic needs to meet developmental 
programs. For example, naïve ES cells are metabolically flexible and utilize both glycolysis 
and OXPHOS metabolism. However, the transition to a primed state is marked by a switch 
to glycolytic metabolism, which is largely due to HIF1α stabilization within the cell [19]. 
While changes in the levels of metabolic enzymes play a role in remodelling cellular 
metabolism, the metabolites resulting from the activity of these enzymes are instrumental 
in regulating pluripotency and/or differentiation. Our study is the first to provide a 
comprehensive snapshot of the intracellular metabolite profile of feeder-free XEN cells 
and reveals how elevated levels of key metabolites, mainly lactate, influence 
differentiation.  
Lactate, the primary source of carbon for the TCA cycle in both normal and cancer tissues 
[53], is generated by the activity of LDHA, reportedly enriched in XEN cells (Figure 4-
6A, B). Since lactate can be converted to pyruvate by LDHB, the stoichiometric ratio 
between the two isoforms dictates the fate of pyruvate and lactate. In addition, the oxidation 
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of pyruvate by the PDC is required for its conversion to acetyl CoA, and the activity of the 
complex is regulated by the PDK family. Despite detecting elevated intracellular (Figure 
4-3C) and extracellular (Figure 4-6C) lactate levels in XEN cells, the PDC was not 
phosphorylated and is therefore active in XEN cells (Figure 4-6J). While reduced 
expression of Mpc1 was found in XEN cells (Figure 4-6K), which may explain the 
rerouting of pyruvate to lactate, PDC is known to have moonlighting abilities and can 
translocate to the nucleus where it generates acetyl CoA for acetylation of H3K9 and 
H3K18 [54]. Thus, since total lysates were used to analyze the phosphorylation status of 
the PDC in ES and XEN cells, it is possible that a higher proportion of the active complex 
is nuclear and not mitochondrial. Nevertheless, since elevated intracellular lactate levels 
were found in XEN cells (Figure 4-3C), it was hypothesized that lactate plays a crucial role 
during XEN differentiation.  
Chemical inhibition to promote intracellular lactate accumulation (Figure 4-8H, I) or 
supplementation of XEN induction media with L-lactate (Figure 4-8L, M) showed 
enhanced XEN differentiation. Surprisingly, blocking pyruvate uptake into the 
mitochondria using UK5099 led to cell mortality (Figure 4-8D, E). Alternatively, 
promoting pyruvate uptake into the mitochondria by inhibiting PDKs resulted in significant 
reduction in XEN differentiation (Figure 4-8P, Q). Therefore, our results support the notion 
that maintaining intracellular lactate levels potentiates ES cells towards a XEN lineage. 
Since lactate can stabilize HIF1α and promote a glycolytic phenotype [55], the lactate-
HIF1α axis may provide a mechanism for XEN differentiation. In addition, lactate can also 
inhibit histone deacetylases [56], and in conjunction with active PDC (Figure 4-8J), 
promote hyperacetylation, which we observed in XEN cells (data not shown). Thus, it 
appears lactate is a key player linking metabolism with epigenetic factors and transcription. 
These links provide insight into the role lactate plays in directing the differentiation of 
XEN cells, and together they underscore the importance of how the metabolic profile 
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5 « General Discussion and Conclusions » 
5.1 « Summary of findings » 
The mammalian embryo undergoes coordinated cell divisions resulting in the formation of 
the blastocyst, a structure comprised of three cell lineages: embryonic stem cells, primitive 
endoderm cells and trophoblast stem cells. These three cell types can be isolated, derived 
and maintained indefinitely in vitro, allowing for their exploitation to answer fundamental 
questions pertaining to development. It is well-understood that manipulating signaling 
pathways can alter cell fate decisions. More recently, metabolism and its downstream 
products have garnered attention with their influence on pluripotency and differentiation. 
Overall, I hypothesized that both undifferentiated F9 and ES cells have distinct metabolic 
and Nox expression profiles compared to their XEN counterparts, and that changes in these 
profiles direct cell fate determination. 
In Chapter 2 using F9 cells, I observed a significant increase in Nox1 and Nox4 expression, 
protein abundance and activity in differentiated XEN-like cells. However, no observable 
changes were seen in the various accessory components of the NOX family. Since RA 
induces Gata6 expression [1] and GATA6 is involved in the XEN identity [2-4] and the 
Nox1 promoter region contains a GATA6 binding site [5], I tested if GATA6 regulates 
Nox1 and/or Nox4 expression. Overexpressing Gata6 induced XEN-like differentiation and 
notably, both Nox1 and Nox4 expression were significantly upregulated. Next, I examined 
the necessity of NOX activity using chemical inhibitors and genetic perturbations where 
both showed an attenuation in XEN-like differentiation. Alternatively, while Nox1 and 
Nox4 overexpressing-cells produced ROS, no differentiation was observed, despite having 
a mildly active canonical WNT/β-catenin signaling. I concluded that a secondary source of 
ROS (potentially mitochondrial), in combination with NOX-derived ROS is required to 
induce differentiation.  
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In Chapter 3, I attempted to answer two biological questions: first, whether XEN-like cells 
produce mitochondrial ROS sufficient to induce differentiation; and second, the effect 
passaging has on the differentiation potential and bioenergetic profile of XEN-like cells. 
Initially, I examined the transcript and protein abundance of key metabolic enzymes 
involved in glycolysis and OXPHOS metabolism. Analysing the levels of LDHA, LDHB, 
PDKs and the phosphorylation status of PDH-E1α subunits suggested that the 
differentiation towards a XEN-like lineage is accompanied by a switch from OXPHOS to 
glycolytic metabolism. To test whether the reliance on glycolysis is due to mitochondrial 
defects, I examined the levels of ETC proteins, and the expression of various markers 
involved in mitochondrial dynamics. The SDHB subunit in complex II was significantly 
downregulated in XEN-like cells, inferring reduced mitochondrial activity; however, the 
expression of mitochondrial fusion markers was significantly higher. Therefore, XEN-like 
cells exhibit a molecular signature indictive of fused mitochondria, but it is possible that 
they do not rely on OXPHOS metabolism due to the downregulation in ETC components. 
To address whether this observation is reminiscent of in vivo development, a more 
comprehensive multiomic analyses approach on embryo-derived XEN cells was taken 
(Chapter 4). 
With respect to passage number on the differentiation and metabolism of XEN-like cells, 
surprisingly, both early and late-passage cells were able to differentiate by RA. 
Unexpectedly, early- and late-passage cells, however, had a dramatically different 
metabolic profile, signifying the importance of evaluating stem cell metabolism prior to 
their utilization for regenerative medicine.  
Though the data from the F9 model was compelling, I shifted focus to using feeder-free ES 
cells and embryo-derived XEN cells (XEN cells), both of which are relevant models that 
recapitulate either EPI or PrE lineage, respectively. While reports have documented the 
metabolic profile of ES cells, little is known about the bioenergetics of XEN cells and 
inconsistencies exist [6-9]. In Chapter 4, I started by testing the sensitivity of either 
populations to glycolytic or OXPHOS inhibition. The inhibition of either glycolysis or 
OXPHOS in ES cells resulted in a similar reduction in cell viability, namely due to their 
equal reliance on either metabolic pathway [6]. However, XEN cells showed a stark 
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reduction in cell viability when glycolysis was perturbed, indicating their dependence on 
glycolytic metabolism. Targeted and untargeted metabolomics coupled with biochemical 
assays was used to detail the intracellular metabolic composition of both populations. 
Several amino acids were found to be enriched in the XEN population, but more 
specifically lactate and 2-hydroxyglutarate, from glycolysis and the TCA cycle, 
respectively, were highly enriched in XEN cells. To expand our understanding on how 
these metabolites influence cell fate, I performed bulk RNA sequencing and proteomic 
analysis followed by GO and KEGG analysis on differentially expressed targets. In short, 
three targets were highly enriched and had a link to metabolism: ALDH1B1, PKC2 and 
LDHB. Since a switch to glycolysis with XEN-like differentiation was observed (Chapter 
3), with the intracellular enrichment of lactate, and sensitivity to glycolytic inhibition in 
XEN cells (Chapter 4), my conclusions were that XEN cells preferentially rely on 
glycolytic metabolism. This conclusion was further supported by analysis of transcript and 
protein abundance of LDHA, LDHB and various lactate transporters. However, unlike that 
in the F9 model, the PDH-E1αpSer232/pSer293 levels declined significantly in XEN cells, 
indicative of an active complex, despite pyruvate preferentially being converted into 
lactate. One explanation for the reliance on glycolysis may be due to the low abundance of 
Mpcs, thus restricting pyruvate availability for acetyl-CoA production. Despite 
observations being largely phenomenology, would altering lactate levels chemically 
influence cell fate? Results revealed that inhibiting mitochondrial pyruvate uptake was 
lethal, whereas inhibiting MCT1 or supplementing with exogenous L-lactate enhanced 
XEN differentiation in vitro. Alternatively, blocking the phosphorylation of the PDC 





5.2 « Discussion and Significance of Research » 
5.2.1 ROS is required for stem cell-like differentiation 
The NOX family of enzymes catalyze the reduction of oxygen into ROS using NAPDH as 
an electron acceptor. In the F9 teratocarcinoma model, all Nox family members are 
expressed, and exogenous ROS supplementation induced XEN-like differentiation [10]. I 
also showed significant enrichment at the transcript and protein levels of both NOX1 and 
NOX4 in XEN-like cells (Chapter 2). Although no reports have analyzed in detail the 
expression and protein levels of the NOXs in the mouse embryo during preimplantation 
development, publicly available scRNA-seq datasets show that the expression of Nox4 is 
exclusive to the PrE with p22phox and Rac1 present in both PrE and TE lineages (data not 
shown). The focus was on both NOX1 and NOX4, because Nox1 expression is regulated 
by GATA6 in colorectal adenocarcinoma cells [11] and in F9 cells (Chapter 2), NOX4 
requires the least number of subunits (p22phox only) [12] and can produce H2O2 directly. 
Since both chemical agents and genetic perturbations attenuated XEN-like differentiation 
(Chapter 2), a link must exist between NOX proteins, ROS, and differentiation towards the 
XEN lineage.  
The canonical WNT/β-catenin pathway connects NOX-derived ROS to differentiation, and 
our lab has shown that WNT6 activates the pathway [13] by recruiting disheveled (DVL) 
to the plasma membrane thus disrupting the destruction complex. Active WNT signaling 
allows the translocation of β-catenin into the nucleus where it binds to TCF/LEF to induce 
the expression of WNT target genes. At the transcript and protein level, DVL and its 
interactor nucleoredoxin (NRX) are expressed, albeit no change during differentiation [14]. 
However, the DVL-NRX complex is regulated post-translationally by redox signaling 
[14,15] where NRX binds DVL when reduced while it dissociates under oxidative 
conditions. Therefore, it is possible that the physiological levels of ROS generated by the 
NOX proteins result in the disassociation of NRX from DVL, thereby activating the 
WNT/β-catenin pathway and promoting XEN-like differentiation. This observation was 
also seen in colonic epithelial cells where WNT alone was not sufficient to activate the 
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pathway, but instead it required ROS produced by NOX1 for the dissociation of NRX from 
DVL [16].  
NOX proteins subunits also play an important role in ROS production and WNT/β-catenin 
pathway activation. For instance, RAC1 is required for the oxidase activity of NOX1 and 
NOX2 [17], but when a dominant negative RAC1 is expressed, ROS production is 
significantly reduced resulting in the destabilization of β-catenin [16]. Similar observations 
have been made regarding the WNT/β-catenin pathway and PrE formation in vitro as 
treating mouse ES cells with WNT3A induces Gata6 and Dab2 expression [18]. In vivo 
experiments also show that embryos lacking β-catenin display inappropriate visceral 
endoderm organization and subsequent failure to form an anterior-posterior axis. However, 
embryos injected with GSK3-insenstive β-catenin display high number of visceral 
endoderm cells [19]. Whether NOX-derived ROS regulates WNT/β-catenin signaling in 
the embryo remains unknown. One caveat is that Nox1 and/or Nox4 overexpression alone 
did not promote XEN-like differentiation and failed to produce sufficient ROS to activate 
the WNT/β-catenin pathway. Therefore, an additional source of ROS, including that from 




5.2.2 Metabolic regulation of cell fate specification  
It is widely accepted that metabolism plays an active role in modulating signaling pathways 
and the epigenetic landscape to direct stem cell fate [20,21]. Evidence from the increase in 
intra- and extracellular lactate levels would indicate XEN-like cells (Chapter 3) and XEN 
cells (Chapter 4) display a metabolic signature dependent on glycolysis with lactate playing 
a central role. 
Lactate, once considered an end-product of glycolysis, is implicated in bioenergetic 
demands, redox homeostasis, epigenetic modifications [22] and many more [23]. In mice, 
glucose-derived lactate is the primary carbon source for the TCA cycle in all tissues apart 
from the brain; a similar trend was seen in cancer cells [24]. With regard to in vivo 
development and in preparation for implantation, glycolysis is favoured as the secreted 
lactate creates an acidic environment activating matrix metalloproteinases [25], which aid 
in the degradation of the uterine lining [26]. As the embryo begins to implant, the 
environment becomes more hypoxic, thus more lactate is produced, which induces 
angiogenesis and oxygenation of the embryo [27].  
In addition to the abovementioned roles, recent evidence has implicated lactate in 
epigenetic regulation [22]. Zhang and colleagues demonstrated that lysine residues on 
histones can be modified with a lactyl group. This group was from glucose-derived lactate, 
a modification sensitive to changes in lactate levels or perturbations to glycolysis. During 
the reprogramming of fibroblasts into pluripotent stem cells, the high glycolytic flux 
increases acetyl-CoA and lactate levels, which in turn enhance histone acetylation and 
lactylation, respectively [28]. These modifications favour an open chromatin state, 
particularly at loci of pluripotency genes. In addition, lactate inhibits histone deacetylases 
(HDACs) in vitro with concentrations ranging from 10-40mM, in comparison to the more 
potent inhibitors, including TSA (nanomolar range) and butyrate (micromolar range), with 
all treatments resulting in hyperacetylation and similar changes in gene expression [29]. 
Based on these results I predict that a similar mechanism occurs in XEN specification, 
where the lactate produced is involved in histone lactylation as well as inhibiting HDACs 
thereby facilitating H3K27Ac.  
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Lactate levels can be regulated by hypoxia through HIF1α. Under normoxic conditions, 
HIF1α is synthesized and degraded rapidly through the PHD-VHL complex while under 
hypoxic conditions, the oxygen-dependent activity of PHD is halted [30], thus allowing for 
the stabilization and subsequent translocation of HIF1α into the nucleus to upregulate genes 
involved in glycolysis [31]. In tumours, poor angiogenesis in masses larger than 1mm 
creates hypoxic pockets that stabilize HIF1α. Additionally, HIF1α can be stabilized 
through oncogenes such as v-src and HRAS or by inactivating tumour suppressors like p53 
and PTEN [32,33]. EpiSCs, which are glycolytic in nature and express high levels of 
glycolytic enzymes such as Ldha, Pdk1 and Pygl, stabilize HIF1α under normoxic 
conditions [6]. HIF1α is also stabilized by the product of its transcriptional targets such as 
LDHA [34]. Lactate and pyruvate compete with α-ketoglutarate, the latter being required 
for PHD activity, thus inhibiting it [35]. ROS has also been implicated in HIF1α 
stabilization through the oxidation of Fe2+ into Fe3+ thus blocking the hydroxylase activity 
of the PHD enzyme [36].  
Together, my working model begins upstream with GATA6 upregulating Nox1 and Nox4, 
which in turn produce physiological levels of ROS that result in the activation of the 
WNT/β-catenin pathway (Chapter 2). Simultaneously, the ROS stabilizes HIF1α, which in 
turn upregulates enzymes involved in glycolysis such as LDHA and PDK1 (Chapter 3 and 
4). LDHA converts pyruvate into lactate, which acts in a positive feedback loop to block 
PHD activity thereby further stabilizing HIF1α. Consequently, the accumulation of 
intracellular lactate (Chapter 4) acts as substrate for lactylation and inhibits HDACs 








Figure 5-1: Model of the role ROS and lactate play in XEN cells. 
In this working model, GATA6 binds and upregulates the expression of Nox1 and Nox4, 
which in turn result in the production of ROS. First, NOX-derived ROS plays a central 
role by stabilizing β-catenin by promoting the release of NRX from DVL, which results 
in the activation of the WNT/β-catenin pathway. Second, ROS stabilizes HIF1α under 
normoxic conditions by indirectly inhibiting PHD activity. Stabilized HIF1a promotes a 
glycolytic phenotype by upregulating LDHA, thus increasing the levels of intracellular 
lactate. Lactate then further stabilizes HIF1a by inhibiting PHD activity and participates 
in epigenetic regulation by promoting histone lactylation (La) and acetylation (Ac). 
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5.3 Study Limitations and Future Studies » 
It is extraordinary how stem cells can be propagated indefinitely and directed towards 
specific cell fates. To-date, ES cells have been established from a variety of species 
including mouse [37], primate [38], human [39], pig [40], and canine [41] to name a few. 
While the in vitro systems used in my thesis capture certain aspects of development and 
are accepted tools, they remain limited due to their 2D nature and more importantly, lack 
in vivo data. Thus, they are unable to reproduce the spatial patterning, shape, size and in 
utero environment observed in vivo. Despite these limitations, several new methods exist 
to improve the 2D system and recapitulate in vivo settings.  
Recent reports have shown that culturing human [42] or mouse [43] ES cells on defined 
micropattern surfaces under specific morphogens results in the self-organization and 
formation of the three germ layers, which allows for the examination of signaling pathways 
and its components. Various modalities such as single-cell resolution imaging and single-
cell multi-omics provide a comprehensive understanding of aspects of development that 
would be technically difficult to capture in vivo. In addition, generation of knockout lines 
in ES cells is achievable thus allowing researchers to investigate the role of signaling 
pathways during development. While the micropattern system does have its advantages, 
the cells are limited to 2D, therefore, experiments should always be validated using an in 
vivo system.  
One of the earliest ways researchers used to recapitulate the 3D environment of the embryo 
is to form embryoid bodies (EBs) from ES cells. Historically, EBs were first generated 
using EC cells [44] and have been later adopted in ES cells [45,46]. The generation of EBs 
from ES culture is done by the removal of self-renewal conditions and culturing cells in 
suspension or on bacterial grade plates or as hanging drops. While this process is relatively 
simple, the EBs generated are heterogenous in size and cellular composition, thus making 
it difficult to reach experimental conclusions. To bypass these inconsistencies, ES cells can 
be cultured in micro-well plates, which produce large EBs, with uniform size and shape, 
making them a reproducible model to study differentiation with a 3D context. While EBs 
are generated and differentiated spontaneously or under defined conditions, they remain 
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limited in mimicking early embryonic development. Recently, Rivron and colleagues 
established a method of mixing embryonic and trophoblast stem cells in vitro resulting in 
their self-assembly into a structure, a blastoid, which morphologically and transcriptionally 
resemble the E3.5 blastocyst [47]. Despite their ability to implant in a host, blastoids fail 
to give rise to mature blastocysts in vitro and in vivo. Remarkably, co-culturing of ES, XEN 
and TS cells in an extracellular matrix scaffold yielded a structure containing all three 
lineages and mimic the gastrula with enhanced developmental potential [48,49]. 
Collectively, any of these systems can be used to help us better understand the role of ROS 
and metabolism in embryonic development. 
While the 2D and 3D models provide cues to embryonic development they do not mimic 
the environment around the embryo seen in vivo. Specifically, oxygen tension plays an 
important role in regulating metabolism and cell fate. However, many studies on 
pluripotent stem cells have been conducted at atmospheric conditions (21% O2), while the 
oxygen tension in the female reproductive tract is roughly 5% [50-52]. Embryos that 
develop under 21% oxygen tension are developmentally compromised when compared to 
their 5% counterparts [53,54]. Despite the high oxygen levels, these embryos show 
significantly higher levels of pyruvate uptake, which not only acts as a substrate but as a 
powerful antioxidant to reduce hydrogen peroxide levels [55]. The embryo can utilize its 
antioxidant defense system but prolonged exposure to high oxygen levels exhausts the 
system resulting in ROS buildup and arrest. Alternatively, hypoxia can regulate stem cell 
fate [6], with HIF1α stabilization enhancing glycolytic metabolism and subsequently the 
transition from a naïve to a primed state. However, chronic exposure to hypoxic conditions 
can be lethal to the embryo [56]. Therefore, optimizing the culture condition environment 
to recapitulate in utero setting would be crucial to capture a true glimpse of the role 
metabolism plays during embryonic development. 
Lastly, a major limitation of this thesis is the lack of genetic studies (except for Chapter 2). 
While chemical inhibitors used in Chapter 3 and 4 do alter metabolism and cell fate, they 
have the potential to do so through off targeting effects. For example, 2-DG, a chemical 
used to inhibit glycolysis, can activate AKT signaling through PI3K [57,58]. To minimalize 
this limitation, I used additional chemical agents that target different enzymes involved in 
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glycolysis or OXPHOS. However, genetic approaches using CRISPR-Cas9 to knockout 
various key enzymes, most notably LDHA and LDHB, are necessary to corroborate the 
chemical data. Collectively, however, with the resources provided I implicated NOX1/4-
derived ROS in XEN-like differentiation and expanded on our knowledge of the metabolic 
phenotype to XEN cells, particularly a role for lactate in XEN induction in vitro.   
While these limitations serve as key points to consider in future experiments, corroborating 
the data by other means would not only serve to better understand the role of ROS and 
lactate in an in vivo model or synthetic embryo, but by examining the effects of hypoxia 
and knocking out key metabolic enzymes would provide invaluable clues on how 
metabolism influences primitive endoderm formation. Briefly, I will suggest specific 
experiments pertaining to each chapter. In Chapter 2, GATA6 was suggested as being 
responsible for upregulating Nox1 and Nox4 expression. Although a report exists pertaining 
to GATA6-Nox1 interaction [11], no data supports this for Nox4. Thus, performing a ChIP 
assay to identify whether GATA6 directly binds to the Nox4 promoter is required. 
Although differentiated F9 cells are XEN-like, it is possible that NOXs play a different role 
in embryo-derived XEN cells, hence it also necessary to test directly whether NOX1 and 
NOX4 and the ROS generated by them, are required for PrE formation in vivo. 
In Chapters 3 and 4, the metabolic profile in XEN-like cells and XEN cells were 
characterized. While studies were extended in Chapter 4 and metabolomics was used to 
identify specific intracellular metabolites in XEN cells, more detailed analyses are required 
to identify the role lactate plays in XEN differentiation. For example, fluorescent-labeled 
lactate could be used to track its localization (cytoplasmic versus nuclear). Typically, 
cytoplasmic lactate participates as a signaling molecule or in metabolism [59], whereas 
nuclear lactate was recently shown to modify histones, thus influencing the epigenetic 
signature of a cell [22,28,60].  
In addition to the abovementioned experiments, preliminary data showed basal 
mitochondrial respiration was significantly lower in XEN cells when compared to ES cells 
(See Appendix 1 for details). This reduced activity was not, however, due to structural 
issues as immunoblot analysis of fission and fusion markers, corroborated by TEM and 
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morphometric analysis, was indicative of mitochondrial fusion. Instead, immunoblot 
analysis revealed the downregulation of various subunits in the electron transport chain 
(ETC), namely from complex II, III and V. Therefore, in combination with the reduced 
mitochondrial substrate availability (Chapter 4), deregulation in ETC stichometry may also 
explain the reduced mitochondrial activity observed in XEN cells. In addition, one target 
that was highly enriched in our transcriptomic and proteomic datasets is the estrogen-
related receptor beta (ESRRB; Chapter 4), which has been shown to play a role in 
development and pluripotency [61-69], modulating cell cycle to drive ES cells towards 
either EpiSCs or XEN cells in vitro (bioRxiv) and metabolism [70,71]. I predict that 
ESRRB will act as a linchpin by regulating mitochondrial dynamics and metabolism, which 
consequently influences cell fate decisions. In collaboration with Bedzhov lab, a tamoxifen 
inducible Esrrb deletion and overexpression ES lines were derived and will be used to first 
assess the effects Esrrb will have on mitochondrial morphology. Next, both ES lines 
harboring either Esrrb deletion or overexpression will be differentiated towards the XEN 
lineage and characterized based on a panel of pluripotency and differentiation markers. 
Overall, these experiments will shed light on a novel role for ESRRB in modulating 





5.4 « Conclusion » 
Embryonic development is a complex process of orchestrating various signaling pathways 
and multiomic changes that ultimately establish cell fates. The first lineage specification 
segregates the TE from the pluripotent ICM, which is subsequently followed by the 
establishment of the EPI and the PE. While the focus has been on how transcription factors 
and signaling pathways instruct cells to adopt either EPI or PE fate, my thesis has provided 
insight on the role ROS and metabolism play during this fate decision. Specifically, the 
ROS generated by NOX1 and NOX4, which themselves are regulated by the endoderm 
master regulator GATA6, is necessary but not sufficient for XEN-like differentiation. I 
hypothesized that mitochondrial ROS acts in conjunction with NOX-derived ROS to 
induce XEN-like differentiation. Surprisingly, both XEN-like cells and XEN cells favour 
glycolytic metabolism over OXPHOS and when interrogated the intracellular metabolome, 
lactate was identified as a factor, which I later show is involved in enhancing XEN 
differentiation in vitro. Furthermore, I found that XEN cells re-route pyruvate from the 
mitochondria and despite having mature mitochondria, various ETC subunits were 
downregulated. Overall, my work implicates both ROS and metabolism in the acquisition 
of XEN fate in vitro and this work sets the stage to test whether these mechanisms are 
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In this section, I showcase two studies that do not directly contribute to the thesis but are 
relevant to the topic of metabolism and differentiation. Both studies are preliminary in 
nature and are incomplete to be considered a full chapter in the thesis. 
In appendix 1, we assessed mitochondrial activity and dynamics in both ES and XEN 
populations to try and explain the reliance on glycolytic metabolism we observed in 
Chapter 4. A portion of this has been accepted for publication in Stem Cells alongside a 
version of Chapter 4. 
In appendix 2, we uncovered a new role for the posttranslational modification O-
GlcNAcylation during extraembryonic endoderm differentiation in vitro. More 
importantly, in collaboration with the lab of Dr. Alexander Timoshenko, we implicated 






6 « Analysis of mitochondrial activity and ultrastructure in 
XEN cells » 
6.1 « Introduction » 
The late preimplantation blastocyst consists of two structures, the inner cell mass, which 
houses the pluripotent epiblast and primitive endoderm (PrE) cells and the trophectoderm 
(TE, placenta precursor). Epiblast cells give rise to the embryo proper while the PrE cells 
differentiate into parietal and visceral endoderm cells, which contribute to the yolk sacs 
and gut endoderm later in development [1]. While studying these lineages in vivo is 
advantageous, these specific lineages can be isolated from the blastocyst and maintained 
indefinitely in vitro.  
From the inner cell mass, embryonic stem (ES) cells or naïve ES cells are derived from the 
preimplantation epiblast and can either be cultured under FBS and leukemia inhibitory 
factor (LIF) [2,3] or under serum-free in LIF-2i (2i: inhibitors of GSK3 and MEK) [4]. 
Alternatively, ES cells can be isolated from the post-implantation epiblast as primed 
epiblast stem cells (EpiSCs) and are maintained with Activin A and FGF2 in culture [5,6]. 
Naïve and primed stem cells are interconvertible in vitro and possess different profiles of 
pluripotency markers, epigenetic signatures, clonogenicity, chimera contribution and 
developmental potential in vivo [7]. In addition to these stem cells, extraembryonic 
endoderm (XEN) cells can also be isolated from the pre- and post-implantation blastocyst 
and maintained indefinitely in vitro in FBS without exogenous factors [8,9]. XEN cells are 
morphologically heterogenous with the co-existence of round/refractile cells and 
epithelial-like cells, and while ES cells can repopulate the inner cell mass and contribute 
to chimeras, XEN cells mainly repopulate the parietal endoderm in vivo [8] with little 
contribution to the visceral endoderm [9]. Nevertheless, XEN cells can be differentiated 
chemically [10-12] or by overexpressing Gata4, Gata6 [13,14] and Sox17 [15] 
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transcription factors in ES cells. Regardless of the derivation method, downstream effectors 
activate the endoderm signaling program driving cells towards the XEN lineage in vitro. 
A major question that has recently surfaced is the role mitochondrial metabolism plays in 
influencing XEN, and other cell fate decisions. The mitochondrion is an important 
organelle involved in energy production, but it also plays key roles in macromolecule 
anabolism and catabolism, redox maintenance, Ca2+ signalling and waste management 
[16]. Mitochondrial activity is intimately linked to its structure, and it is implicated in 
directing cell fate decisions [17,18]. Mitochondrial morphology is altered by fission or 
fusion in response to metabolic requirement, stress and pluripotency or differentiation cues 
[19]. Fission is initiated by the mitochondrial fission factor (MFF), which recruits the 
dynamin-related protein 1 (DRP1). Once recruited from the cytosol, it is then 
phosphorylated on serine 616 making it active, thereby forming rings to constrict 
mitochondrial tubules. In contrast, mitochondrial transmembrane GTPases mitofusion-1 
and mitofusion-2 (MFN1 and MFN2, respectively) promote fusion of the outer 
mitochondrial membrane, while optic atrophy 1 (OPA1) operates on the inner 
mitochondrial membrane and cristae. Collectively, the relative levels of these players 
dictate the morphology of the mitochondria and cristae structure, and hence its activity. 
Differentiated F9 teratocarcinoma cells, a model that can recapitulate primitive endoderm-
like differentiation in vitro, express high levels of Mfn1 and Mfn2, yet have significantly 
downregulated levels of the complex II protein succinate dehydrogenase B (Chapter 3), 
indicative of reduced mitochondrial activity. More importantly, despite these high levels 
of mitochondrial fusion markers, these cells exhibit a metabolic phenotype reliant on 
glycolysis, as evident by elevated extracellular lactate levels in these cells. This 
counterintuitive phenomenon of cells having high levels of mitochondrial fusion markers 
but reliant on a glycolytic metabolism is also observed in pluripotent stem cells of the 
epiblast [20]. Naïve ES cells exhibit a bivalent metabolic profile, relying on both glycolysis 
and oxidative phosphorylation (OXPHOS), and possess a mitochondrial structure 
reminiscent of inactive mitochondria, round with immature cristae. However, primed 
EpiSCs are exclusively glycolytic, largely due to downregulation of complex IV proteins, 
yet they possess an elongated mitochondrial morphology with prominent cristae. It has 
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been suggested that the low levels of estrogen-related receptor beta (ESRRB) in EpiSCs 
relative to naïve ES cells may contribute to the deregulation in complex IV components 
resulting in low mitochondrial respiration [20]. Recently, Choi and colleagues 
characterized the metabolic profile of all three lineages of the blastocyst and found that 
basal mitochondrial respiration was significantly lower in XEN cells when compared to ES 
cells [21]. When cells were challenged with a mitochondrial uncoupler, respiration of XEN 
cells was higher, suggesting that they can use OXPHOS metabolism.  
In addition, one target that was highly enriched in our transcriptomic and proteomic 
datasets is the estrogen-related receptor beta (ESRRB; Chapter 4), which has been shown 
to play a role in development and pluripotency [22-30], modulating cell cycle to drive ES 
cells towards either EpiSCs or XEN cells in vitro (bioRxiv) and metabolism [31,32]. I 
predict that ESRRB will act as a linchpin by regulating mitochondrial dynamics and 
metabolism, which consequently influences cell fate decisions. 
In this report, we examined mitochondrial activity using flow cytometry and mitochondrial 
ultrastructure with transmission electron microscopy (TEM), which was corroborated by a 
detailed morphometric analysis on mouse ES and XEN cells in vitro. Results showed basal 
mitochondrial respiration was significantly lower in XEN cells when compared to ES cells. 
This reduced activity was not, however, due to structural issues as immunoblot analysis of 
fission and fusion markers, corroborated by TEM and morphometric analysis, was 
indicative of mitochondrial fusion. Instead, transcriptomic, and biochemical analysis 
revealed the downregulation of various subunits in the electron transport chain (ETC), 
namely from complex II, III and V. Despite these findings, the mechanism(s) for XEN cells 





6.2 « Materials and Methods » 
ES and XEN cell culture, in vitro XEN differentiation, protein extraction, quantification 
and immunoblot analysis and RNA isolation, cDNA synthesis and qRT-PCR analysis are 
as previously described in Chapter 4. 
6.2.1 Mitochondrial copy number by digital droplet PCR (ddPCR) 
RNA extraction and cDNA synthesis were as in Chapter 4 and ddPCR performed according 
to the manufacturer’s instructions (Bio-Rad). Briefly, reactions were with 50pg–50ng of 
cDNA, 100nM of forward and reverse primers and QX200TM ddPCRTM EvaGreenTM 
supermix (Bio-Rad). Samples and oil were loaded onto a DG8TM cartridge (Bio-Rad) and 
used in a QX200 droplet generator (Bio-Rad). Sample-oil mixtures were transferred into a 
96-well plate and processed using a C1000 Touch thermocycler (Bio-Rad). PCR steps were 
as follows: enzyme activation for 5 minutes at 95°C, denaturation for 30s at 95°C, 
annealing/extension for 1 minute at 58°C, and signal stabilization for 5 minutes at 4°C. 
Once complete, data acquisition was performed on QX200 Droplet reader using 
QuantaSoftTM Software (Bio-Rad). 
6.2.2 Transmission Electron Microscopy and Mitochondrial 
Morphometric Analysis 
Samples were prepared, fixed, and imaged as described previously [33]. Briefly, cells were 
seeded onto 0.1% gelatin-coated Nunc™Thermanox™ coverslips (Thermo Fisher 
Scientific) and grown for 48h at 37°C and 5% CO2. Cells were rinsed with pre-warmed 
PBS solution and fixed in a 1:1 mixture of Karnovsky’s fixative (2.5% glutaraldehyde and 
2% paraformaldehyde in 0.1M cacodylate buffer, pH 7.4) and maintenance media for 15 
minutes at 37°C. Cells were then fixed with 100% Karnovsky’s fixative for 2h at room 
temperature followed by four washes with cacodylate buffer for 10 minutes. Post-fixation 
was carried out with 0.5% osmium tetroxide in 0.1M cacodylate buffer for 1h followed by 
en-bloc staining overnight with 2% aqueous uranyl acetate at 4°C. Samples were 
dehydrated in an ascending series of ethanol solutions and embedded in Spurr’s resin at 
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60°C for 48h and sectioned (70nm) using an ultramicrotome (Reichert-Jung Ultracut E; 
Leica Microsystems, Wetzlar, Denmark). Images were examined and captured using a 
Philips CM10 TEM (Philips). Mitochondrial morphometric analysis was conducted using 
ImageJ software (Version 1.51).  
6.2.3 Mitochondrial membrane potential 
Cells were cultured under normal conditions to 70% confluency, followed by dissociation 
with Accutase and resuspension in 1X HBSS. Cells were counted and incubated with 5nM 
Tetramethylrhodamine, Methyl Ester, Perchlorate (TMRM; Thermo Fisher Scientific) for 
30 minutes at 37°C and 5% CO2 in the dark, with gentle mixing every 5 minutes. Samples 
were washed three times with 1X HBSS and 20,000 events were analyzed by flow 
cytometry using a FACSCanto SORP (BD Biosciences). Once a basal mitochondrial 
membrane potential was established, 50µM of carbonyl cyanide 3-chlorophenylhydrazone 
(CCCP) was added to each sample and reanalyzed. Data was analyzed using FlowJoTM 
(v10.7) and presented as mean florescence intensity (MFI). 
6.2.4 Statistical analysis 
All values are presented as mean ± SEM from at least three biological experiments. In TEM 
experiments, three technical replicates were also included. Comparisons between two 
groups were performed using Student’s t-test, while comparisons between three or more 
groups were done using an ANOVA test followed by Tukey’s honest significant difference 
test. All graphs and statistics were generated using Prism (v8.4.3). P-values were 






6.3 « Results » 
6.3.1 Reduced mitochondrial activity in feeder-free XEN cells in 
vitro 
Differentiated F9 cells, which resemble XEN cells, exhibit a higher oxidative state and 
more reactive oxygen species (ROS) production than their undifferentiated counterparts 
[34]. Towards that end, we examined the oxidative state and mitochondrial activity in ES 
and XEN cells (Figure 6-1A). To assess the oxidative state of ES and XEN cells, we 
employed a modified MTT assay where the percentage of formazan crystals formed 
relative to the control were normalized to total protein concentration [35]. No significant 
difference was found in the oxidative state between the two populations. However, when 
mitochondrial copy number was analyzed using ddPCR, lower levels of mitochondrial 
copy number were detected in XEN cells relative to ES cells (P < 0.05; Figure 6-1B). Since 
mtDNA copy number is a strong indicator of mitochondrial function and because 
mitochondria contain their own genome where mutations are common due to the proximity 
of ROS generated from the ETC [36], the possibility existed that respiration in XEN cells 
was directly correlated to the fewer mitochondria present in these cell and hence less ROS. 
To investigate this, we employed flow cytometry to measure mitochondrial membrane 
potential using TMRM stain on ES and XEN cells cultured under basal conditions or 
treated with a mitochondrial uncoupler, CCCP (Figure 6-1C). Basal respiration was 
significantly higher in ES cells when compared to XEN cells (P < 0.001; Figure 6-1C), 
which was reported previously [21]. A significant reduction in mitochondrial membrane 
potential was observed when either population was treated with CCCP, but it was lowest 
in XEN cells (P < 0.001; Figure 6-1C). Together, the data indicates that feeder-free XEN 





































































































































Figure 6-1: XEN cells exhibit low mitochondrial activity relative to ES cells.  
(A) Relative oxidative state of ES and XEN cells. (B) ES and XEN cells assessed for 
mitochondrial copy number. Nd5 was used as a mitochondrial gene and Rpl14 as a 
nuclear gene. (C) Flow cytometric analysis of untreated and CCCP-treated ES and XEN 
cells. A total of at least 3 independent experiments were analyzed and results are 
presented as mean ± SEM. Asterisks denote groups of significance tested by a either 




6.3.2 XEN cells exhibit mature mitochondrial morphology 
Another mechanism to explain why mitochondrial activity was significantly lower in XEN 
cells (Figure 6-1C) when compared to ES cells, might involve the lack of substrate uptake 
and utilization of pyruvate. When the status of the pyruvate dehydrogenase complex 
(PDC), which is responsible for the oxidative decarboxylation of pyruvate into acetyl-CoA 
in the mitochondria, was examined it was found to be de-phosphorylated and hence active 
(Chapter 4). Since mitochondria can utilize pyruvate and mitochondrial morphology is 
linked to activity [17,18], morphological identity may explain the reduced activity 
observed in XEN cells. Protein levels of fission and fusion markers were examined, and 
results show the mitochondrial fission marker, MFF was not significantly different between 
the two populations (Figure 6-2A, B). However, DRP1pSer616, which promotes 
mitochondrial fission, was significantly higher in ES cells (Figure 6-2A, C; P < 0.05). 
Alternatively, the mitochondrial fusion marker MFN2 was significantly higher in XEN 
cells (Figure 6-2A). TEM and morphometric analysis to corroborate the molecular analysis 
(Figure 6-2E-I) showed no significant difference in overall size of mitochondria between 
cell populations (Figure 6-2F). The mitochondria of XEN cells, however, appeared 
significantly more elongated (Figure 6-2E, G) with lower mean incident cristae angle 
(Figure 6-2E, H), which agrees with elevated MFN2 levels (Figure 6-2A, D). In contrast, 
the mitochondria in ES cells were round with bent cristae (Figure 6-2E). Lastly, the 
quantification of cristae length to overall surface area, an indirect indicator of 
mitochondrial activity, was significantly lower in XEN cells (Figure 6-2I; P < 0.05). Thus, 
the reduced activity seen was not due to mitochondrial structure but could be also explained 
















































Figure 6-2: XEN cells exhibit mature mitochondria with prominent cristae.  
(A) Immunoblot analysis and (B-D) densitometric analysis of fission markers MFF and 
DRP1pSer616 and fusion marker MFN2 in ES and XEN cells. TOM20 was used a 
mitochondrial loading control. (E) Representative TEM micrograph of mitochondria 
from ES and XEN cells cultured under maintenance conditions. Scale bars is 400nm 
and images were captured at 11000x magnification. Mitochondrial morphometric 
analysis such as (F) area, (G) mean aspect ratio, (H) mean incident cristae angle and 
(I) cristae length-to-area ratio in ES and XEN cells. For image analysis 105 and 95 
mitochondria were analyzed from ES and XEN cells, respectively. A total of 3 
independent experiments were analyzed and results are presented as mean ± SEM. 
Asterisks denote groups of significance tested by a Student’s t-Test. *P < 0.05, ***P < 
0.001, ****P < 0.0001. 
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6.3.3 ETC complex II, III and V are reduced in XEN cells 
Previous reports indicate that the reduced mitochondrial activity in EpiSCs is largely due 
to reduction in complex IV cytochrome c oxidase levels and activity [20]. Using publicly 
available RNA sequencing data of ES and XEN cells [12], the expression profile of various 
components from the ETC were examined (Figure 6-3A). Surprisingly, most of the targets 
from complex I-IV were downregulated in XEN cells when compared to ES cells. 
Specifically, 23 out of 38 targets from complex I, 3 out of 8 targets from complex II, 4 out 
of 6 targets from complex III, and 12 out of 19 targets from complex IV were significantly 
downregulated in XEN cells. A total OXPHOS rodent westernblot antibody cocktail, which 
probes for complex I subunit (NDUFB8), complex II subunit (SDHB), complex III subunit 
(UQCRC2), complex IV subunit (MTCO1) and complex V subunit (ATP5A) was used to 
validate the transcriptomic data and immunoblot analysis showed a significant reduction 
in complex II, III and V subunits in XEN cells relative to ES cells (Figure 6-3B, C). 
Together, this data indicates that the reduction in mitochondrial activity in XEN cells is 



























































































































Figure 6-3: Downregulation of ETC components in XEN cells.  
(A) Expression heatmap of components in the ETC complexes from ES and XEN cells. 
The data was adopted from Anderson and colleagues (12). (B) Immunoblot analysis 
and (C) densitometric analysis of ETC components in ES and XEN cells using the 
MitoProfile antibody. TOM20 was used a mitochondrial loading control. A total of 3 
independent experiments were analyzed and results are presented as mean ± SEM. 
Asterisks denote groups of significance tested by a One-Way ANOVA followed by a 
Tukey’s test. **P < 0.01, ***P < 0.001. 
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6.4 « Discussion » 
We have previously shown that differentiated F9 cells (Chapter 3) [37] and embryo-derived 
XEN cells (Chapter 4) rely on glycolytic metabolism by uncovering a mechanism where 
the expression of mitochondrial pyruvate carrier (Mpcs) is downregulated thereby 
restricting substrate availability for the active PDC. Despite this finding, we were interested 
in examining whether mitochondrial activity was altered due to reduced substrate 
availability and if mitochondrial structure was a culprit in this process. XEN cells exhibited 
a significant reduction in mtDNA (Figure 6-1A) and activity when assessed by flow 
cytometry using TMRM (Figure 6-1C). Surprisingly, biochemical analysis, TEM, and in-
depth morphometric analysis of the mitochondria in both populations demonstrated mature 
and elongated mitochondria with prominent cristae in XEN cells (Figure 6-2). Previous 
reports have shown similar observations regarding mitochondrial remodelling when 
transitioning from naïve-to-primed states, with naïve being more globular and primed more 
elongated with complex cristae network [20,38]. However, mechanistic studies have yet to 
explain whether the changes in mitochondrial structure between naïve and primed states is 
due to fission and fusion stoichiometry or mitophagy. In XEN cells, we observed a 
significant decrease in the levels of DRP1pSer616 (Figure 6-2A, C) coinciding with an 
increase in MFN2 levels (Figure 6-2A, D), which was corroborated by imaging and 
morphometric analyses (Figure 6-2E-I). Therefore, XEN cells undergo mitochondrial 
remodelling by tipping the scale towards mitochondrial fusion. 
Mature mitochondria with complex cristae networks are expected to produce energy 
efficiently mainly due to the increased space for intermembrane proteins for energy 
production [39]. However, in XEN cells, despite having mature mitochondria with 
prominent cristae, the reduced cristae length-to-area ratio in XEN cells (Figure 6-2I) 
alluded to the fact that less space is available for ETC proteins and their reactions to take 
place. We analyzed levels of various ETC subunits at the transcript and protein level and 
like the F9 model, deregulation in ETC stoichiometry was observed in XEN cells, namely 
in complex II, III and V subunits (Figure 6-3). Notably, cytochrome c oxidase family in 
complex IV were largely downregulated in EpiSCs when compared to ES cells, and a 
similar observation was made in human ES cells, suggesting that reduced mitochondrial 
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activity due to deregulation in ETC components may be conserved in cells of the inner cell 
mass [20]. Mechanistically in EpiSCs, the low levels of estrogen-related receptor beta 
(ESRRB) may contribute to the deregulation in complex IV components resulting in the 
low mitochondrial respiration observed in these cells [20], while we observed a similar 
reduction in ESRRB levels during XEN differentiation (unpublished data), we predict that 







6.5 « Future Directions » 
ESRRB is part of the nuclear receptor family characterized by a weak transactivation 
domain at the N-terminus, a zinc finger DNA-binding region in the centre of the 
polypeptide and a ligand-binding domain at the C-terminus of the protein. Esrrb is 
expressed in the oocyte and the zygote [40] and declines until the morula stage and inner 
cell mass at 3.5dpf where it is restricted to the epiblast [25]. Esrrb expression is abruptly 
downregulated in the epiblast and is turned on in the extraembryonic ectoderm, where it is 
involved in trophoblast development [30]. Knocking out Esrrb in mouse results in 
embryonic lethality at E10.5 due to placental abnormalities [29]. In addition to its role in 
vivo, ESRRB also maintains pluripotency of ES cells in vitro, and can bind NANOG and 
OCT4, but is significantly downregulated when they are disrupted [25,28]. Knocking down 
Esrrb in ES cells impacts their self-renewal [22,28] and induces the upregulation of TE 
markers [26,28]. Conversely, overexpression of Esrrb enhances the primed-to-naïve 
transition [23] and blocks embryoid body-induced differentiation with the exception of the 
endodermal lineage [27]. Other than its role in regulating pluripotency, ESRRB is also 
implicated in metabolism. Generally, estrogen-related receptors (ERRs) are involved in 
promoting OXPHOS metabolism by recruiting the coactivators peroxisome proliferator-
activated receptor-γ coactivator-1 α and β (PGC-1α and PGC-1β, respectively). 
Interestingly, this ERR-PGC-1α/β complex promotes an OXPHOS to glycolysis metabolic 
transition [31], which is necessary for the reprogramming of fibroblasts into induced 
pluripotent stem cells (iPSCs) [32]. Collectively, we predict that ESRRB acts as linchpin 
by regulating mitochondrial dynamics and metabolism, which consequently influences cell 
fate decisions. 
In collaboration with Bedzhov lab, a tamoxifen inducible Esrrb deletion and 
overexpression ES lines were derived and will be used to first assess the effects Esrrb will 
have on mitochondrial morphology. Next, both ES lines harboring either Esrrb deletion or 
overexpression will be differentiated towards the XEN lineage and characterized based on 
a panel of pluripotency and differentiation markers. Overall, these experiments will shed 
light on a new role for ESRRB in regulating metabolism through modulating mitochondrial 
dynamics and influencing XEN cell differentiation in vitro.   
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7 « O-GlcNAcylation and regulation of Galectin-3 in 
extraembryonic endoderm differentiation » 
7.1 « Introduction » 
Many proteins in vertebrates are regulated through the addition of 𝛽-N-acetylglucosamine 
(GlcNAc) to the hydroxide moiety of serine or threonine residues, known as O-
GlcNAcylation [1,2]. The addition of O-GlcNAc acts in competition with phosphorylation 
at the same, or nearby amino acids [3-5], demonstrating its integral function in protein 
regulation. Unlike protein phosphorylation and dephosphorylation, which are carried out 
by a variety of kinases and phosphatases, respectively, O-GlcNAcylation is regulated by 
only two enzymes: O-GlcNAc transferase (OGT), which transfers GlcNAc to proteins from 
a donor UDP-GlcNAc derived from the hexosamine biosynthesis pathway [6], and N-
acetyl-𝛽-D-glucosaminidase (O-GlcNAcase, OGA), which removes GlcNAc from 
proteins [7]. 
O-GlcNAcylation is a dynamic process that is regulated through multiple mechanisms. As 
UDP-GlcNAc is derived through the hexosamine biosynthesis pathway, the availability of 
GlcNAc is highly regulated by glucose metabolism [8,9] and insulin [10]. This post-
translational modification is also sensitive to free fatty acids [11], thermal stress [12] and 
oxidative stress [12-14]. The addition or removal of O-GlcNAc in response to nutrients 
and stress is not universal as the O-GlcNAcylated proteome during oxidative stress is 
dynamic where many proteins have increased O-GlcNAcylation, while many others have 
decreased O-GlcNAcylation despite an overall increase in global O-GlcNAc in the cell 
[14]. O-GlcNAc is also differentially regulated during development and differentiation. 
High levels of O-GlcNAc are known to be important in pluripotency in mouse embryonic 
stem (ES) cells by regulating the activity of OCT4 and SOX2, transcription factors 
necessary in maintaining pluripotency [15]. Additionally, global O-GlcNAc has been 
reported to decrease in response to induced differentiation of neutrophils [16] and 
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cardiomyocytes [17] and excess O-GlcNAc in human ES cells inhibits ectodermal lineage 
differentiation [18].  
The 𝛽-galactoside and carbohydrate binding family of proteins, Galectins, have members 
that are known to be O-GlcNAcylated [14,19]. This family of proteins has an array of 
cellular functions including involvement in autophagy, transcriptional regulation, WNT 
signaling, and cell division when inside of the cell and interacts with soluble and 
membrane-bound glycoproteins when outside of the cell [20,21]. Like O-GlcNAcylation, 
Galectins are known to be involved in cellular stress responses [22], where we have 
demonstrated increased expression of multiple Galectin family members in response to 
oxidative stress [23]. Galectin family member expression is also regulated during 
differentiation of neutrophils and in the differentiation of bone marrow and mesenchymal 
stem cell precursors [24]. 
Extraembryonic endoderm (XEN) is a vital structure in the developing embryo, 
differentiating from the inner cell mass in mice at E4.5, is essential for later patterning and 
segmentation [25]. We have demonstrated a role of oxidative molecules in the 
differentiation of the F9 teratocarcinoma cell line, a model of XEN differentiation [26,27]. 
Although ourselves and others have elucidated much about the differentiation of XEN, to 
our knowledge there are no studies investigating the role of O-GlcNAc in this early cell 
lineage. Furthermore, very little is known about the role of Galectins in XEN, with only a 
single study in the literature citing decreased expression of Lgals3 (the gene encoding 
Galectin 3) in F9 cell XEN differentiation [28]. 
The goal of our study was to understand the role of O-GlcNAcylation, specifically on 
galectins, may regulate XEN differentiation. Using established in vitro models, we 
demonstrated that O-GlcNAc levels decrease in response to XEN differentiation and that 
Galectin 3 alters its intracellular versus extracellular localization depending on its O-
GlcNAc status during XEN differentiation. However, increasing global O-GlcNAc levels, 





7.2 « Materials and Methods » 
ES and XEN cell culture, in vitro XEN differentiation, protein extraction, quantification 
and immunoblot analysis and RNA isolation, cDNA synthesis and qRT-PCR analysis are 
as previously described in Chapter 4 [29,30]. 
7.2.1 Dot blot assay 
Global O-GlcNAcylation status in cells was analyzed using Bio-Dot® Microfiltration 
apparatus (Bio-Rad) as described previously [16]. Briefly, nitrocellulose membranes were 
pre-wetted with 1X Tris-buffered saline with Tween-20 (TBS-T). 4µg of protein was 
loaded into the dot blot apparatus and proteins were transferred to the membrane through 
a 1.5-hour gravity filtration. Membranes were incubated in blocking solution (3% bovine 
serum albumin (BSA) and 1% skim milk in 1X TBS-T) for 1 hour. After washing blots in 
1X TBS-T, they were incubated in primary antibody to detect O-GlcNAc (RL2; 1:1000; 
Thermo Scientific) with 5% BSA and 0.1% NaN3 in 1X TBS-T overnight at 4°C. Blots 
were washed in 1X TBS-T and incubated with goat anti-mouse secondary antibody 
(1:10,000; Millipore-Sigma) in 5% skim milk in 1X TBS-T for 2 hours at room 
temperature. After washing in TBS-T, blots were incubated in Luminata™ Classico 
Western HRP Substrate (Millipore-Sigma) and imaged using a Chemi Doc Touch Imaging 
System (Bio-Rad). Densitometry of dot blots were performed using ImageLab (Bio-Rad). 
7.2.2 Galectin-3 ELISA 
Extracellular Galectin 3 was detected using the Galectin-3 Mouse SimpleStep ELISA® Kit 
(Abcam). Briefly, cell supernatant was collected for 3 days of cell culture and was 
centrifuged at 2000 g for 10 minutes. Supernatants were diluted 50% with Sample Diluent 
NS (supplied from kit). Subsequent steps were carried out according to manufacturer’s 
instructions in triplicate. Data analysis was performed after obtaining a standard curve from 
provided reagents in the kit to determine pg/mL concentrations of Galectin 3. Galectin 3 
concentrations in E14 and E4 cells were normalized to intracellular protein concentration 
which was determined using a Bradford Assay using DC™ Protein Assay (Bio-Rad). 
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7.2.3 Statistical analysis 
All figures are representative of at least 3 independent biological replicates. For data 
comparisons between two groups an unpaired Student’s t-test was performed. For data 
comparisons between two groups where one group was set as a relative value of 1, a One 
Sample t-test was performed. For data comparisons between 3 or more groups, a One-way 
ANOVA was performed with Tukey’s Honest Significant Difference post-hoc analysis. 
All statistical analyses were performed using GraphPad Prism version 8.4.2, (GraphPad 
Software, San Diego, California USA). P-values were considered statistically significant 






7.3 « Results » 
7.3.1 Global reduction in O-GlcNAcylation levels in feeder-free 
XEN cells 
Using the terminally differentiated, feeder-free mouse XEN cell line E4, hereby referred 
to as XEN cells, and the E14 mouse embryonic stem cell line, E14, hereby referred to as 
ES cells, we evaluated the global O-GlcNAcylation levels in pluripotent ES cells compared 
to XEN cells. Immunoblot probing for O-GlcNAcylation showed high variation in the XEN 
line (Figure 7-1A and B), which lead us to adopt the dot blot technique which is commonly 
used to assess global levels of post-translational modifications including phosphorylation 
and O-GlcNAcylation [31,32]. This technique showed less variation and demonstrated a 
significant decrease in global O-GlcNAcylation in XEN cells compared to ES cells (Figure 
7-1C and D). O-GlcNAcylation is regulated by two enzymes: OGT and OGA. OGT 
catalyzes the addition of GlcNAc to serine/threonine residues and OGA is responsible for 
removing the modification. Ogt and Oga expression levels are significantly decreased in 
XEN cells (Figure 7-E and F, respectively), however the Ogt/Oga expression ratio in XEN 
cells was significantly increased, suggesting that although relative expression of both 
enzymes are decreased in XEN cells, there is more relative expression of Ogt than Oga 
(Figure 7-1G). Overall, despite observing a higher Ogt/Oga expression, global O-































































































































Figure 7-1: Global O-GlcNAcylation is decreased in XEN compared to ES cells. 
(A) Immunoblot and (B) densitometry of O-GlcNAc detecting antibody RL2 in ES and 
XEN cells. (C) Immuno-dot blot and (D) densitometry and of RL2 in ES and XEN cells. 
RT-qPCR of the O-GlcNAc adding enzyme Ogt (E) and the O-GlcNAc removing 
enzyme Oga (F) in ES and XEN cells. (G) Ratio of relative expressions from E-F of 




7.3.2 OGA inhibition alters pluripotency and XEN marker 
expression patterns 
To determine the effects of global O-GlcNAcylation levels on pluripotency and 
endodermal markers in their respective cell lines, we treated ES and XEN cells with 10𝜇M 
Thiamet G (TG), an OGA inhibitor. We confirmed TG is effective in inhibiting OGA after 
24 hours as we observed a significant increase in global O-GlcNAcylation in XEN cells 
(Figure 7-2A and B). Unexpectedly inhibition of OGA for 24 hours in ES cells resulted in 
no change in Oct4 expression (Figure 7-2C) and decreased expression of Nanog (Figure 7-
2D). Conversely, OGA inhibition in XEN cells resulted in no change in Gata6 expression 
(Figure 7-2E) and an expected decrease in FoxA2 levels (Figure 7-2F). Together, our 













































































































































Figure 7-2: OGA inhibition alters pluripotency marker expression in ES and 
XEN marker expression in XEN cells.  
(A) Immuno-dot blot and (B) densitometry of O-GlcNAc detecting antibody RL2 in 
XEN cells treated with or without 10 µM TG, an OGA inhibitor. RT-qPCR of 
pluripotency gene expression Oct4 (C) and Nanog (D) in ES cells treated with 10 
µM TG for 24 hours. RT-qPCR of XEN marker gene expression Gata6 (E) and 
FoxA2 (F) in XEN cells treated with 10 µM TG for 24 hours. Bars represent mean 
values ± SEM. N=3. *P<0.05, **P<0.01. 
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7.3.3 Lgals3 expression is decreased in XEN cells 
Since global O-GlcNAcylation is decreased in XEN compared to ES cells and XEN marker 
FoxA2 is inhibited when global O-GlcNAcylation is increased through OGA inhibition, we 
sought to identify a candidate protein that may play a role in XEN differentiation; one that 
is likely regulated through O-GlcNAcylation. We previously demonstrated altered 
oxidative stress during XEN-like cell differentiation [26] and have showed that galectins 
show altered expression patterns in response to differentiation and oxidative stress [23]. 
RNA sequencing analysis of transcripts from ES and XEN cells show changes in many 
galectin genes and genes involved in O-GlcNAcylation (Figure 7-3A). We validated the 
changes observed in galectin genes by RT-qPCR and showed that all but Lgals3 (Figure 7-
3D) showed no difference in expression between ES and XEN cells. Further in silico 
analysis of the GALECTIN 3 (GAL3) amino acid sequence identified four putative O-
GlcNAcylation sites: S6, T189, T151 and S208 [33]. Equipped with the transcriptomic and 
expression data and the in-silico work, we sought to elucidate the role of O-GlcNAcylation 









































Figure 3: Lgals3 expression is decreased in XEN cells compared to ES cells 
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ES-A ES-B ES-C XEN-A XEN-B XEN-C
Figure 7-3: RNA sequencing and gene expression analysis of Galectin genes in 
ES and XEN cells.  
(A) Heat map of RNA sequencing of transcripts in ES and XEN cells showing Lgal 
genes 1-4, 7-9 and 12 and genes involved in O-GlcNAcylation Ogt, Mgea5, Gfpt1 
and 2. RT-qPCR of Lgal1 (B), Lgal2 (C), Lgal3 (D), Lgal4 (E), Lgal7 (F), Lgal8 
(G), Lgal9 (H) and Lgal12 (I). Bars represent mean values ± SEM. N=3. **P<0.01. 
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7.3.4 Elevated extracellular to intracellular ratio of 
GAL3 in XEN cells 
GAL3 was our candidate as a protein that may be regulated by O-GlcNAcylation and a 
protein that has functions inside and outside of the cell [20]. Immunoblot analysis of GAL3 
showed a significant decrease in intracellular GAL3 levels in XEN cells compared to ES 
cells (Figure 7-4A and B), in agreement with the expression data (Figure 7-3D). As 
galectins have different function depending on intracellular versus extracellular 
localization, we performed GAL3 ELISA to determine the extracellular levels relative to 
intracellular protein concentration. XEN cells displayed a significant decrease in relative 
extracellular GAL3 when compared to ES cells (Figure 7-4C). However, when comparing 
the intracellular to extracellular concentration ratio, we found a significant decrease in 
GAL3 in XEN cells relative to ES cells (Figure 7-4D). Although a decrease in Lgals3 
expression and GAL3 levels intracellularly was observed in XEN cells, more extracellular 
GAL3 is present in XEN cells than their ES counterparts. Therefore, the reduction observed 
in GAL3 intracellularly is due to increased GAL3 secretion, and O-GlcNAcylation may 


























































































































Figure 7-4: ES cells have increased intracellular GAL3 while XEN have 
increased extracellular GAL3 levels compared to their own intracellular 
levels.  
(A) Immunoblot and (B) densitometry of GAL3 in ES and XEN cells. (C) ELISA 
of extracellular GAL3 in the media of ES and XEN cells. (D) Relative 
intracellular to extracellular ratio of GAL3 in ESC and XEN. Bars represent mean 
values ± SEM. N=3. *P<0.05, **P<0.01, ***P<0.001. 
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7.3.5 Inhibiting OGT in ES cells increases extracellular GAL3 
levels 
The intracellular versus the extracellular localization of GAL3 alters its function [20]. We 
sought to understand the effects of global O-GlcNAcylation changes on the intracellular 
and extracellular levels of GAL3 in ES and XEN cells. OGA inhibition by TG was 
confirmed to increase O-GlcNAcylation levels in XEN cells (Figure 7-2A and B). We also 
confirmed Alloxan, an OGT inhibitor, was effective in reducing global O-GlcNAcylation 
levels in ES cells (Figure 7-5A and B). To confirm that O-GlcNAcylation status of GAL3 
was indeed altering its intracellular versus extracellular localization, we performed an 
ELISA to detect extracellular GAL3 levels. We observed a significant increase in 
extracellular GAL3 relative to intracellular protein concentrations in ES cells treated with 
Alloxan, but no change with TG treatment (Figure 7-5E). Alternatively, no change in 
extracellular GAL3 in XEN cells treated with either Alloxan or TG (Figure 7-5F) was 
observed. Our results suggest that GAL3 localization is dependent on its O-GlcNAcylation 


































































































































Figure 7-5: OGT inhibition in ESC increases extracellular GAL3.  
(A) Immuno-dot blot and (B) densitometry of O-GlcNAc detecting 
antibody RL2 in ESC treated with 5 mM Alloxan, an OGT inhibitor. (C) 
ELISA of extracellular GAL3 in the media of ES cells treated with 10 µM 
TG or 5 mM Alloxan. (D) ELISA of extracellular GAL3 in the media of 
XEN cells treated with 10 µM TG or 5 mM Alloxan. Bars represent mean 
values ± SEM. N=3. *P<0.05. 
 
 226 
7.3.6 OGA inhibition is not sufficient to inhibit XEN differentiation 
in vitro 
Given that global O-GlcNAc levels are decreased in XEN (Figure 7-2C and D) we sought 
to determine the role global O-GlcNAc, and thus by proxy the role of extracellular GAL3 
on XEN differentiation. ES cells were differentiated towards a XEN lineage for 8 days in 
the presence or absence of OGA inhibitor, TG. To our surprise, the relative expression of 
pluripotency markers Oct4 (Figure 7-6A) and Nanog (Figure 7-6B) showed either lower 
expression or no change in expression with TG treatment during differentiation than 
untreated differentiation controls, respectively. This suggests that inhibition of OGA, and 
likely the forced intracellular localization of GAL3, does not block ESC exit from 
pluripotency. Investigating XEN markers Gata6 (Figure 7-6C) and FoxA2 (Figure 7-6 D), 
neither showed any difference in relative expression with TG treatment during 
differentiation compared to untreated differentiated controls. This also suggests that global 
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Figure 7-6: OGA inhibition is not sufficient to inhibit ES differentiation towards 
XEN in vitro.  
(A) Representative phase contrast images of ES, XEN and cXEN cells. RT-qPCR of 
pluripotency markers Oct4 (B) and Nanog (C) and XEN markers Gata6 (D) and Dab2 
(E) of ES cells differentiated towards XEN. RT-qPCR of pluripotency markers Oct4 (F) 
and Nanog (G) and XEN markers Gata6 (H) and FoxA2 (I) of ES cells differentiated 
towards XEN with control or 10 µM TG. Bars represent mean values ± SEM. N=3. 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
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7.4 « Discussion » 
The objective of this study was to better understand the role of O-GlcNAcylation during 
XEN differentiation and explore how it can regulate galectin expression and localization. 
Here, we report that global O-GlcNAc is decreased in XEN cells and that inhibiting OGA 
has no effect on XEN differentiation. Lastly, GAL3 localization is dependent on both 
differentiation and O-GlcNAc status.  
Decreased O-GlcNAc in response to differentiation is consistent in many models. We 
observed decreased global O-GlcNAc in XEN compared to ES cells (Fig. 1), which is 
consistent with previous work by Kim et al., who showed decreased global O-GlcNAc 
when ES cells were differentiated towards cardiomyocytes [17]. In addition, we have 
shown that neutrophil differentiation of HL-60 cells also has decreased global O-GlcNAc 
[16]. We also observed that this global decrease in O-GlcNAc coincided with decreased 
expression of Ogt, the gene expressing the enzyme responsible for adding the modification 
(Figure 7-1). The decreased expression of the modifying enzyme has also been observed 
in the cardiomyocyte differentiation model [17]. Although previous work has demonstrated 
the complexity of the O-GlcNAc modification in response to cell stress [14] the overall 
decrease in O-GlcNAc is likely in response to the exit from pluripotency. Jang and 
colleagues demonstrated transcription factors involved in pluripotency OCT4 and SOX2 
are both modified by O-GlcNAc in pluripotent ES cells and have this modification removed 
with induced differentiation [15]. 
As the O-GlcNAc modification has been shown consistently to be high in pluripotency and 
to decrease in response to differentiation, we explored how chemical inhibition of the 
modification-removing enzyme, OGA, would affect both cell populations. We expected 
blocking OGA, and thus increasing the amount of global O-GlcNAc, would increase the 
expression of pluripotency markers in ES cells and would decrease the expression of XEN 
markers in XEN. To our surprise OGA inhibition had no effect or the opposite effect on 
pluripotency markers in ES cells (Figure 7-2), which may highlight the yet unexplored 
complexity of the O-GlcNAc network in pluripotency, as OGA inhibition may be altering 
the enzyme’s ability to regulate proteins involved in pluripotency that should not have an 
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O-GlcNAc modification. On the other hand, in XEN cells OGA inhibition either had no 
change or decreased XEN marker expression (Figure 7-2), which suggests the activity of 
the modification enzymes OGT and OGA, and thus the number proteins with O-GlcNAc 
may be playing a role in maintaining the XEN phenotype.  
Previous work has identified the galectin family of proteins being regulated by 
glycosylation [14,19,34] where particularly GAL3 was identified to be modified by O-
GlcNAcylation [14]. To our knowledge only a single study has been published exploring 
galectins in a XEN model, the F9 cell. Consistent with this work we observed a similar 
decrease in Lgals3 expression in XEN cells compared to ES cells (Figure 7-3) that was 
observed in Lu and colleagues’ differentiation of F9 cells towards the XEN-like lineage 
[28]. Unlike the changes in O-GlcNAc levels, which have been consistent in the literature, 
galectins appear to have context specific changes in expression [21]. For example, in 
contrast to our results, HL-60 cell differentiation towards neutrophils have increased 
expression of Lgals3 and Lgals10 [23] and decreased expression of Lgals12 [16], where 
we only observed changes in Lgals3 expression. 
As Lgals3 expression was the only observed change in XEN cells compared to ES cells, 
we further explored the regulation of this protein in pluripotency and differentiation. As a 
family of proteins galectins have many functions, and GAL3 has functions both inside and 
outside of the cell [20]. We observed decreased intracellular GAL3 in XEN cells, however, 
XEN cells also showed an increased extracellular to intracellular ratio GAL3 in when 
compared to ES cells (Figure 7-4). Iacobini and colleagues discussed the role of GAL3 in 
bone lineage differentiation, however, this group highlighted that GAL3 extracellular, or 
intracellular localization could enhance or inhibit specific lineage differentiation [35]. 
Given our results showing increased intracellular GAL3 in ES cells compared to XEN 
cells, it is likely that extracellular GAL3 is playing a role in enhancing XEN differentiation. 
To further explore the question of GAL3 regulation through O-GlcNAcylation, we 
inhibited the O-GlcNAc addition enzyme, OGT, in ES cells. We determined that OGT 
inhibition did decrease global O-GlcNAc levels (Figure 7-5A, B), while simultaneously 
increased extracellular GAL3 levels (Figure 7-5C). GAL3 secretion is considered non-
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classical, meaning it does not exit the cell through the secretory pathway and has been 
found to exit the cell in exosomes [36]. O-GlcNAcylation has been shown to regulate 
protein sorting exosomes, however, it is still unclear if it is binary or a more dynamic 
regulation process [37]. To our knowledge no studies have investigated the composition or 
role of exosomes in XEN differentiation, so GAL3 may be exiting the cell in response to 
altered O-GlcNAc status through this mechanism. Regardless, our evidence indicates that 
the change in O-GlcNAc status of GAL3 during the exit from pluripotency induces its 
extracellular secretion.  
Given the differences in the two populations, ES and XEN cells, we wanted to explore the 
role of OGA inhibition when ES cells were induced towards the XEN lineage. We expected 
that OGA inhibition, and thus increased global O-GlcNAc, would inhibit XEN 
differentiation. When observing pluripotency and XEN marker expression, there was no 
change in the OGA inhibited cells during differentiation and the differentiated cells without 
OGA inhibition (Figure 7-6). As other groups have demonstrated the importance of 
increased O-GlcNAc in ES cells self-renewal and maintenance of pluripotency 
transcription factor function [15], we were surprised by this result. Although not entirely 
consistent with our results, Maury and colleagues demonstrated that excess O-GlcNAc in 
human pluripotent stem cell differentiation inhibited ectodermal marker expression 
without inhibiting the cell’s exit from pluripotency [18]. Together this suggests that 
although there are changes in O-GlcNAc globally in XEN cells compared to ES cells, 
inhibiting only the enzyme involved in removing O-GlcNAc modifications is not sufficient 
to inhibit XEN differentiation.  
To our knowledge, we are the first to explore the role of O-GlcNAcylation in XEN 
maintenance and differentiation. Our work demonstrated the differences in global O-
GlcNAc between ES and XEN cells, yet OGA inhibition alone is not sufficient to inhibit 
XEN differentiation. We also provide a candidate protein, GAL3, whose localization 
through O-GlcNAcylation may regulate XEN differentiation. Although this study is a 
beginning many questions remain in not only the role of O-GlcNAc but also the role and 
regulation of GAL3 in XEN differentiation.  
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